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Abstract

G protein-coupled receptors (GPCRs) are a class of integral membrane receptor
proteins that are characterized by a signature seven-transmembrane (7TM) configuration.
These receptors comprise a large and diverse gene family found in fungi, plants, and the
animal kingdom. Recent studies with GPCRs have begun to elucidate their importance in
many physiological processes, thus various human diseases are associated with GPCR
pathology. Although the overall 3D structure of these receptors carry similar features,
binding of an extraordinarily diverse array of ligands trigger many different biological
pathways.
The α-factor receptor (Ste2p) of Saccharomyces cerevisiae belongs to the GPCR
family. Upon the α-factor binding to Ste2p, a signal is transduced via an associated
guanine-nucleotide binding protein initiating a cascade of events that leads to the mating
of haploid yeast cells. As only two GPCRs and two G proteins are encoded in the S.
cerevisiae genome, this yeast presents a relatively simple system to study GPCR signal
transduction in comparison to mammalian cells that possess hundreds of GPCRs and tens
of G proteins. Part I of this dissertation is an overview of GPCRs in general with specific
emphasis on the peptide pheromone α-factor and its receptorSte2p.
Part II of this dissertation details the design and characterization of a number of
iodinatable α-factor pheromone analogs containing the photo-cross-linkable 4-benzoyl-Lphenylalanine (Bpa) group. One of these analogs [Bpa1, Y3, R7, Nle12, F13] was
radioiodinated for detection and used as a probe for cross-linking studies with Ste2p.
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Chemical (with CNBr & BNPS-skatole) and enzymatic (with Trypsin) cleavage of the
receptor/analog complex after the cross-linking was examined to determine the
interaction between the α-factor probe and a fragment of the receptor. Data from these
digestions indicated that the position one of the α-factor interacts with residues 251 to
294 in the receptor.
Similarly Part III of this dissertation describes the design and synthesis of five
photoactivatable α-factor analogs that carry Bpa at positions one, three, five, eight, or
thirteen. All of these analogs were biotinylated at the ε-amine of the Lys7 for detection
and purification purposes. The biological activity (growth arrest assay) and binding
affinities of all analogs for Ste2p were determined. Two of the analogs tested, Bpa1 and
Bpa5, showed three- to four-fold lower affinity compared to α-factor, whereas Bpa3 and
Bpa13 had seven- to twelve-fold lower affinities, respectively. Bpa8 competed poorly with
[3H]α-factor for Ste2p. All of the analogs tested had detectable halos in the growth arrest
assay indicating that these analogs are α-factor agonists. Cross-linking studies
demonstrated that [Bpa1]α-factor, [Bpa3]α-factor, [Bpa5]α-factor and [Bpa13]α-factor
were cross-linked to Ste2p; the biotin tag on the pheromone was detected by a
NeutrAvidin-HRP conjugate on Western blots. Digestion of Bpa1, Bpa3, and Bpa13 crosslinked receptors with chemical and enzymatic reagents suggested that the N-terminus of
the pheromone interacts with a binding domain consisting of residues from the
extracellular ends of TM5, TM6, and TM7 and portions of EL2 and EL3 close to these
TMs. Additionally it was concluded that there is a direct interaction between the position
13 side chain and a region of Ste2p (F55-R58) at the extracellular end of TM1. Parts II
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and III of this dissertation indicate that Bpa-containing α-factor probes are useful in
determining contacts between α-factor and Ste2p and initiating mapping of the ligand
binding site of the GPCR for its peptide ligand.
This dissertation (Part IV) also presents the application of different purification
methods and the use of two mass spectrometry instruments for identification of ligandreceptor interactions at the molecular level. Results presented in this part showed that
although a single step purification was enough for western blot analyses of the crosslinked receptor fragments, at least a two-step purification and enrichment of the
biotinylated peptide fragments were necessary for mass spectrometric studies. MALDITOF experiments showed that the affinity purification of the biotinylated fragments by
monomeric avidin beads was successful. Data obtained from CNBr fragments of Bpa1
cross-linked membranes were in agreement with the previous results discussed in Parts II
and III of this dissertation suggesting the cross-linking between position one of α-factor
and a region of Ste2p covering residues 251 to 294. This part also illustrated that the
analyses of the MS/MS data from the cross-linked fragments were more complex than the
fragmentation data obtained from biotinylated α-factor; the presence of multiple charge
states of fragment ions and unusual fragmentation of branched peptides indicated the
necessity of using an instrument with higher resolution. In addition, analyses of the
MS/MS data with a customized algorithm would be required to deconvolute the sequence
of the cross-linked fragment(s) to identify the cross-linked residue(s) on Ste2p.
The final part of this dissertation reviews the overall conclusions and discussion.
This part also contains suggestions for future experiments that could help identification of
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contact points between Ste2p and its peptide ligand α-factor. Additional studies on this
GPCR system employing high-resolution mass spectral characterization of fragments
should allow identification of residue-to-residue interactions between the analogs used in
this study and Ste2p. Such information will aid the mapping of the ligand-binding site of
the pheromone receptor and has the potential to provide key insights into peptide ligand
mediated activation of GPCRs. This and similar studies may ultimately lead to the
discovery of how peptide ligands initiate signal transduction through GPCRs.
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PART I
General Introduction

1

CHAPTER 1
G Protein-coupled Receptors: An overview

A class of integral membrane receptor proteins that are characterized by a
signature seven-transmembrane (7TM) configuration consists of large and diverse gene
families found in fungi, plants, and the animal kingdom. Members of this class of
receptors are coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins);
thus they are called G protein-coupled receptors (GPCRs) [1]. GPCRs are located at the
cell surface and are responsible for the transduction of an extracellular signal into an
intracellular response [2]. The natural ligands of this receptor superfamily are
extraordinarily diverse, embracing biogenic amines (for example, adrenaline, dopamine,
histamine, and serotonin), peptide and protein hormones (such as angiotensin, bradykinin,
endothelin, and melanocortin), peptide pheromones (i.e. α-factor, a-factor of various
fungi species), nucleosides and nucleotides (adenosine, adenosine triphosphate, uridine
triphosphate), and lipids and eicosanoids (cannabinoids, leukotrienes, prostaglandins, and
thromboxanes) [3]. Furthermore, the awareness of exogenous stimuli, such as light, odor,
and taste, is also mediated via this class of receptors [3-5].
Heterotrimeric G proteins transduce ligand binding to GPCRs into intracellular
responses. These proteins are composed of three subunits (α, βγ-dimer) and each subunit
plays important roles in determining the specificity and temporal characteristics of the
cellular responses to signals [6]. Activation of GPCRs by agonists induces a
conformational change in the associated G protein α-subunit leading to release of GDP
2

followed by binding of GTP [7]. This change initiates the dissociation of the α-subunit
from the receptor and the βγ-dimer. Both the GTP bound α-subunit and the released βγdimer can mediate the stimulation or inhibition of a diverse collection of effector
enzymes and ion channels, including adenylate cyclase, guanylyl cyclase, phospholipase
C, mitogen-activated protein kinases (MAPKs), Ca+2, and K+ channels. Thus, stimulation
of different cell-surface GPCRs with specific agonists results in changes in levels of a
wide variety of second-messenger molecules [8, 9]. G protein deactivation is rate-limiting
for turnoff of the cellular response and occurs when the Gα subunit hydrolyzes GTP to
GDP.
Considering the wide variety of biological pathways regulated by GPCRs it is not
surprising that irregularities of signaling by these receptors are at the root of disorders
that affect tissues and organs in the human body [10]. So widespread are the
physiological processes controlled by GPCRs that it has been estimated approximately
50% of all modern prescription drugs and 25% of the top-selling drugs directly or
indirectly affect GPCRs [2, 11] (Table 1). In contrast, only a very small portion of the
known GPCRs represent targets of currently marketed drugs. With the completion of the
human genome it has been estimated that hundreds of genes code for the GPCR family
[12] of which only approximately 30 represent targets of currently marketed drugs.
Hundreds of so-called ‘orphan receptors’ have been identified within the human genome,
for which the ligand and the (patho)physiological function is unknown [13], and the
GPCR target family represents approximately a quarter of the portfolio of many
pharmaceutical companies [14]. It is thus clear that future studies of GPCRs should make
a dramatic impact on understanding and treatment of a variety of diseases.
3

Table 1: GPCR-based drugs among the 200 best-selling prescriptions in 2000 and
their GPCR targets*.
GPCR target

Histamine
receptors

Drug

Disease

Zantac

Ulcers

Pepcid

Company

2000 sales
(US $m)
870

Ulcers

GlaxoSmithKline
Merck

850

Claritin

Allergies

Schering-Plough

3,000

Allegra

Allergies

Aventis

1,100

Risperdal

Psychosis

Imitrex

Migraine

BuSpar

Anxiety

Zyprexa

Johnson &
Johnson
GlaxoSmithKline
Bristol-Myers
Squibb

1,100

Schizophrenia

Eli Lilly

2,400

Cozaar

Hypertension

Merck

1,700

Toprol-XL

Hypertension

AstraZeneca

580

Coreg

Congestive heart
failure

GlaxoSmithKline

250

Serevent

Asthma

GlaxoSmithKline

940

Muscarinic
acetylcholine
receptors

Atrovent

COPD

Boehringer
Ingelheim

600

GnRH receptors

Zoladex

Cancer

AstraZeneca

740

Dopamine
receptors

Requip

Parkinson’s
diseases

GlaxoSmithKline

90

Prostaglandin
(PGE1) receptors

Cytotec

Ulcers

Pharmacia

100

5-HT receptors

Angiotensin
receptors

Adrenoceptors

1,600

714

Bristol-Myers
900
Squibb
*Source: McKinsey Analysis “http://www.predixpharm.com/market_table.htm”.
ADP receptors

Plavix

Stroke

Abbreviations: COPD, chronic obstructive pulmonary disease; 5HT, 5hydroxytryptamine (serotonin); GnRH, Gonadotrophin-releasing-hormone
4

Classification of GPCRs:
Despite the wide variety of agonists that stimulate the diverse secondarymessenger pathways activated by the GPCR family, these receptors share structure
similarities [8]. All members of the superfamily contains seven transmembrane-spanning
α-helical segments connected by alternating intracellular and extracellular loops (IL and
EL, respectively), with the amino terminus located on the extracellular side of the
cytoplasmic membrane and the carboxy terminus on the intracellular side. Although
GPCRs share common membrane topological features, they are diverse in sequence and
vary especially in size of the extracellular amino-terminal tails, extracellular and
intracellular loops, and carboxy-terminal tails. Currently several classification systems
based on these differences have been used to sort out the GPCR superfamily. Some
systems group the receptors by their ligand, and others have used both physiological and
structural features. Today one of the most commonly used systems classifies GPCRs into
six distinct families (A to F clans). This A-F system is designed to cover all GPCRs, in
both vertebrates and invertebrates with regard to their sequence similarity. According to
this classification a ‘Superfamily’ is a collection of proteins with structural and functional
characteristics in common, but which lack obvious sequence similarity. A GPCR ‘Clan’
is a collection of receptors, within a superfamily, whose protein sequences share greater
then 20% sequence identity in their transmembrane regions, and is presumed to have
evolved from a common ancestor. A ‘Family’ within a clan shares obvious common
biochemical properties [15, 16] (Table 2).

5

Table 2: Sequence-based groupings within the G-protein-coupled receptors.

Clan A: Rhodopsin-like receptors
Olfactory receptors, adenosine receptors, melanocortin receptors,
Family I
and others
Family II
Family III
Family IV
Family V
Family VI

Biogenic amine receptors
Vertebrate opsins and neuropeptide receptors
Invertebrate opsins
Chemokine, chemotactic, somatostatin, opioids and others
Melatonin receptors and others

Clan B: Calcitonin and related receptors
Calcitonin, calcitonin-like, and CRF receptors
Family I
PTH/PTHrP receptors
Family II
Glucagon, secretin receptors and others
Family III
Latrotoxin receptors and others
Family IV
Clan C: Metabotropic glutamate and related receptors
Metabotropic glutamate receptors
Family I
Calcium receptors
Family II
GABA-B receptors
Family II
Putative pheromone receptors
Family IV
Clan D: STE2 pheromone receptors
Clan E: STE3 pheromone receptors
Clan F: cAMP and archaebacterial opsin receptors

Table adapted from Flower et al. [17]

6

According to A-F classification the rhodopsin-like family (Clan A) has the largest
number of receptors and is by far the most studied. This group contains receptors for
odorants, small molecules such as the catecholamines and amines, some peptides and
glycoprotein hormones [18]. The overall sequence identity among all type A receptors is
low compared to the sequence identity among the members of other clans, and restricted
to a number of highly conserved motifs such as NSxxNPxxY motif in transmembrane
domain seven (TMVII) and the DRY motif or D(E)-R-Y(F) at the border between TMIII
and IL2[19]. Clan B is presently the next largest family, with around 25 distinct
members, including receptors for a variety of gastrointestinal peptide hormones (secretin,
glucagons, vasoactive intestinal peptide, and growth-hormone-releasing hormone),
calcitonin, corticotrophin-releasing hormone and parathyroid hormone [1]. Receptors in
this clan do not contain any of the structural features characterizing Clan A receptors
except the presence of a disulfide bridge between the second (EL2) and third extracellular
loops (EL3). The most noticeable characteristic of this clan is that the amino terminus
contains several cysteines, presumably forming a network of disulfide bridges [20]. Clan
C on the other hand is relatively a smaller group, containing the metabotropic glutamate
and γ-amino-butyric acid receptors, the calcium receptors, the vomeronasal, mammalian
pheromone receptors, as well as some taste receptors [5]. All receptors in this clan have a
very large extracellular amino terminus (500-600 amino acids) that seems to be crucial
for ligand binding and activation [21, 22]. Clan D is the STE2 yeast pheromone
receptors, and clan E is the STE3 yeast pheromone receptors. These two groups will be
discussed in the next section (Chapter 2). Finally Clan F comprises the receptors that are

7

related to slime mold cyclic adenosine monophosphate (cAMP) receptors and
archaebacterial opsins.

The tertiary structure of GPCRs:
Information about the tertiary structure of a GPCR is crucial for the understanding
of its function and for the design of drugs to correct possible problems caused by failure
of this function. Currently methods used to understand the interactions between the
ligand and its receptor at the atomic level include X-ray crystallography, electron
microscopy or diffraction, NMR spectroscopy and molecular modeling. One of the
advantages for NMR spectroscopy compared to the other methods is that dynamic
information can be obtained. However, for solving structures by this method, high
concentrations of dissolved protein (fairly pure) are needed; unfortunately at these high
concentrations GPCRs are mostly insoluble. Except for several studies where single
helices were measured in a membrane, using solid state NMR, technical problems have
precluded NMR studies from giving structural information on GPCRs [23]. Electron
diffraction has so far been successful in obtaining information on structure of one GPCRlike molecule (bacterio-rhodopsin) at medium high resolution (3.5 A) [24], and one l
GPCR (rhodopsin) at low resolution (9.0 A) [25, 26]. These studies with the addition of
further biochemical and theoretical studies led to structural information about other
members of the superfamily through homology-modeling studies [27-34].
Similar to NMR studies, X-ray studies of GPCRs are hampered by poor solubility
and suboptimal purification methods of integral membrane proteins. Thus, so far there is
only one high-resolution 3D GPCR structure determined by X-ray crystallography. The
8

3D structural determination of the dark-adapted bovine rhodopsin by X-ray
crystallography provides deep insight into the structure of the rhodopsin family of
GPCRs and related GPCRs in general [35, 36](see review [37]). Remarkably, the X-ray
structure of rhodopsin was generally in good agreement with the models of various
GPCRs derived from low-resolution structures of rhodopsin.
The crystal structure of rhodopsin revealed a highly organized heptahelical
transmembrane bundle with 11-cis-retinal as a key cofactor involved in maintaining
rhodopsin in the ground state. The EL2 is connected to TM3 via a disulfide bridge and
fits tightly into this helix bundle [38]. A significant feature, from the crystal structure, is
that the transmembrane helices in rhodopsin are not regular α-helices [39]. The helices
are bent and contain segments with 310- or π-helical conformation. One of the strongest
distortions is in TM6 induced by the presence of Pro 267 (a highly conserved residue
among GPCRs). It has been shown that mutations at this residue can have long range
effects such as conformational changes on IL3 [27]. In addition a pronounced kink is
observed in TM2, caused by flexibility in the Gly-Gly sequence in the middle of this
helix. The crystal structure also revealed a short 8th helix, which runs parallel to the
cytoplasmic membrane. This helix and the generated fourth cytoplasmic loop cover part
of the binding site for the C-terminus of the Gα subunit and plays a role in Gγ binding. A
set of residues including portions of IL3 and the 8th helix likely undergoes a
conformational change upon photoactivation of the chromophore that leads to the
receptor activation and signal transduction (see review[40]).
It is generally agreed that 3D models of rhodopsin guided by the crystal structure
will provide a general picture of the other GPCR classes, especially rhodopsin-like
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GPCRs (Clan A) (see review[41]). Comparisons of the tertiary structures of homologous
proteins have shown that three-dimensional structures have been better conserved in
evolution than primary structures, indicating the feasibility of model-building by
homology. However differences between 3D structures increase with decreasing
sequence identity and accordingly the accuracy of models built by homology decreases.
Unfortunately the sequence similarity between different clans of GPCRs is very low, thus
homology modeling is difficult for GPCRs in non-rhodopsin like families. In case of low
homology (≤ 25% sequence identity) the alignment of the sequences is the main
bottleneck for model building, and large errors are often generated. To overcome this
problem development of secondary structure predictions and ab initio 3D modeling
techniques with experimental constraints are being used [42, 43].

Ligand binding and receptor activation:
The family of G protein-coupled receptors binds and is activated by a wide
variety of ligands, ranging in size from small molecules to large glycoproteins. Much of
the current emphasis on receptor research is focused on identification of the binding
domains for these structurally divergent ligands, using genetic, biochemical, and
biophysical approaches [8]. Receptor mutagenesis (site-directed or random), domain
swapping, and use of fluorescence probes are the most commonly used methods for
elucidating structure-function relationship between GPCRs and their ligands. The
binding sites of endogenous “small-molecule” ligands in family A receptors, such as for
the retinal chromophore in rhodopsin and for catecholamines in the adrenergic receptors
are the most widely studied and well characterized of these receptor-binding domains
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(see reviews [44-46]). Recent studies on several peptide receptors such as the receptors
for angiotensin [47-49], parathyroid hormone [50, 51], secretin [52], bradykinin B2 [53,
54], gonadotropin-releasing hormone [55], opioids [56, 57], neurokinin (NK) [58, 59],
vasopressin/oxytocin [60-62], cholecystokinin/gastrin [63, 64], and neurotensin 1 [65]
supplied valuable information on the binding domains for other classes of GPCRs.
Although the specific ligand receptor interactions vary, certain similarities are observed
in ligand GPCR interactions. Large ligands, such as proteins, bind to extracellular loops,
while small molecules, including pharmacological agents, bind within the transmembrane
region of receptor. Peptides on the other hand can exhibit a combined binding mode
whereby they bind primarily to the extracellular loops while part of the structure
penetrates the transmembrane region and interacts with residues buried in lipids [66-69].
Photo-affinity cross-linking is one of the few direct methods applied to identify
the contact regions between the peptide ligands and their GPCRs, thus providing
information on how the ligand interacts with its receptor. Benzophenones have been used
extensively as photophysical probes to identify and map peptide-protein interactions [70].
In contrast to other cross-linkers, like aryl azides, diazoesters, and diazarenes, they are
chemically stable under ambient light and could be activated by low energy UV (at 350360 nm) minimizing protein damage. They preferentially react with carbon-hydrogen
bonds resulting in a covalent adduct, which would be stable to chemical and enzymatic
peptide cleavage [71]. Furthermore, relative to other photo cross-linkers, benzophenones
do not photo-dissociate and their photo-excited state readily relaxes in the absence of a
suitable C-H bond. This relaxed state could be excited again which will result in higher
cross-linking yields upon repeated excitation by long-wavelength UV light [72]. This
11

dissertation will mainly focus on the use of photoactivatable analogs carrying 4-benzoylL-phenylalanine (Bpa), for cross-linking the pheromone to its GPCR, and analysis of the
results by the aid of other techniques such as site-directed mutagenesis, use of analogs
and mass spectrometry. The discussions of these methodologies are expanded in parts 2,
3, and 4 of this dissertation.

Conformational Changes Involved in Agonist Induced GPCR Activation:
Several studies on GPCR activation by agonist binding suggested that relative
movements of the transmembrane domains are the key to transfer the extracellular signal
to the heterotrimeric G protein. Spin-labeling studies on cysteine-substituted mutants of
rhodopsin showed that a rigid body motion of TM6 relative to TM3 accompanied by anticlockwise rotation (as viewed from the extracellular side) (Figure 1) [73]. Disulfide
cross-linking of these helices prevented activation of transducin, thus suggesting the
importance of this movement for activation of rhodopsin. More detailed analysis of
conformational changes in TM6 of the β2-adrenergic receptor (β2AR) provides evidence
for a rigid body motion similar to that observed upon activation of rhodopsin [74, 75].
Additional support for movement of TM3 and TM6 in the β2AR comes from zinc crosslinking studies [76] and chemical reactivity measurements in constitutively active β2AR
mutants [77, 78]. Cysteine cross-linking studies in the muscarinic acetylcholine M3
receptor provided evidence for the movement of the cytoplasmic ends of TM5 and TM6.
These results indicated that there are intermolecular interactions allowing the receptor to
undergo conversion between its inactive and active state.

12

Figure 1: A model for the structure of inactive rhodopsin (dark) and lightdependent changes (activated) in the relative positions. Figure adapted from Farrens
et al. [73].
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There are currently two widely accepted models for GPCR activation. One of
these models is the extended ternary complex model (often referred to simply as twostate model) [79]. According to this model the receptor exists in an equilibrium between
an inactive conformation (R) and an active conformation (R*). In the absence of agonist,
the inactive R state is predominant; however, the energy required to convert R to R* is
sufficiently low, allowing a certain fraction of the receptors spontaneously to assume the
R* state. In 1994, it was demonstrated that a G protein coupled receptor can be
spontaneously active in the absence of agonists and that ligands, which were previously
considered as neutral antagonists, can act as inverse agonist by inhibiting spontaneous
activity[80]. This concept, originally demonstrated for the β2AR, was then extended to
many GPCRs including the 5-HT2c serotonin [81], δ-pioid [82] and V2-vasopressin
receptors [83]. In fact, spontaneous activity and inverse agonism are now considered to
be general properties of GPCRs that may have physiological implications (reviewed in:
[84] and [85]). These observations were rationalized by proposing that receptors
spontaneously isomerize between inactive (R) and active (R*) conformations and that
inverse agonists and agonists function by stabilizing R and R*, respectively. Agonists are
predicted to bind with highest affinity to the R* conformation and in this way shift the
equilibrium and increase the ratio of receptor in R* (conformational selection). On the
other hand, inverse agonists (also called negative antagonists) have higher affinity to the
R state, thus bind and stabilize the inactive state shifting the equilibrium away from R*.
Neutral antagonists, according to this model, are defined as compounds that bind with the
same affinity to both R and R* thus cause no change in the equilibrium. This model can
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explain the basal activity of GPCRs in the absence of agonist and the action of inverse
agonists that inhibit the activity of constitutively-activated receptors.
The second model for GPCR activation is called multi-state model and suggests
that the receptor alternates spontaneously between multiple active and inactive
conformations [86]. This model is becoming more popular due to the limitations of the
two-state model to explain the complex behavior of GPCRs. Several experiments have
provided strong support that GPCRs may exist in multiple conformational states. For
example, a two-state model cannot explain how mutation of certain residues of the
dopamine D2 receptor can lead to loss of functional coupling in response to some
agonists, but only had modest effect on the others [87]. Likewise, different
constitutively-active mutants of the α1b-receptor are differentially phosphorylated and
internalized although they express a similar agonist-independent activity to the receptor,
which suggests the existence of more then one active receptor state [88]. Furthermore,
direct structural evidence has been obtained by fluorescence spectroscopy analysis of the
purified β2AR[89]. This study indicated that most ligands promote alterations in receptor
structure consistent with the existence of multiple ligand specific conformation states.
The most critical point in this model is that the biological response to a given ligand is
determined by the conformation to which the ligand binds with highest affinity. Thus this
model is considered as an extension of conformational selection in which ligand binding
depends on the conformational status of receptor. However, there is evidence suggesting
that ligand might have an active role of inducing conformational changes in the receptor
([90-92] for review see [93]).
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It has been recently shown that norepinephrine binds to the β2AR in a sequential
manner and can induce at least two kinetically and functionally distinct conformational
states [94]. Similarly studies on µ-opioid receptor demonstrates that different ligands
induce distinct conformational states that differ in promoting G protein activation and
receptor internalization [95]. Time-resolved peptide binding studies on the neurokinin
receptor revealed that an agonist peptide binds with biphasic kinetics. The rapid binding
component was associated with a cellular calcium response, whereas the slow component
was required for cAMP signaling [96]. More recently it has been shown that compounds
which act as inverse agonists on the β-adrenergic-stimulated adenylyl cyclase pathway
are partial agonists for the receptor-stimulated MAP-kinase activity [83]. These data,
which support a multi-state model of receptor activation, indicate that different receptor
conformations lead to the activation of distinct signaling pathways and that ligands can
selectively activate one while inhibiting the other. Thus, it is likely that a single agonist
can induce or stabilize multiple functionally distinct conformational states will be
generalizable to other GPCRs, particularly those activated by peptides and protein
hormones where there are a larger number of sites of interaction between receptor and
agonist. A better understanding of this conformational heterogeneity will facilitate the
design of more effective and selective pharmaceuticals.
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CHAPTER 2
α-factor Pheromone and its G Protein-coupled Receptor (Ste2p) in
Saccharomyces cerevisiae

One of the biggest challenges facing GPCR research is the complexity of
eukaryotic systems. The presence of receptor subtypes, known and unknown, within the
same biological system and cross-talk between different types of receptors regulating
many different pathways complicate biochemical and physiological studies. S. cerevisiae
is a species of budding yeast which is most widely known to mankind both for its use
since ancient times in baking and brewing, and for being one of the most intensively
studied eukaryotic model organisms in molecular and cell biology. The simplicity of
single-celled yeast and widely studied mitogen-activated protein kinase (MAPK) system
regulated by the mating pathway made it a perfect model system for the study of GPCRs.
After the completion of the sequencing of its genome it is now known that S. cerevisiae
has only three GPCRs. Two of these are the pheromone receptors (either Ste2p or Ste3p)
and the other is the Gpr1p which is a carbohydrate sensor. While the pheromone and
carbohydrate-sensing pathways share some down-stream components, there is no crosstalk between the two systems as the pheromone receptors and the Gpr1p couple to two
different G-proteins (Gpa1p and Gpa2p, respectively) [97, 98]. Thus S. cerevisiae
provides an ideal system to study the relation between a peptide ligand and its GPCR in
the absence of interfering biological complexities.
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Mating in yeast, Saccharomyces cerevisiae:
S. cerevisiae, commonly referred to as Brewer’s or Baker’s yeast, can grow as a
haploid or diploid [99, 100]. Haploid cells exist in two mating cell types MATa and
MATα. The secretion and reciprocal detection of peptide pheromones (α-factor and afactor) by GPCRs (Ste2p and Ste3p, respectively) initiate mating and eventual fusion of
two haploids. a-cells secrete a-factor, a hydrophobic farnesylated, carboxymethylated,
dodecapeptide with the sequence YIIKGVFWDPAC(Farnesyl)-OCH3 while α-cells
secrete α-factor, a tridecapeptide with the sequence WHWLQLKPGQPMY (see Figure 2
for schematic representation).
Pheromone binding to its GPCR and activation of the G protein induces initiation
of the downstream MAPK cascade which, in turn, activates the transcription of genes
involved in the production of pheromone itself, pheromone receptor and the proteins of
the signaling pathway. Also components mediating cellular adhesion (sex-specific
agglutinins), arresting the cell cycle in the G1 phase by eliminating the function of G1
cyclin complex and Cdc28 protein kinase, inducing cell and nuclear fusion and also genes
reducing the reactivity of the cell to pheromone and those releasing the cell cycle arrest
(desensitization) are activated [101, 102] (Figure 3). The activation of cells by
pheromone results in morphological changes. First, conjugation projections are formed to
facilitate connection of the cells. By the action of agglutinins, the tips of the projections
fuse forming a conjugation bridge. Next, the nuclei migrate into the bridge and
subsequently fuse to produce a diploid nucleus of the zygote. All these morphological
processes occur with an involvement of cytoskeletal components, i.e., microtubules and
actin structures, and the cell wall [103].
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MAT a

Figure 2: Pheromone mediated mating in Saccharomyces cerevisiae. Schematic representation of pheromone/receptor mediated
communication between MATa and MATα haploid cells prior to mating.
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Figure 3: Saccharomyces cerevisiae mating pathway. Binding of the pheromone to its
GPCR stimulates downstream responses such as transcriptional activation of pheromone
induced genes, cell cycle arrest, and polarization of the cytoskeleton. (Adapted from
Madden and Snyder [103]). Ste5p is the scaffold protein, Ste20p is mitogen-activated
quadruple protein kinase (MKKKK), Ste11p is MKKK, Ste7p is MKK, Fus3p and Kss1p
are MAPK.
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Structure-function analysis of α-factor pheromone:
The α-factor is a tridecapeptide secreted by MATα cells and has the sequence of
WHWLQLKPGQPMY. Extensive analyses of α-factor analogs in combination with
receptor mutagenesis have provided insights into the structural basis of α-factor activity
[104-108]. These studies aided the discovery of several antagonists, partial agonists and a
ligand with novel function which is able to enhance the activity of α-factor but, alone,
has no agonistic activity termed a synergist. Additionally biochemical and biophysical
analysis of α-factor and its analogs have suggested structural and functional information.
Briefly the results of these studies indicated that residues near the amino terminus play an
important role in receptor activation, the carboxyl terminus of the peptide contributes
mostly to the binding affinity and the central residues of the peptide form a β-turn around
the Pro8-Gly9 bound aiding the orientation of the signaling and the binding domains of
the pheromone (Figure 4) [109-111].
Several of the D-Ala series analogs, near the N-terminus, specifically [D-Ala2]αfactor, [D-Ala3]α-factor and [D-Ala4]α-factor had no measurable biological activity
[107]. However, these peptides bound relatively strongly to Ste2p and antagonized the
biological activity of wild type ligand (α-factor pheromone). Previous studies from our
laboratory showed that most of the antagonists discovered involved changes in residues
near the amine terminus. Based on these findings it seems clear that residues near this
region play an important role in triggering cell signaling through Ste2p or in stabilizing
the activated state of this receptor.
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Figure 4: Functional domains of α-factor ligand. Studies of α-factor analogs have
revealed two regions according to their major contributions to activity and binding
affinity. The residues at the N-terminus appeared to mainly function in activation of the
receptor signaling, the residues at the C-terminus strongly contribute to the binding
affinity. However the two functions cannot be completely separated. The loop domain
corresponds to residues of the peptide which are thought to induce a bend in the ligand
structure. (Figure adapted from Abel et al. [107])
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On the other hand the residues at the carboxyl terminus of α-factor strongly
influence the binding. Replacement of these residues by either L- or D-Ala caused
decreases in affinity of up to 3000-fold [107]. Moreover, these carboxy-terminal residues
are not sufficient to cause signaling as evidenced by the total absence of agonist activity
in [D-Ala3]α-factor. Removal of the carboxyl terminal residues result in pheromones
with drastically reduced receptor affinity and, in some cases, also with complete loss of
affinity. Similar observations for other peptide receptors, where the functional domains
for binding and activity are separated, have been reported [112-115].
As mentioned above, the central residues of α-factor contains a Pro-Gly sequence.
This sequence has been associated with a high probability of β-turns, in particular Type II
β-turns [116, 117]. Studies on desTrp1-α-factor analogs indicated that a turn at this
position was involved in biological activity of the pheromone [118]. Additional studies
with L- or D-Ala α-factor analogs suggested that this region of the peptide may lead to
create the proper overall conformation for the pheromone [107].

Interactions between α-factor pheromone and its GPCR, Ste2p:
The yeast α-factor pheromone receptor is one of the most extensively studied
GPCRs. While many techniques have been applied to study the structure-function
relationship for this receptor, much of our knowledge comes from the characterization of
mutant receptors and α-factor analogs. Today several research groups (5 in the United
States) are working with Ste2p as a model system. Mutagenesis studies carried out by
these groups cover almost 70-80% of all the residues present in this 431 amino acid
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receptor. Although it is not possible to summarize all of these mutational analyses in the
context of this dissertation, studies relevant to our results will be discussed in parts 2 & 3.
In addition to the mutagenesis studies, chimeric receptors between S. cerevisiae
and S. kluyveri α-factor receptors also supplied important information to understand the
ligand receptor interaction(s) [119, 120]. These studies helped the identification of three
small regions that are mostly contributing to the specificity of the two receptors to their
wild type ligands. A substitution at residues 47-49 (region of N-terminus connected to
TM1) affected specificity for pheromone binding but not for pheromone activation of
response. Substitution of residues 267-269 (extracellular portion of TM6) affected
pheromone specificity for activation of cellular responses, but not for pheromone
binding. Finally substitution of residues 104-123 (part of EL1 attached to TM2) modestly
affected both types of specificity.

Regulation of Ste2p in Saccharomyces cerevisiae:
The coordination of complex cellular processes, from growth and differentiation
to responses of environmental changes, often depend on careful regulation of GPCRs.
Like many other GPCRs, Ste2p is highly regulated by several control mechanisms. The
most well characterized regulation of Ste2p are: rapid phosphorylation and
desensitization [121]; internalization and recycling [122]; and down-regulation and
degradation [123, 124]. GPCRs often become less responsive (desensitize) after
prolonged agonist exposure. In many eukaryotic systems a highly conserved mechanism
involving multiple protein-protein interactions, receptor phosphorylation [by G-protein
coupled receptor kinases (GRKs)] and receptor endocytosis (internalization) is
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responsible for this desensitization [125]. Phosphorylation by GRKs and trafficking
events are usually associated with acute desensitization as the immediate occurrence of
these events coincides with the rapid desensitization observed with most receptors. On
the other hand receptor down-regulation results in an overall reduction in receptor levels
in the cell, which usually has a longer term effect on signaling [126].
The mating process in yeast is further regulated by the control of the expression
levels or the activities of the downstream elements in the signaling pathway (i.e. subunits
of the G protein or/and MAPK). One of the well characterized regulators is Sst2p, a yeast
homologue of regulators of G protein signaling (RGS), which effect the G protein
signaling by accelerating the GTP hydrolysis and promoting re-association of the
heterotrimer [127, 128]. Additionally, expression of some proteases like Bar1p (Sst1p),
which specifically cleaves α-factor pheromone, adds further complexity to the regulation
of mating [129]. Furthermore, several different types of post-translational modifications
have been described for the heterotrimeric G protein subunits, which may be involved in
signal regulation. Details of these modifications are beyond the scope of this study,
however a few of the well characterized modifications are: 1) palmitoylation [130],
myristoylation [131, 132] and ubiquitination of the Gα (Gpa1p) [133]; 2) isoprenylation
[134], farnesylation [135] and palmitoylation of the Gγ (Ste18p) [136]; and 3)
phosphorylation of the Gβ (Ste4p) [137].
Although the S. cerevisiae mating signal transduction pathway is one of the best
defined MAPK pathways, the mechanism that triggers this pathway is poorly understood.
The lack of information how the peptide pheromone interacts with its GPCR and causes
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conformational changes leading to the dissociation of the G protein limits our
understanding of α-factor receptor activation. Mapping the α-factor binding region(s) in
Ste2p could supply great insights for understanding the overall mechanism of GPCR
activation by peptide ligands. This dissertation mainly describes the use of novel α-factor
ligand analogs as tools and probes to study receptor binding and activation. Parts II and
III detail the construction, characterization and use of α-factor probes that contain the
photo-cross-linkable group, 4-benzoyl-L-phenylalanine (Bpa), for use in determining
ligand-receptor contact sites. Part III also introduces the use of biotin for detection of the
ligand as an alternative to radioactive ligand. Part IV describes the methods applied for
cross-linked sample preparation for mass spectrometry (MS) analysis. This part also
covers some of the preliminary MS results that support our findings presented in part II
and III. Finally part IV is an overall evaluation of these studies, contributions to the
working model of α-factor-Ste2p interaction and future studies that could be performed
to refine this model, thus aiding us to better understand how peptide ligands interact with
their GPCRs.
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CHAPTER 1
Introduction

G protein-coupled receptors (GPCRs) comprise one of the largest super-families
of proteins with over 1000 members represented in the human genome alone [1, 2]. One
of the key steps in understanding the mechanisms of action of these diverse GPCRs is to
elucidate the structure of their ligand binding sites. With this information in hand, the
mechanism of activation of the GPCR can begin to be understood.
While there has been considerable data published on the GPCR ligand binding
sites for biogenic amines (see [3] for a review), much less information exists concerning
the binding sites of peptide-responsive GPCRs. Recently, several reports have addressed
this issue with the use of 4-benzoyl-L-phenylalanine (Bpa) photoreactive chemical groups
[4-10]. Incorporation of Bpa into the first position of parathyroid hormone (PTH) and its
use as a cross-linkable probe resulted in evidence that the N-terminal residue of PTH
interacts with the extracellular end of transmembrane helix 6 of its receptor PTH1-Rc
[11]. A recent study by Mouledous et al. [8] investigating the interaction between the
heptadecapeptide nociceptin and the opioid receptor-like (ORL1) GPCR made use of
[Bpa10, Tyr14]nociceptin and found that the photoactivatable Bpa moiety cross-linked to a
six amino acid fragment (amino acids 296-302). These studies and others using Bpacontaining peptides have allowed for the identification of interacting receptor fragments
and in some cases even specific contact residues [5-7, 9]. Identification of these crosslinked receptor fragments is a first but critical step in the elucidation of direct residue to
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residue contacts between ligand and receptor and has the potential to provide significant
insight into the mechanism of activation of GPCRs by peptide ligands.
GPCRs can bind a variety of molecules including biogenic amines, peptides, and
sugars. The unicellular yeast Saccharomyces cerevisiae contains two GPCRs used by
haploid cells in the detection and response to peptide pheromones secreted by cells of the
opposite mating type during sexual reproduction (see [12, 13]for reviews). One of these
receptors, Ste2p, responds to the α-factor peptide pheromone (WHWLQLKPGQPMY)
while the other receptor, Ste3p, responds to the post-translationally modified a-factor
peptide (YIIKGVFWDPAC[S-farnesyl]-OCH3).
The study of the pheromone receptors in S. cerevisiae has led to many critical
findings concerning the biology of GPCRs, such as the discovery of the Regulator of Gprotein Signaling (RGS) family of proteins [14, 15]. Additionally, Ste2p serves as a
model protein for the study of GPCRs, as (i) its transmembrane domains (TMDs) appear
to be arranged similarly to those of other GPCRs, (ii) interactions between the fifth and
sixth transmembrane domains appear to be critical for proper signal transduction to the G
protein, and (iii) close packing of the fifth and sixth TMDs appears to be structurally
similar to that of rhodopsin [16]. All of these factors suggest that while most GPCRs do
not share sequence homology, they do have strong structural and functional similarities.
Therefore, elucidation of contact residues between receptor and ligand should provide
insight into structure-function relationships in binding and activation of peptideresponsive GPCRs.
Part II of this dissertation describes the synthesis, the chemical, and biochemical
characterization of iodinatable Bpa-containing α-factor analogs. One of the analogs,
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[Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor, was specifically cross-linked into the α-factor
binding pocket of Ste2p and used to determine direct contacts between the pheromone
and the receptor. Biochemical analysis localized the cross-link site within residues 251294 of the Ste2p receptor.
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CHAPTER 2
Materials and Methods

Organisms:
S. cerevisiae DK102 [MATa ste2::HIS3 bar1 leu2 ura3 lys2 ade2 his3 trp1]
transformed with pNED1[STE2] [17] was used in binding studies and in the growth arrest
assays of various α-factor analogs. Strain LM23-3AZ [MATa FUS1::lacZ bar1-1] from
Lorraine Marsh, Albert Einstein College of Medicine, New York, NY, was used in
FUS1-lacZ gene induction assays. Strain BJ2168 [MATa prc1-407 prb1-1122 pep4-3
leu2 trp1 ura3-52] transformed with pNED1[STE2] [17] and BJS21 [MATa ste2::kanR
prc1-407 prb1-1122 pep4-3 leu2 trp1 ura3-52] transformed with pJL147 [STE2-T7] were
used in cross-linking assays. Strain BJS21 was constructed by deleting STE2 from strain
BJ2168 using the kanamycin deletion cassette. pJL147 (a gift from J. Konopka, [16])
encoded Ste2p containing the T7 epitope (Met-Ala-Ser-Met-Thr-Gly-Gly-Gln-Gln-MetGly) introduced between Ste2p residues 303 and 304. All strains used had similar binding
of α-factor. However, the BJ2168pNED and BJS21 strains lacked several peptidases, so
they were used to increase the yield of Ste2p in experiments involving cross-linking.

Chemical Reagents:
All reagents and solvents used for the solid-phase peptide synthesis of the
photoactivatable peptides were analytical grade and were purchased from Advanced
Chem Tech (Louisville, KY), VWR Scientific (Piscataway, NJ), or Aldrich Chemical Co.
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(Milwaukee, WI). High-performance liquid chromatography (HPLC) grade
dichloromethane (CH2Cl2), acetonitrile (ACN), methanol (MeOH), and water were
purchased from VWR Scientific and Fisher Scientific (Springfield, NJ).

Synthesis of Bpa-Containing [Nle12]α-Factor Analogs:
Automated syntheses were carried out on an Applied Biosystem 433A peptide
synthesizer (Applied Biosystem, Foster City, CA) using preloaded Wang resins (0.70
mmol/g, Advanced ChemTech) for most of the peptides. Two series of peptides were
synthesized. In the first series, 4-benzoyl-L-phenylalanine (Bpa) was systematically used
to replace the wild-type residue in all positions of the tridecapeptide except for Gly9. The
latter residue was not replaced because previous studies had concluded that substitution
of Gly9 by an L-residue results in a marked decrease in activity and affinity [18, 19]. In
the second series of peptides, Tyr13 was replaced by Phe, Bpa was substituted at either
position 1, 3, or 5, and a Tyr residue was substituted at either position 1 or 3. The goal of
the second series of analogs was to prepare a photo-cross-linkable peptide which could
also be followed by autoradiography. In most peptides, L-norleucine (Nle), which is
isosteric with L-methionine, was incorporated at position 12 to replace the naturally
occurring L-methionine to prevent oxidation of the sulfur atom of this amino acid during
peptide synthesis and purification. Replacement of Met by Nle was shown previously to
result in an analogue with equal activity and receptor affinity to those of the native
pheromone [20]. Since all analogs have Nle in place of Met12, this residue is eliminated
from the abbreviated names for simplicity. The 0.1 mmol FastMoc chemistry of Applied
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Biosystems was used for the elongation of the peptide chain with an HBTU/HOBt/DIEAcatalyzed, single coupling step using 10 equiv of protected amino acids for 30 min.

Cleavage of Peptide:
The N-α-deprotected peptidyl resin was washed thoroughly with 1-methyl-2pyrrolidinone and dichloromethane and dried in vacuum for 2 h. The peptide was cleaved
from the resin support with simultaneous side chain deprotection using a cleavage
cocktail containing trifluoroacetic acid (10 mL), crystalline phenol (0.75 g), thioanisole
(0.5 mL), and water (0.5 mL) at room temperature for 1.5 h with the omission of 1,2ethanedithiol in the cleavage reaction, because it was known to transform Bpa-containing
peptides to cyclic dithioketal derivatives [21]. The filtrates from the cleavage reaction
were collected, combined with trifluoroacetic acid washes of the resin, concentrated
under reduced pressure, and treated with cold ether to precipitate the crude product.

Purification and Characterization:
The crude peptide so obtained was purified by reversed phase HPLC (HewlettPackard Series 1050) on a semipreparative Waters µ-Bondapack C18 (19 × 300 mm)
column with detection at 220 nm. The crude product (50 mg) was dissolved in about 4
mL of aqueous acetonitrile (20%) containing 0.025% TFA, applied to the column, and
eluted with a linear gradient of water/acetonitrile containing 0.025% TFA (0-70%
acetonitrile over 2 h at a flow rate of 5 mL/min). The fractions were collected and
analyzed at 220 nm by reversed phase HPLC (Hewlett-Packard Series 1050) on an
analytical Waters µ-Bondapack C18 (3.9 × 300 mm) column. Fractions of over 99%
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homogeneity were pooled and subjected to lyophilization. The purity of the final peptide
was assessed by analytical HPLC using two different solvent systems (10-55%
acetonitrile gradient, 15 min, with 0.025% trifluoroacetic acid; and 50-80% methanol
gradient, 30 min, with 0.025% trifluoroacetic acid), amino acid analysis (Biopolymer lab,
Brigham and Women's Hospital, Cambridge, MA), and electrospray ionization mass
spectrometry (ESI-MS Peptido Genic Inc., Livermore, CA).

Growth Arrest (Halo) Assay:
Solid MLT medium [yeast nitrogen base without amino acids (Difco), 6.7 g/L;
casamino acids (Difco), 10 g/L; glucose, 20 g/L; adenine sulfate, 0.058 g/L; arginine,
0.026 g/L; asparagine, 0.058 g/L; aspartic acid, 0.14 g/L; glutamic acid, 0.14 g/L;
histidine, 0.028 g/L; isoleucine, 0.058 g/L; leucine, 0.083 g/L; lysine, 0.042 g/L;
methionine, 0.028 g/L; phenylalanine, 0.69 g/L; serine, 0.52 g/L; threonine, 0.28 g/L;
tyrosine, 0.042 g/L; valine, 0.21 g/L; and uracil, 0.028 g/L] [11] was overlaid with 4 mL
of S. cerevisiae DK102pNED cell suspension (2.5 × 105 cells/mL of Nobel agar). Filter
disks (sterile blanks from Difco), 8 mm in diameter, were impregnated with 10 µL
portions of peptide solutions at various concentrations and placed onto the overlay. The
plates were incubated at 30 ˚C for 24-36 h and then observed for clear zones (halos)
around the disks. The data were expressed as the diameter of the halo including the
diameter of the disk. A minimum value for growth arrest is 9 mm, which represents the
disk diameter (8 mm) and a small zone of inhibition. All assays were carried out at least 3
times with no more than a 2 mm variation in halo size at a particular amount applied for
each peptide. The values reported represent the mean of these tests.
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Effect of α-Factor Analogs on Gene Induction:
S. cerevisiae LM23-3AZ carries a FUS1 gene that is inducible by mating
pheromone and which is fused to the reporter gene β-galactosidase. Cells were grown
overnight in MLT at 30 ˚C to 5 × 106 cells/mL, washed by centrifugation, and grown for
one doubling at 30 ˚C. Induction was performed by adding 15 µL of peptide at various
concentrations to 135 µL of concentrated cells (2 × 108 cells/mL) in a 96 well microtiter
plate. The mixtures were placed at 30 ˚C with shaking for 2 h. After this time, cells were
harvested by centrifugation, and each pellet was resuspended in Z-Buffer containing βmercaptoethanol [22] and assayed for β-galactosidase production (expressed as Miller
units) in triplicate. Each experiment was carried out at least 3 times with the results
similar in each assay. As cells were suspended in liquid medium, any contribution of
diffusion through agar potentially present in the halo assay was eliminated in the gene
induction assay.

Binding Competition Assay with [3H]α-Factor:
This assay was performed using strain DK102pNED and tritiated α-factor
prepared by reduction of [dehydroproline8, Nle12]α-factor as described previously [20].
In general, cells were grown at 30 ˚C overnight and harvested at 1 × 107 cells/mL by
centrifugation at 5000g at 4 ˚C. The pelleted cells were washed 2 times in ice-cold buffer
[PPBi: 0.5 M potassium phosphate (pH 6.24) containing 10 mM TAME, 10 mM sodium
azide, 10 mM potassium fluoride, 1% BSA (fraction IV)] and resuspended to 4 × 107
cells/mL. The binding assay was started by addition of [3H]α-factor and various
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concentrations of nonlabeled peptide (140 µL) to a 560 µL cell suspension so that the
final concentration of radioactive peptide was 6 × 10-9 M (20 Ci/mmol). Analogue
concentrations were adjusted using UV absorption at 280 nm and the corresponding
extinction coefficients. After 30 min incubation, triplicate samples of 200 µL were
filtered and washed over glass fiber filtermats using the Standard Cell Harvester (Skatron
Instruments, Sterling, VA) and placed in scintillation vials for counting. Each experiment
was carried out at least 3 times with the results similar in each assay. Binding of labeled
α-factor to filters in the absence of cells was less than 20 cpm. The Ki values were
calculated by using the equation of Cheng and Prusoff, where Ki = EC50/(1 + [ligand]/Kd)
[23].

Synthesis of Iodinated α-Factor Peptides:
Peptides were iodinated with Iodogen tubes from Pierce, Inc., using conditions
recommended by the manufacturer. Briefly, Iodogen tubes were pre-wet with 2× Tris
Iodination Buffer (TIB: 50 mM Tris, pH 7.5, 0.8 M NaCl). The TIB was decanted, 100
µL of fresh TIB was added directly to the bottom of the Iodogen tube, and either 10 µL
of Na127I (1.86 mg/mL) or 10 µL of Na125I (100 µCi/µL, pH 10, ICN) was added and
incubated for 15 min with gentle swirling every 30 s. Activated iodide was transferred to
a siliconized microfuge tube containing 100 µL of the peptide (0.5 mmol/L in TIB) and
incubated for 20 min with gentle mixing every 30 sec. Scavenging buffer (50 µL at 10
mg/mL tyrosine in TIB) was added and incubated for 5 min with mixing at minutes 1 and
4. Following incubation, 1 mL of TIB containing 5 mM EDTA was added. The
remaining unreacted iodine was separated from peptide using a Waters Sep-Pak C18
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minicolumn. The eluted products were separated by HPLC using water/acetonitrile/
0.025% TFA with an acetonitrile percentage of 20-35% over 30 min at 1.4 mL/min on a
Waters µBondapak C18 reversed phase analytical column (3.9 × 300 mm). 127I-labeled
peptides were quantitated by UV spectrophotometry using their extinction coefficients.
Radioiodinated peptides were labeled using carrier-free Na125I, and the resulting
monoiodinated peptides were quantitated by converting total dpm associated with the
HPLC-purified peptide to millimoles of peptide using the specific activity of carrier-free
Na125I (2159 Ci/mmol).

Synthesis of [Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-Factor:
This analogue was synthesized by first adding Boc-β-alanine hydroxysuccinimide
ester and then hydroxysuccinimido biotin ester to [α-Fmoc-Bpa1]α-factor that had been
prepared by solid-phase peptide synthesis. After removal of all protecting groups, the
final peptide was purified to near-homogeneity by reversed phase HPLC. Its molecular
weight was determined by electron spray mass spectrometry to be 2028.0 (theoretical =
2028.35). This compound was a full agonist in the growth arrest assay and exhibited a
binding affinity close to that of α-factor.

Binding Assays with 125I-Labeled α-Factor:
DK102 pNED1 cells (grown in MLT medium) [17] and DK102 cells (grown in
MLT medium supplemented with tryptophan) were harvested at 1 × 107 cells/mL by
centrifugation and resuspended to 6.25 × 107 cells/mL in PPBi buffer (pH 6.24) and
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placed at 4 ˚C. In competition binding assays, [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor (2.4
× 10-9 M final concentration) was premixed with various concentrations of cold
competitor. In saturation binding assays, radiolabeled α-factor analogs were diluted with
cold analogue to obtain the peptide concentrations used in the assay. Cells in PPBi were
then added to peptide solutions to a final density of 6.25 × 106 cells/mL and incubated for
45 min at room temperature. Following incubation, the suspension was transferred (3 ×
200 µL) to wells of a 0.45 µm MultiScreen-HV, 96 well plate (Millipore MHVBN4510)
preblocked with PPBi. Samples were vacuum-filtered, washed with PPBi (2 × 200 µL),
and counted on an LKB-Wallac CliniGamma 1272 gamma counter. Using this
methodology, nonspecific binding of radiolabeled peptide to the filter was at background
levels. Specific binding was determined by subtracting counts associated with the DK102
(ste2) strain from counts bound to the DK102pNED1 (STE2) strain.

Cross-Linking of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-Factor to Ste2p:
BJ2168pNED1 membranes (220 µg of protein) [17] were incubated with 975 µL
of PPBi buffer (with 0.1%BSA) in siliconized microfuge tubes for 10 min at ambient
temperature. [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor (10 and 20 million cpm) was added,
and the reaction was incubated for 2 h at room temperature with gentle mixing. The
reaction mixture was aliquoted into 3 wells of a chilled 24 well plastic culture plate
preblocked with PPBi (0.1% BSA). Separation of the reaction mixtures into separate
wells kept the depth of the samples minimal (~2 mm) for efficient UV penetration of the
sample. The samples were held at 4 ˚C and irradiated without the culture plate lid at 365
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nm for 1 h at a distance of 12 cm in a Stratlinker (Stratagene, La Jolla, CA). Membrane
samples were recombined in siliconized microfuge tubes and washed twice by
centrifugation (14000g) with PPBi (0.1% BSA). Membrane pellets were dissolved in 2 ×
sample buffer (0.25 M Tris-HCl, pH 8.8, 0.005% bromphenol blue, 5% glycerol, 1.25%
β-mercaptoethanol, 2% SDS). Samples were heated to 37 ˚C for 10 min and separated by
SDS-PAGE (10% gel; 30 mA). In competition cross-linking experiments, cold α-factor
was added together with radioiodinated peptide. For subsequent receptor digestion
analysis, the gel was exposed to a phosphorimager screen (STORM, Molecular
Dynamics), and the band of radioactivity corresponding to Ste2p was excised and placed
into dialysis tubing (15 000 molecular weight cutoff) with buffer (0.2 M Tris-acetate, pH
7.4, 1.0% SDS, 100 mM dithiothreitol). Electroelution was performed by placing dialysis
tubing containing the gel in a horizontal electrophoresis chamber with running buffer (50
mM Tris-acetate, pH 7.4, 0.1% SDS, 0.5 mM sodium thiogylcolate). Elution was carried
out at 100 V for 3 h. The buffer in the dialysis tubing was transferred to a Millipore
Ultrafree-15 centrifuge filter device (30 000 molecular weight cutoff) and concentrated
by centrifugation. Concentrated sample was washed 3 times with 50 mM Tris-HCl, pH
7.5. Half of the sample was further treated with PNGaseF (Glyco) according to the
supplier's instructions.

Digestion of Cross-Linked Ste2p:
Cross-linked samples were digested with BNPS-skatole, CNBr, or trypsin. For
BNPS-skatole digestions, samples were dissolved in 70% acetic acid, and approximately
10 mg of BNPS-skatole was added. For CNBr digestion, samples were dissolved in 70%
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formic acid, and a few crystals of CNBr were added. For trypsin digestion, samples were
dissolved in trypsin digestion buffer (Promega), and 20 µg of trypsin (Sequencing Grade
modified trypsin, Promega) was added. All digestion reactions took place under nitrogen
and complete darkness. After digestion, samples were dried by vacuum centrifugation,
resuspended in 50 µL of 0.5 M Tris, pH 8.25, and re-dried. BNPS-skatole and CNBr
samples were then dissolved in Tris-tricine sample buffer from Novex (San Diego, CA)
and run on 16% and 10-20% tricine gels (Novex). Trypsin-digested samples were
dissolved in loading buffer (Invitrogen) and run on 12% Bis-tris gels with MES running
buffer (Invitrogen). Gels were dried and exposed to a phosphorimager screen for 1-4
days.

Cross-Linking of Biotinylated α-Factor to Ste2p-T7:
[Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-factor was used in cross-linking studies with
strain BJS21-pJL147 membranes. Receptors cross-linked with the biotinylated probe as
described above were digested with trypsin for 18 h with addition of fresh trypsin after 12
h at 30 ˚C. Digested samples were run on two separate gels (18% SDS-PAGE),
transferred to Immobilon-P, and blocked with 5% milk-TBS for 1 h. One blot was probed
with NeurtAvidin-HRP (Pierce Chemical) and detected with Western Lightning
Chemiluminescence Reagent plus (WLCR+, PerkinElmer). The second blot was probed
with T7-HRP antibody (Novagen) according to manufacturer's instructions, and detected
by WLCR+.
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CHAPTER 3
Results

Synthesis of α-Factor Analogs:
The automated solid-phase synthesis of most of the α-factor analogs yielded
crude peptides which were 60-70% homogeneous. Lower purities (<50%) were observed
with the peptides containing diiodoTyr. In previous studies, we obtained better
incorporation of diiodotyrosine into α-factor when arginine replaced lysine in the seventh
position [24, 25]. Therefore, all α-factor analogs synthesized in this investigation
contained Arg7. [Arg7]α-Factor was previously shown to have the same activity and
binding affinity as α-factor [20]. The crude peptides were all purified by reversed phase
HPLC to over 99% homogeneity based on analytical HPLC in both an
acetonitrile/water/TFA and a methanol/water/TFA gradient system. All peptides were
subjected to amino acid analysis and electrospray ionization mass spectrometry.
Physicochemical data for peptides containing both Bpa and Tyr substitutions are
summarized in Table 1. Similar characterization of the series containing only the Bpa
substitution was also carried out (data not shown). Amino acid analysis and mass
spectrometry verified the purity and composition of the synthetic α-factor analogs used in
this study.
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Table 1: Physicochemical properties of photo activatable peptides

a

Calculated monoisotopic molecular weight.

b

Molecular mass determined using electron ionization mass spectroscopy (ESI-MS).

c

K is defined as (Vp - Vf)/Vf where Vp = the elution volume for the peptide and Vf = the breakthrough volume.

K-values (a) were determined on a C18 µ-Bondpack column using a 10-55% acetonitrile gradient (0.025% trifluoroacetic
acid) over 15 min and (b) were determined using 50-80% methanol gradient (0.025% trifluoroacetic acid) over 30 min.
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Receptor Affinities of Bpa-Scanned α-Factor Analogs:
To attain efficient cross-linking of a ligand into a receptor binding site, it is
necessary to employ ligands that bind tightly to the receptor. To ascertain the positions at
which Bpa replacements would be tolerated, introduction of this residue throughout the
peptide backbone was tested. As seen in Figure 1, Bpa replacements at positions 1 (Trp),
3 (Trp), 5 (Gln), 7 (Lys), 8 (Pro), 12 (Met), and 13 (Tyr) were well tolerated, exhibiting
decreases in Ki from 4-fold to 45-fold in comparison to α-factor (Figure 1). In contrast,
substitutions at positions 2, 4, 6, 10, and 11 resulted in 100-fold to greater than 1500-fold
decreases in affinity. Based on these data and our working model for pheromone binding
to receptor [26], analogs with Bpa at positions 1, 3, 5, and 13 were chosen for further
evaluation as photo-cross-linkable α-factors.

Bioactivities of Iodinatable Bpa Analogs of α-Factor:
To determine cross-link points between a ligand and its binding protein, tags are
useful to reveal the covalent linkage point of the ligand. The most powerful tag available
in terms of sensitivity is 125I [26, 27]. Previous studies showed that iodination of the Cterminal residue (Tyr13) resulted in biological inactivation of α-factor [28]. Another
report by Masui et al. [29] suggested that Tyr13 in α-factor was essential and could not be
substituted by other amino acids without loss of activity. However, it was recently
demonstrated that Tyr13 was replaceable by Phe with little to no effect on biological
activity or binding affinity of α-factor [25, 30]. Therefore, α-factor analogs [Bpax, Phe13]

62

WT 1

2

3

4

5

6 7 8 10 11 12 13
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Figure 1: Binding affinity of Bpa-substituted α-factor analogs. The binding affinities
of Bpa-scanned α-factor analogs were measured using [3H]α-factor and the binding
competition assay described under Materials and Methods. The figure shows the
calculated Ki (23) for each analogue. The numbers on the abscissa represent the position
of the Bpa replacement. Each measurement was carried out at least 3 times with an error
of not more than 10% for each value shown. The number above each bar represents the Ki
value (×108) of that analogue.
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(where x = 1, 3, or 5) and [Bpa13]α-factor analogs in which Tyr residues were substituted
at other positions were evaluated. Based on the occurrence of Trp in positions 1 and 3 of
the native α-factor structure, analogs 1-8 were synthesized (Table 1).
Growth arrest assays and FUS1 gene induction assays were performed to
determine the biological activity of these analogs (Table 2). Semi-logarithmic plots of
halo diameter versus amount of peptide applied to the disk were all linear and exhibited
similar slopes (data not shown). All analogs used in this assay were stable to enzymatic
cleavage under the conditions tested as strains used in this analysis lacked the Bar1p
protease that cleaves α-factor. Therefore, the growth arrest data were indicative of the
relative agonist activity of each peptide. The data show that peptides containing Bpa1
with either Tyr3 (compound 1) or (I2)Tyr3 (compound 5) retain good agonist activity,
requiring about 2.3-fold and 4-fold more of the pheromone derivative, respectively, to
trigger the receptor. In contrast, tyrosine substituted analogs with Bpa3 (2 and 6), with
Bpa5 (3 and 7), or with Bpa13 (4 and 8) had little or no activity in the growth arrest assay.
In the solution-phase, gene induction assay, compound 1 caused 50% of the maximal
gene induction at only 33% higher concentration than α-factor, and compound 5 required
a 4-fold higher concentration. These results correlated with those of the growth arrest
assay. Several of the peptides that were not active at the highest tested amount (10
µg/disk) in the halo assay were agonists in the gene induction assay. In fact, all four
iodinated compounds (5-8) had comparable activities in this assay. None of the α-factor
analogs
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Table 2: Biological activity of α-factor analogs

a

Peptide
(compound no.)

Growth arresta
(µg of peptide)

FUS1-lacZb induction
potency (nM)

Binding affinity,c
Ki (nM)

α-factor

0.4

3.1

9

Bpa1Y3R7F13 (1)

1.0

4.4

127

Y1Bpa3R7F13 (2)

inactive

149

157

Y1Bpa5R7F13 (3)

>10

184

150

Y1R7Bpa13 (4)

inactive

inactive

132

Bpa1(I2)Y3R7F13 (5)

1.5

14

199

(I2)Y1Bpa3R7F13 (6)

7.3d

19

216

(I2)Y1Bpa5R7F13 (7)

>10

26

22

(I2)Y1R7Bpa13 (8)

inactive

33

315

Values represent micrograms of peptide necessary to produce a halo with a diameter of

15 mm. Each assay was done in duplicate at least 3 times with a standard error of ±0.1.
b

Values represent nanomolar concentration of ligand to give 50% maximal activity in a

FUS1-lacZ gene induction assay. Each assay was done in duplicate 3 times with a
standard error of about 10% for each value shown.
c

Binding affinities were determined by calculation of Ki in competition binding assays

using [(125I)Y1R7F13]α-factor. Each assay was done in duplicate 3 times with a standard
error of about 10% for each value shown.
d

The zone of growth inhibition was partially filled in, giving the halo a fuzzy

appearance.
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induced growth arrest or FUS1-lacZ activation in a mutant lacking Ste2p, confirming that
the α-factor receptor was required for the biological activity of these peptides. Overall,
the bioassays demonstrate that α-factor analogs containing both Bpa and iodotyrosine can
induce Ste2p-dependent signaling.

Binding Affinities of α-Factor Analogs:
Binding affinities of the peptides were determined by competition and saturation
binding assays as described under Materials and Methods. Representative competition
binding data for α-factor, and 1, 3, and 5 are presented in Figure 2. For most analogs,
substitution of Bpa at positions 1, 3, 5, and 13 resulted in only 15-17-fold reduction in
binding affinity versus native α-factor (Table 2). With the exception of [(I2)Tyr1, Bpa5,
Arg7, Phe13]α-factor which showed increased binding, di-iodination of the Bpa analogs
resulted in a slight reduction (1.5-2.4-fold) in binding compared to the noniodinated
peptides.

Iodination and Purification of α-Factor Analogs:
Several of the Bpa-containing analogs were chosen for radioiodination based on
the criteria that they had relatively good biological activity and binding affinities in the
submicromolar range. [Bpa1, Tyr3, Arg7, Phe13]α-Factor, [Tyr1, Bpa5, Arg7, Phe13]αfactor, and [Tyr1, Arg7, Bpa13]α-factor were successfully iodinated, but the iodination of
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[125I]-Y1-R7F13 α-factor Binding (%)

Competitor Concentration (Log)

Figure 2: Competition binding assay of various α-factor analogs vs. [(125I)Tyr1,
Arg7, Phe13]α-factor. Competitors were α-factor (○), compound 1 (▲), compound 5
(∇), and compound 7 (♦).
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[Tyr1, Bpa3, Arg7, Phe13]α-factor led to an unresolvable mixture (Figure 3B). This latter
result was consistent with the recent observation that certain α-factor analogs are
resistant to iodination [25]. As seen in Figure 3A, iodination of [Bpa1, Tyr3, Arg7,
Phe13]α-factor resulted in both the mono- and di-iodinated derivatives. The masses of the
iodinated peptides were verified by electrospray mass spectrometry (data not shown).
Based on the relatively high biological activity of [Bpa1, Tyr3, Arg7, Phe13]α-factor (1)
and its diiodinated homologue (5), the radio-iodinated form of this peptide was chosen
for photolabeling of Ste2p.

Competition of α-Factor for [Bpa1, ( 125I)Tyr3, Arg7, Phe13]α-Factor Binding to Ste2p:
[Bpa1, (125I)Tyr3, Arg7, Phe13]α-Factor was shown to be displaced from Ste2p by
α-factor in a competition binding assay (Figure 4). The amount of bound peptide was
expressed in dpm and plotted against the amount of cold competitor added. The binding
competition was greater than 90%. The shape of the curve is consistent with competitive
binding inhibition, indicating the radioligand is specific for Ste2p. Similar results were
also obtained with [Bpa1, (125I2)Tyr3, Arg7, Phe13]α-factor, the di-iodinated form of this
photoactivatable peptide (data not shown).

Cross-Linking of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-Factor to Ste2p:
Membranes were incubated with [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor, and
cross-linking was carried out using light at 365 nm. A portion (20 µL) of the reaction
mixture was removed following irradiation and tested for incorporation of radioactivity
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mAU 280 nm

A

B

Minutes
Figure 3: HPLC analysis of products from iodination of tyrosine-substituted αfactor analogs. α-Factor analogs were chemically iodinated using Iodogen reagent and
products separated by HPLC. (Panel A) Iodination of [Bpa1, Tyr3, Arg7, Phe13]α-factor: I,
noniodinated peptide; II, mono-iodinated peptide; III, di-iodinated peptide. (Panel B)
Iodination of [Tyr1, Bpa3, Arg7, Phe13]α-factor.

69

Bound Ligand (x 103 DPM)

Log Concentration of Competitor [M]

Figure 4: Competition binding of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor by
nonradiolabeled α-factor. Data were analyzed using a single-site competition binding
equation. Error bars on some points were contained within the symbol and cannot be
seen.
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by processing over Multiscreen durapore membranes [26]. The radioactive counts of the
samples with and without competitor reveal a 76% reduction in cross-linked product in
the presence of 100-fold excess α-factor (Figure 5). The remainder of the reaction
mixture was analyzed by SDS-PAGE, and a cross-linked product (54 kDa) which
migrated to the expected size of Ste2p (52 kDa) + probe (2 kDa) was detected by
autoradiography (Figure 6). No cross-linked products were observed with samples that
were not UV-irradiated (Figure 6, lanes 3 and 4). Co-incubation of membranes with
radiolabeled probe and cold α-factor resulted in a decrease in cross-linked product,
showing that the cross-linking to Ste2p was specific (Figure 6, lane 1 vs. lane 2). Western
analysis using anti-Flag antibodies to detect Ste2p showed that all lanes had equivalent
amounts of the receptor (data not shown).

Fragmentation Analysis of Cross-Linked Ste2p:
Based on the specific cross-linking of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor to
Ste2p, digestion of the receptor was initiated to identify the cross-linked fragment(s) of
the receptor. Chemical cleavage with CNBr and BNPS-skatole was performed. These
methods take place under strongly acidic conditions, which should result in unfolding of
the receptor, thereby making it more accessible to cleavage [17]. Chemical digestion of
the receptor was carried out on native and deglycosylated Ste2p prepared by treatment of
Ste2p with PNGaseF. Deglycosylation of the receptor was verified by SDS-PAGE with
the deglycosylated receptor migrating with a molecular mass that was approximately 2
kDa smaller than the native receptor (data not shown). Similar results of deglycosylation
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DPM (x 103)
Figure 5: Total radioactive counts of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor bound to
membranes following cross-linking in the presence and absence of nonradiolabeled
α-factor. Bars represent amount of ligand associated with membranes. Cross-linking was
carried out in the presence (open bar) or absence (shaded bar) of nonlabeled α-factor. The
experiment was performed 3 times, and the error bars represent the variance observed.
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Figure 6: Autoradiograph of SDS-PAGE analysis of UV-irradiated DK102pNED
membranes in the presence of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor. Membranes
containing Ste2p were incubated with [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor and
irradiated at 365 nm as described under Materials and Methods. Control samples either
were not irradiated or contained α-factor as a competitor. Lane 1, UV irradiated plus 100fold excess nonradiolabeled α-factor; lane 2, UV irradiated; lane 3, 100-fold excess
nonradiolabeled α-factor without UV irradiation; lane 4, without excess nonradiolabeled
α-factor and without UV irradiation; lane 5, molecular weight markers.
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Lane
α-factor
UV irradiation

1

2

3

4

+
+

+

+
-

-

kDa

200
116
97

66
XLSte2p

45
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of Ste2p were obtained previously by others [31, 32]. In certain gels, Ste2p appeared as a
diffuse band and sometimes appeared as a doublet. This is most likely due to the fact that
strain BJ2168pNED1 expresses both a native chromosomal copy of STE2 which codes
for a 50 kDa protein when glycosylated, and an epitope-tagged, episomally expressed
STE2 which contains two epitope tags and codes for a 52 kDa protein when glycosylated.
BNPS-skatole, which cleaves at tryptophan residues, theoretically fragments the
receptor into four pieces [IA: 9.5 kDa (7.5 kDa for residues 1-70 of Ste2p plus glycosyl
groups of 2.5 kDa), IIA: 25 kDa (71-295), IIIA: 15 kDa (296-424), and IVA: 3.6 kDa
(425-457)] (Figure 7A). Western analysis of native receptor with polyclonal antibodies
against residues 1-60 revealed that, after 2 min incubation with the BNPS-skatole
reagent, a broad band at approximately 35 kDa began to appear (Figure 8, lane B). The
size of this band contains glycosylated and deglycosylated forms of a fragment consisting
of residues 1-295 (fragments IA + IIA). After 24 h incubation with the BNPS-skatole
reagent, two fragments of 7.5 and 9.5 kDa, corresponding to glycosylated and
deglycosylated forms of fragment IA, were detectable (Figure 8, lane D) by a similar
Western analysis. Thus, 24 h incubation was required to ensure complete digestion of the
Ste2p under the conditions used.
Ste2p containing cross-linked [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor was digested
for 24 h with BNPS-skatole, dissolved in tricine sample buffer, and run on gradient
tricine gels. Phosphorimaging of the gels revealed two fragments of approximately 27
and 6 kDa (Figure 9, panel B). The 27 kDa fragment corresponds to that expected for
complete BNPS-skatole cleavage of Ste2p (25 kDa fragment IIA, Figure 7A), plus 2 kDa
for the probe. The 6 kDa fragment appears to be anomalous (see Discussion). In this
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Figure 7: Schematic representation of chemical and enzymatic cleavage of Ste2p.
These figures represent the BNPS-skatole, CNBr, and trypsin cleavage sites for the Ste2p
receptor. Ste2p receptor is shown here using snake diagrams to represent the putative
transmembrane domains. (Panel A) Cleavage of the receptor by BNPS-skatole results in
four fragments labeled IA (residues 1-70 of Ste2p), IIA (71-295), IIIA (296-424), and
IVA (425-458) with their respective molecular masses given in parentheses. Fragment IA
contains the putative N-linked glycosylation sites as represented by the goalpost symbols.
The oligosaccharides add 2 kDa of mass to fragment IA. Panel B represents the peptides
resulting from a complete CNBr cleavage of Ste2p. Panel C represents the peptides
resulting from a complete trypsin cleavage of Ste2p.
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Ste2p
43
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Figure 8: Western blot analysis of BNPS-skatole-digested membranes. Membranes
were digested with BNPS-skatole, and at various time points, portions of the reaction
mixture were removed and dried under vacuum centrifugation. Samples were then
dissolved in tricine sample buffer and run on gradient tricine gels. Protein was transferred
to Immobilon P membranes and probed with polyclonal antibodies specific for the first
60 amino acids of Ste2p. Lanes A and C were loaded with undigested membrane protein
with intact Ste2p indicated in the figure. Lane B represents a 2 min digestion, and lane D
shows a 24 h digestion with BNPS-skatole. The sizes of the detected fragments were
indicated by arrows. Detected bands above 52 kDa are routinely observed in Western blot
analysis of Ste2p and are widely believed to represent multimeric or aggregate structures
of Step2 [32].
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31
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Figure 9: Autoradiograph of SDS-PAGE 10-20% tricine gel analysis of membranes
photolabeled with [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor. (A) Photo-cross-linked
membranes, untreated, and (B) photo-cross-linked membranes treated with BNPS-skatole
and PNGaseF to remove N-linked oligosaccharides. Arrows denote cross-linked Ste2p
receptor (lane A) and receptor fragments (lane B). Detected bands above 52 kDa are
routinely observed in Western blot analysis of Ste2p and are widely believed to represent
multimeric or aggregate structures of Step2 [32].
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gel and subsequent ones, an unidentified, low molecular weight form of radioactive
iodine was readily discernible in the portion of the gel corresponding to a molecular size
less than 4 kDa.
Complete cleavage of the cross-linked receptor with CNBr yielded one labeled
fragment of ~6 kDa (Figure 10, panel I, lane B). Total cleavage of Ste2p labeled with
[Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor could result in several possible radioactive
fragments with a molecular mass of 6 kDa. Therefore, a partial CNBr digestion of crosslinked Ste2p was performed. This resulted in fragments of 35, 22, 9, and 6 kDa (Figure
10, panel II, lane B). All of these fragments can be rationalized in terms of theoretical
CNBr cleavage points in Ste2p (Table 3). For example, the 35 kDa band (Figure 7B)
could correspond to fragments IVB through XB (32.5 kDa) plus ligand (2 kDa). The
smaller bands [23 (fragments VIIB-IXB plus ligand), 10 (fragments VIIB-VIIIB plus
ligand), and 6 kDa (fragment VIIIB plus ligand)] could all result from cleavages at Met
residues within the 35 kDa peptide (Table 3). PNGaseF treatment of the mixture of
fragments obtained by partial CNBr degradation did not result in any shifts in the band
sizes (Figure 10, lane C). This was interpreted as ruling out fragment IB (glycosylated) in
any of the cross-linked fragments detected.
Digestion of the cross-linked receptor with trypsin revealed one band of
approximately 9 kDa corresponding to fragment XC (Figure 7C). It should be noted that
cleavage at the Arg residue within the α-factor analogue does not occur because Arg is
followed by a Pro residue. Cross-linking of ligand into VIIIC or IXC (Figure 7), two
fragments of trypsin-hydrolyzed Ste2p that could correspond to fragments of CNBr-
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Figure 10: Autoradiographs of membranes photo-cross-linked with [Bpa1,
(125I)Tyr3, Arg7, Phe13]α-factor and treated with CNBr. Samples run on an SDSPAGE 10-20% tricine gel. I: lane A, photo-cross-linked membranes; lane B, complete
digestion of photo-cross-linked membranes with CNBr. Arrows indicate photolabeled
Ste2p and 6.7 kDa cleavage fragment of Ste2p. II: lane A, photo-cross-linked
membranes; lane B, incomplete digestion of photo-cross-linked membranes; lane C,
PNGaseF treatment of membranes from lane B.
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Table 3: Peptides of CNBr-digested Ste2p

a

Peptides are named in order from the N-terminus to the C-terminus of Ste2p. Peptides of only one or two amino

acids resulting from CNBr cleavage are not included in the table.
b

The residue within Ste2p of the first amino acid of this CNBr fragment.

c

The residue within Ste2p of the last amino acid of this CNBr fragment.

d

The total molecular mass of all fragments within a possible partial digest. For example, in the first column,

fragments IB through IIIB have a molecular mass of 17.8 kDa.
e

The carboxyl terminus of Ste2p used in this study contained a His-tag and a FLAG tag (see Materials and Methods).
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digested Ste2p, would have led to a much smaller band of radioactivity (approximately
3.5-4.5 kDa). Taken together, examination of all the digestion maps [BNPS-skatole
(Figure 7A), CNBr (Figure 7B), and trypsin (Figure 7C)] indicated that the cyanogen
bromide fragment VIIIB (Figure 7B, residues 251-294) was the smallest common crosslinked fragment. This portion of Ste2p corresponds to transmembrane domain 6, the
extracellular loop between transmembrane domains 6 and 7, and transmembrane domain
7.
The position of cross-linking on Ste2p and the probe was further examined using
an epitope-tagged Ste2p (Ste2p-T7) and biotinylated, photoactivatable [Bpa1, Lys7(εbiotinyl-β-alanyl)]α-factor. The T7 epitope, introduced between residues 303 and 304 at
the C-terminal end of the tryptic fragment that spans TMD6 and TMD7, was fully
tolerated by Ste2p [16]. Trypsin digestion of Ste2p-T7 results in fragments similar to the
wild-type Ste2p receptor (Figure 11), but fragment XC (Figure 7C) is tagged with the T7
epitope (1.1 kDa), allowing identification of this receptor fragment by western blotting
with anti-T7 antibodies. Ste2p-T7 was cross-linked with [Bpa1, Lys7(ε-biotinyl-βalanyl)]α-factor, digested with trypsin (18 h, 30 ˚C), run on SDS-PAGE, and probed with
T7 antibodies to detect the epitope or probed with NeutrAvidin to detect biotin of the
cross-linked α-factor analogue (Figure 12). The 14 kDa band corresponds to a partial
trypsin digestion product containing IXC, IL3, and XC (Figure 7C) covering TMD5TMD7 plus the cross-linked ligand (2.0 kDa) and the T7 epitope (1.1 kDa), and the 11
kDa band corresponds to fragment XC (Figure 7C) plus the cross-linked ligand and the
T7 epitope. These fragments of cross-linked Ste2p-T7 were detected in lanes probed with
either anti-T7 antibody or NeutrAvidin. In a parallel experiment (data not shown), the
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Figure 11: Autoradiograph of membranes photo-cross-linked with [Bpa1, (125I)Tyr3,
Arg7, Phe13]α-factor and treated with trypsin. Samples run on SDS-PAGE 12% BisTris with MES buffer. Lane B, cross-linked receptor before trypsin digestion; lane D,
after trypsin digestion; lanes A and C, molecular mass markers with sizes indicated in the
left and right margins.
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Figure 12: Western blot analysis of [Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-factor crosslinked membranes. [Bpa1, K7(ε-biotinyl-β-alanyl)]α-factor was cross-linked into Ste2pT7, treated with trypsin, and run on 18% SDS-PAGE. Lane A, before trypsin digestion
probed with NeutrAvidin-horseradish peroxidase (NA-HRP); lane B, after trypsin
digestion probed with NA-HRP; lane C, after trypsin digestion probed with anti-T7-HRP
conjugate.
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same two bands at 11 and 14 kDa were detected when a single gel blot was probed with
anti-T7 antibody and then stripped and reprobed with NeutrAvidin. These results indicate
that one fragment corresponding to XC contained the T7 epitope and the cross-linked
[Bpa1, Lys7(ε-biotinyl-β-alanyl)]α-factor.
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CHAPTER 4
Discussion

Photoaffinity labeling with Bpa has been shown to be a useful tool in elucidating
direct contacts between ligands and their cognate receptors [4-11]. These photoaffinity
studies, which include work on the parathyroid, secretin, and nociceptin receptors, have
used receptor digestion analysis to elucidate fragments of the receptor that were crosslinked to the photo-activatable ligand probe. It should be noted, however, that receptor
fragments may move anomalously on polacrylamide gels and that molecular weights of
small fragments are difficult to determine accurately. In favorable cases, specific residues
involved in cross-linking were identified [5-7, 9]. Site-directed mutagenesis studies can
then be used to corroborate the importance of such residues in the binding of the ligand to
the receptor.
This part (Part II) of the dissertation detailed the synthesis and testing of α-factor
analogs containing Bpa for use as photoprobes to elucidate binding sites on the Ste2p
receptor. Results from the Bpa-scanned α-factor series (Figure 1) allowed the conclusion
that residues at positions 1, 3, 5, and 13 could be replaced with the photoactivatable
amino acid without severe decreases in binding affinity. Based on previous structureactivity analyses [18-20, 24, 27-29], analogs containing iodinatable tyrosine residues at
positions 1 or 3 with phenylalanine at position 13 were designed. Bioassay and receptor
binding studies indicated that these analogs triggered biological responses characteristic
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of Ste2p activation, and retained Ste2p-specific submicromolar binding affinities for this
receptor (Table 2).
One of the analogs tested, [Bpa1, Tyr3, Arg7, Phe13]α-factor, was iodinated and
exhibited relatively good agonistic activity in two standard pheromone response assays
(growth arrest and FUS1-lacZ). Binding of [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor was
found to be specific for the Ste2p receptor based on the ability of native α-factor to
displace [Bpa1, (125I)Tyr3, Arg7, Phe13]α-factor in a competition binding assay (Figure 4).
SDS-PAGE analysis of photolabeling experiments with [Bpa1, (125I)Tyr3, Arg7, Phe13]αfactor resulted in detection of one major radiolabeled product which migrated at the
expected size of Ste2p covalently attached to the probe (54 kDa). The amount of 54 kDa
product was reduced by >70% in the presence of excess cold α-factor, indicating that
cross-linking was occurring at the pheromone binding site of Ste2p. These findings
showed that the radioiodinated probe had biological and binding characteristics similar to
native α-factor and cross-linked specifically to Ste2p. Thus [Bpa1, (125I)Tyr3, Arg7,
Phe13]α-factor can be used to determine the binding site contacts between α-factor and its
receptor.
Receptor cross-linked with the radiolabeled probe was purified by SDS-PAGE,
eluted from the gel, and treated with various cleavage agents to identify a fragment(s)
that covalently attached to the radioprobe. It was expected that cleavage at the Trp
residues of Ste2p with BNPS-skatole would break the receptor into four fragments
(Figure 8A: fragments IA, IIA, IIIA, and IVA). Previous studies by others have shown
that the intracellular C-terminal tail of Ste2p has no effect on binding of α-factor and can
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actually be removed without loss of α-factor binding to Ste2p [31, 32]. Based on this
information, fragments IIIA and IVA were eliminated as possible sites for cross-linking
as they make up the intracellular C-terminal tail of the receptor and are not accessible to
α-factor. SDS-PAGE analysis with high percentage tricine gels resulted in identification
of two major radiolabled products of 27 and 6 kDa in size. The 27 kDa fragment
corresponded to fragment IIA (25 kDa) plus the probe (2 kDa). The 6 kDa fragment was
unexpected in that it does not correspond to a cross-linked form of fragment IA which
would have an expected size of approximately 11 kDa (7.5 kDa + 2 kDa for the probe +2
kDa for the polysaccharides = 11.5 kDa). The unexpected 6 kDa fragment most likely
corresponds to cleavage of receptor fragment IIA at methionines and/or cysteines due to
reagent contamination. It has been reported that slight impurities in BNPS-skatole can
result in cleavage at methionines and cysteines [33]. These impurities can arise from
incomplete removal of N-bromosuccinimide (NBS) substrate during the synthesis of
BNPS-skatole. However, NBS contamination is usually only a small fraction of the total
reagent. As a result, Trp residues were cleaved fast by BNPS-skatole while the Met and
Cys residues were cleaved at a slower rate. Based on this information, it is believed that
the 6 kDa fragment was generated by cleavage at sites other than Trp in the 27 kDa
fragment and would explain why the fragment was not detected in Western analysis by
anti-N-terminal Ste2p antibodies following BNPS cleavage. This argument is
strengthened by the observation that complete cleavage of Ste2p by CNBr at methionines
also resulted in a 6 kDa fragment.
Complete cleavage of the cross-linked receptor with cyanogen bromide resulted in
the identification of a single labeled band ~6 kDa in size. Based on the BNPS-skatole
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results, the band should be part of fragment IIA (Figure 7A). Complete CNBr cleavage of
Fragment IIA should yield six fragments [IIIB: 10.6 kDa (residues 72-165 of Ste2p),
IVB: 1.6 kDa (166-180), VB: 1.0 kDa (181-189), VIB: 3.2 kDa (190-218), VIIB: 3.8
kDa (219-250), and VIIIB: 4.5 kDa (251-294)] (Figure 7B). Of these, fragments VIB,
VIIB, and VIIIB when cross-linked to the probe would give sizes similar to the
identified radiolabeled fragment. Incomplete digestion of the cross-linked receptor with
CNBr yielded four fragments (Figure 10, panel II, lane B). Digestion of the cross-linked
receptor with trypsin revealed one band (Figure 11) of approximately 9 kDa
corresponding to fragment XC (Figure 7C). Taken together, the results of the two
chemical cleavages and trypsin cleavage indicated the receptor was labeled between
residues 251 and 294. This portion of Ste2p corresponds to transmembrane domain 6, the
extracellular loop between transmembrane domains 6 and 7, and transmembrane domain
7.
To verify that the 9 kDa fragment in Figure 11 was composed of a portion of
Ste2p and the cross-linked α-factor analogue, a receptor containing an epitope tag was
utilized. This receptor, Ste2p-T7, carried the T7 epitope (Met-Ala-Ser-Met-Thr-Gly-GlyGln-Gln-Met-Gly) introduced between Ste2p residues 303 and 304. The epitope is thus
N-terminal to a trypsin-sensitive Lys residue at position 304. In this manner, the XC
fragment (Figure 7C) and any fragments resulting from partial digestion of Ste2p-T7
containing this portion of the receptor could be detected by antibody to T7. The Ste2p-T7
receptor was utilized successfully by Dube, DeConstanzo, and Konopka [16] previously
to determine interactions between TMD5 and TMD6. Using Ste2p-T7 and a biotinylated,
photoactivatable α-factor analog, [Bpa1K7(ε-biotinyl-β-alanyl)]α-factor, detection of the
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cross-linked fragment was carried out by anti-T7 antibody and a biotin probe. Two bands
at 11 and 14 kDa, corresponding respectively to XC with the T7 epitope plus the α-factor
and to IXC-IL3-XC with the T7 epitope and the α-factor were observed. The detection
of both bands by the two probing methods indicated that the bands contained cross-linked
[Bpa1K7(ε-biotinyl-β-alanyl)]α-factor and a portion of Ste2p-T7. The increase in size
from 9 kDa (Figure 11, Ste2p cross-linked to iodinated, photoaffinity probe) to 11 kDa
(Figure 12, Ste2p-T7 cross-linked with biotinylated, photoaffinity probe) is consistent
with the extra mass due to the ε-biotinyl-β-alanyl modification and the T7 epitope. These
results strongly indicate that the region of the receptor cross-linked by a Bpa1photoactivatable probe, either iodinated or biotinylated, corresponded to residues 251294 of Ste2p. The fact that the only two bands found on the protein blots were revealed
by both epitope and biotin probes was strong evidence for the position of the crosslinking in the receptor. Although other 11 and 14 kDa fragments might occur during
trypsin cleavage, they would not react with the anti-T7 antibodies.
The determination of a contact between the position 1 side chain of α-factor and
residues of Ste2p allows us to refine our current working model for the placement of αfactor into the active site of this receptor. Based on site-directed mutagenesis and
synthetic analogs, evidence was recently presented for a contact between the side chain of
residue 10 (Gln) of α-factor and residues 47 and/or 48 at the extracellular interface of the
first transmembrane domain of the receptor [26]. Fluorescence spectroscopy studies
indicate that the side chain of Lys7 most likely faces toward a pocket formed by the
extracellular loops and that this pocket has both apolar and polar character [34]. In
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addition, the side chain of Trp3 is in a hydrophobic cavity based on fluorescence analyses
(Ding, Becker, and Naider, unpublished results), and previous studies with position 1
analogs also indicate a strong preference for a large hydrophobic residue at the aminoterminal position of the pheromone [35]. This latter result taken together with the present
photolabeling analysis suggests that cross-linking occurs with residues that are at, or
slightly below, the extracellular interface of transmembrane helices 6 and/or 7 of Ste2p.
Finally, biophysical evidence exists supporting a bend around the Pro-Gly center of αfactor as the biologically relevant conformation of the pheromone. In total, these results
allow us to develop a crude two-dimensional model for fitting the tridecapeptide into the
pheromone binding site. The working model has a contact of Gln10 with residues S47
and/or T48, a contact of residues 1 and 3 with F262 and/or Y266, and a β-turn around the
Pro-Gly sequence in the center of α-factor. Recent studies indicate that F262 and Y266
are important for α-factor binding and activity [36]. Additional features of the bound
structure should be forthcoming as further refinements of side chain contacts using the
other photoactivatable analogs and site-directed mutagenesis studies currently carried out
in our laboratory progresses.
The results presented in this part represent the first direct evidence of contact
between the α-factor ligand and a domain of the Ste2p receptor. Additionally, this is the
first study to use Bpa photo-cross-linkable probes to study ligand-receptor interaction in
class IV GPCRs. Future studies should allow for identification of a residue or residues
that cross-link to the α-factor probe used in this study. These results along with planned
studies to use a series of α-factor probes that will place cross-linkable moieties at various
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positions in the pheromone should allow for mapping of the ligand binding site of the
Ste2p receptor. Results from such studies have the potential to provide key insight into
peptide ligand mediated activation of GPCRs by identifying contact residues.
Identification of the contact residues would be useful in assigning structure-function
relationships between the α-factor pheromone and Ste2p and compare the results to
information gained from other classes of GPCRs.
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PART III
Identification of Ligand Binding Regions of the Saccharomyces
cerevisiae α-factor Pheromone Receptor (Ste2p) by Photo-affinity
Cross-linking
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Part III presents collaborative work with Dr. Fred Naider’s laboratory at the City
University of New York, Staten Island. Cagdas D. Son performed all the studies in th
is part with the exception of synthesis of the peptides used in this study. The peptide
syntheses were carried out by Hasmik Sargsyan in Dr. Naider’s laboratory. This part,
excluding the portions describing optimization of cross-linking and site-directed
mutagenesis of Ste2p residues 54-58, has been submitted for publication in Biochemistry.
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CHAPTER 1
Introduction

The yeast Saccharomyces cerevisiae is a sexual organism that manifests a
conjugative response when opposite mating type cells, MATa and MATα, are mixed
together (For Reviews see [1-5]). The mating reaction is initiated by stimulation of cell
surface receptors on each cell type by a polypeptide pheromone secreted from cells of the
opposite mating type. Ste2p is a G protein-coupled receptor (GPCR) expressed on the
surface of haploid cells of mating type MATa, which is involved in this initiation event.
Binding of the α-factor tridecapeptide mating pheromone (Trp-His-Trp-Leu-Gln-LeuLys-Pro-Gly-Gln-Pro-Met-Tyr), secreted by the mating type MATα, to Ste2p activates
the pheromone-signaling pathway by promoting dissociation of a coupled heterotrimeric
G protein into its constituent α subunit and βγ subunit complex on the cytoplasmic side
of the plasma membrane. The activation of the receptor leads to a series of events
including G1 growth arrest, cellular elongation, gene induction, agglutinin biosynthesis
and ultimately cell fusion with the opposite mating type MATα cells.
GPCRs constitute a major family of human proteins [6]. To date more than 1,000
GPCRs have been identified, and these proteins recognize diverse signaling molecules
including neurotransmitters, sensory molecules and chemotactic agents [7]. The
ubiquitous nature of GPCRs together with their highly specific ligand recognition makes
them an important target for therapeutic agents [8, 9]. Among the most important GPCR
ligands are peptides including hormones, growth factors, and pheromones.
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Understanding the molecular mechanism of peptide recognition by their cognate GPCRs
may lead to design of novel peptide analogs for treatment of disorders involving
defective ligands and/or mutant receptors.
Although there has been considerable literature on the GPCR ligand binding sites
for small molecules like biogenic amines [10], relatively less information exists
concerning the binding sites of peptide-responsive GPCRs. Photoreactive cross-linking
studies, using 4-benzoyl-L-phenylalanine (Bpa)-containing peptide ligands, are a
powerful complement to site-directed mutagenesis studies for mapping peptide-receptor
interaction(s). Studies reported on parathyroid hormone (PTH), opioid receptor (ORL1)
[11-17], substance P [18-20], cholecystokinin [21], and vasopressin [22] showed that
Bpa-containing peptides can be successfully used for identification of receptor fragments
that are interacting with photoactivatable peptide analogs. Recent work on human PTH
receptor [23, 24], the secretin receptor [25], the ORL1 receptor[26] and human
angiotensin type I receptor [27], showed that specific contact residues can be mapped
after photoaffinity labeling by sequencing of the cross-linked fragment and site-directed
mutagenesis in the region of cross-linking. A new method called the methionine
proximity assay took advantage of modified analogs of Bpa, e.g. p-nitro-benzoylphenylalanine (NO2Bpa), that have selectivity for methionine residues [28]. This unique
property allowed the identification of a contact site by methionine scanning of the
putative contact residues of three GPCRs, followed by analysis of the cross-linked
receptor. All of these studies using Bpa-analogs revealed that generation of covalently
linked ligand-receptor conjugates has become a valuable tool for the identification of the
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cross-linked domains allowing mapping of the interface between a peptide ligand and its
GPCR [29].
In part II of this dissertation, a general approach to directly identify the interaction
between position 1 of α-factor and a region between residues 251-294 of the receptor
Ste2p was reported [30]. However, this study was limited to the use of only one Bpa-αfactor analog. Similarly in this part (part III) the evaluation of a series of biotinylated
photoactivatable analogs containing Bpa at various positions throughout the α-factor
pheromone was described. An important aspect of the present part is the use of biotin as a
tag allowing detection of cross-linking using avidin based chromophores and eliminating
problems previously encountered with radioactive iodine [30]. Four analogs studied were
selectively cross-linked into the α-factor binding site of Ste2p. Chemical and enzymatic
fragmentation of the cross-linked receptor allowed the identification of contacts between
the position 3 and 13 side chains of the pheromone and Ste2p residues in the EL2-TM5
and/or TM6-EL3-TM7 region and first transmembrane domain, respectively. In addition,
interaction of position 1 of α-factor with a region of Ste2p covering residues 251-294
was confirmed.
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CHAPTER 2
Materials and Methods

Organisms:
S. cerevisiae DK102 [MATa ste2::HIS3 bar1 leu2 ura3 lys2 ade2 his3 trp1]
transformed with pNED1[STE2] [31] was used in binding studies and in the growth arrest
assays of various α-factor analogs. Strain BJ2168 was used as parental strain to construct
BJS21 by deleting STE2 using the kanamycin deletion cassette according to a standard
protocol [32]. BJS21 [MATa ste2::KanR, prc1-407, prb 1-1122, pep4-3, Leu2, trp1, ura
3-52] strain transformed with pNED1 [STE2] was used in cross-linking studies. Strain
LM102 [33] [MATa ste2::HIS3 bar1 leu2 ura3 lys2 ade2 his3 trp1] transformed with
pGA314.Cys-less.STE2.FT.HT [34] was used for generating site directed Ala mutations
between residues M54 and R58 of Ste2p. All strains used had similar binding of α-factor.
However, the BJS21 pNED strain lacked several peptidases, so it was used to increase the
yield of Ste2p in experiments involving cross-linking.

Chemical Reagents:
All reagents and solvents used for the solid-phase peptide synthesis of the
photoactivatable peptides were analytical grade and were purchased from Advanced
Chem. Tech. (Louisville, KY), VWR Scientific (Piscataway, NJ), or Aldrich Chemical
Co. (Milwaukee, WI). High-performance liquid chromatography (HPLC) grade

105

dichloromethane (CH2Cl2), acetonitrile (ACN), methanol (MeOH), and water were
purchased from VWR Scientific and Fisher Scientific (Springfield, NJ).

Synthesis of N-α-Fmoc-Protected α-factor Analogs:
N-α-Fmoc-protected α-factor analogs needed for the preparation of their
biotinylated derivatives were synthesized by solid-phase peptide synthesis on an Applied
Biosystems 433A peptide synthesizer (Applied Biosystems, Foster City, CA) starting
with N-α-Fmoc-Tyr(OBut) - or N-α-Fmoc-Bpa-Wang resin (0.7 mmol/g substitution,
Advanced ChemTech, Louisville, KY). In all of the peptides, L-norleucine (Nle), which
is isosteric with L-methionine, was incorporated at position 12 to replace the naturally
occurring L-methionine to prevent oxidation of the sulfur atom of this amino acid during
peptide synthesis and purification. Replacement of Met by Nle was shown previously to
result in an analog with equal activity and receptor affinity to that of the native
pheromone [35]. Since all analogs have Nle in place of Met12, this residue is eliminated
from the abbreviated names for simplicity. The 0.1 mmol FastMoc chemistry of Applied
Biosystems was used for the elongation of the peptide chain with an HBTU/HOBt/DIEAcatalyzed, single coupling step using 10 equiv of protected amino acids for 30 min. Upon
completion of chain assembly the N-α-Fmoc group was not removed from the peptide
chain.
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Cleavage, Purification and Characterization of Peptides:
Cleavage, purification and characterization of the peptides were carried out as
detailed in material methods chapter, Part II of this dissertation. Briefly, the N-α-Fmocprotected peptidyl resin was washed thoroughly with 1-methyl-2-pyrrolidinone and
dichloromethane and dried in vacuum. The peptide was cleaved from the resin support
with simultaneous side chain deprotection using a cleavage cocktail at room temperature
for 1.5 hour with the omission of 1,2-ethanedithiol in the cleavage reaction, to transform
Bpa-containing peptides to cyclic dithioketal derivatives [36]. The filtrates from the
cleavage reaction were collected, combined with trifluoroacetic acid washes of the resin,
concentrated under reduced pressure, and treated with cold ether to precipitate the crude
product.
The crude peptide so obtained was purified by reversed phase HPLC (HewlettPackard Series 1050) on a semi-preparative Waters µ-Bondapack C18 (19 x 300 mm)
column with detection at 220 nm. The fractions were collected and analyzed at 220 nm
by reversed phase HPLC (Hewlett-Packard Series 1050) on an analytical Waters µBondapack C18 (3.9 x 300 mm) column. Fractions of over 99% homogeneity were pooled
and subjected to lyophilization. The purity of the final peptide was assessed by analytical
HPLC using two different solvent systems (10- 55% acetonitrile gradient, 15 min, with
0.025% trifluoroacetic acid; and 50-80% methanol gradient, 30 min, with 0.025%
trifluoroacetic acid) and ESI-MS (Hunter College, CUNY).
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Biotinylation of N-α-Fmoc- protected α-factor analogs:
Biotinylation of N-α-Fmoc-protected α-factor analogs was carried out using
biotinylamidocaproate-N-hydroxysuccinimide ester (Sigma). The N-α-Fmoc-protected
α-factor analog (10.0 mg, 5 µmol) was dissolved in 0.5 ml of cold (0 ˚C) DMF, then the
same volume (0.5 ml) of cold buffer (Na2B4O7, pH 9.5, 50mM) was added. The solution
was stirred at 0 ˚C (ice bath) for 2 min., and 10.0 mg (20 µmol) of biotinylamidocaproateN-hydroxysuccinimide ester (Sigma) dissolved in 0.5 ml of cold DMF (0 ˚C) was added
very slowly. Reaction was monitored by analytical reversed phase HPLC using a linear
gradient of 20-70 % ACN in 30 min and when the starting peptide disappeared (20-40
min) 0.5ml of a 20% solution of piperidine in DMF was added, and the reaction mixture
was stirred at room temperature for 30 min until the Fmoc-group was fully deprotected,
as monitored by analytical HPLC. The reaction mixture was neutralized with acidified
buffer (0.2 M HCl), and injected immediately onto a preparative HPLC column
(conditions for preparative HPLC: 20-70% ACN in 150 min, column; Waters µBondopack C18, 19x300 mm). The main fraction was collected and lyophilized. The
purity of the biotinylated peptide was > 99 % by analytical HPLC and the molecular
weight of peptide was confirmed by mass spectral analysis. The overall recovery of
purified biotinylated peptide was 85-90%.

Site-directed mutagenesis:
Oligonucleotide-directed mutagenesis of single-stranded phagemid DNA of
pGA314.Cys-less.STE2.FT.HT [STE2 gene with the wild-type cysteine residues (Cys59
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and Cys292) replaced by alanine and containing the FLAG® and 6xHis tags on the Cterminus] was constructed as described previously [37, 38]. This construct was shown to
have full wild-type Ste2p activity as determined by binding and biological activities.
Briefly, single-stranded DNA was prepared by infecting E.coli strain CJ236 (ung-, dut-)
carrying the pGA314.Cys-less.STE2.FT.HT with the helper phage M13KO7 [39]. In
vitro mutagenesis was performed on the single-stranded DNA using mutagenic
oliogonucleotides according to standard protocols. The product of the mutagenesis
reaction mixture was transformed into DH5α (Invitrogen) E. coli strain, and
transformants were selected on ampicillin-containing plates. Plasmids were then isolated
from transformants using the Wizard Miniprep kit (Promega). After sequencing of the
isolated plasmids to confirm correct incorporation of the intended mutations, constructs
were transformed into yeast strain LM102 (ste2 deletion strain), and transformants were
selected by their growth on medium lacking tryptophan.

Growth Arrest (Halo) Assay:
Solid MLT medium[40] as detailed in material and methods of Part II was
overlaid with 4 mL of S. cerevisiae DK102pNED cell suspension (2.5 x 105 cells/mL of
Nobel agar). Filter disks (sterile blanks from Difco), 8 mm in diameter, were presoaked
with 10 µL portions of peptide solutions at various concentrations and placed onto the
overlay. The plates were incubated at 30 ˚C for 24-36 h and then observed for clear zones
(halos) around the disks. The data were expressed as the diameter of the halo including
the diameter of the disk. A minimum value for growth arrest is 9 mm, which represents
the disk diameter (8 mm) and a small zone of inhibition. All assays were carried out at
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least 3 times with no more than a 2 mm variation in halo size at a particular amount
applied for each peptide. The values reported represent the mean of these tests.

Binding Competition Assay with [3H]α-Factor:
Competition binding assay was performed using strains DK102pNED and
tritiated α-factor prepared by reduction of [dehydroproline8, Nle12]α-factor as described
previously [35]. In general, cells were grown at 30 ˚C overnight and harvested at 1 x107
cells/mL by centrifugation at 5000g at 4 ˚C. The pelleted cells were washed 2 times in
ice-cold buffer [PPBi: 0.5 M potassium phosphate (pH 6.24) containing 10 mM TAME,
10 mM sodium azide, 10 mM potassium fluoride, 1% BSA (fraction IV)] and
resuspended to 4 x 107 cells/mL. The binding assay was started by addition of [3H]αfactor (6 nM) and various concentrations of non-labeled peptide (140 µL) to a 560 µL
cell suspension. Analog concentrations were adjusted using UV absorption at 280 nm and
the corresponding extinction coefficients (Table 1). After 30 min incubation, triplicate
samples of 200 µL were filtered and washed over glass fiber filtermats using the Standard
Cell Harvester (Skatron Instruments, Sterling, VA) and placed in scintillation vials for
counting. Each experiment was carried out at least 3 times with the results similar in each
assay. The Ki values were calculated by using the equation of Cheng and Prusoff, where
Ki = IC50/(1 + [ligand]/Km) [41].
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Binding Saturation Assay with [3H]α-Factor:
LM102 pGA314.Cys-less.STE2.FT.HT and various Ala mutants in this
background strain were used in the saturation binding assay. In these assays, various
concentrations of [3H]α-factor were added to the cell suspension prepared as described in
competition binding assay part. Specific binding was determined by subtracting counts
associated with the LM102 (STE2 deletion) strain from counts bound to the strains
harboring WT or mutant receptors. Each experiment was carried out at least three times
with similar results. Nonspecific binding of labeled α-factor to filters in the absence of
cells was less than 20 counts/min. Data curves for competition and saturation binding
assays were fitted from at least eight triplicate data points using PrismTM software
(GraphPad) with nonlinear regression one site saturation hyperbola equation.

Optimization of Cross-linking conditions:
10 µl of membranes (22 mg/ml of total protein, prepared according to protocols
previously described, see PART II of this dissertation) derived from cells with a deletion
in the α-factor receptor encoding gene STE2 (BJS21) and membranes from these same
cells transformed with a plasmid (pNED) encoding Ste2p (BJS21 pNED) were incubated
with 975 µL of PPBi buffer (with 0.1%BSA) in siliconized microfuge tubes for 10 min at
ambient temperature. Various concentrations (0, 0.3, 5.0, 10.0, and 20 µg/ml) of Bpascanned biotinylated α-factor analogs were added, and the reaction was incubated for 30
min at room temperature with gentle mixing. The reaction mixture was aliquoted into 3
wells of a chilled 24 well plastic culture plate preblocked with PPBi (0.1% BSA).
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Division of the reaction mixtures into separate wells kept the depth of the samples
minimal for efficient UV penetration of the sample. The samples were held at 4 °C and
irradiated without the culture plate lid at 365 nm for 5, 15, 20, 25, 45, 60, and 90 min at a
distance of 12 cm in a Stratlinker (Stratagene, La Jolla, CA). Membrane samples were
recombined in siliconized microfuge tubes and washed twice by centrifugation (14000g)
with PPBi (0.1% BSA). Membrane pellets were dissolved in 5µl sample buffer (0.25 M
Tris-HCl, pH 8.8, 0.005% bromphenol blue, 5% glycerol, 1.25% ‚β-mercaptoethanol, 2%
SDS). Samples were heated to 37 °C for 10 min and separated by SDS-PAGE (10% gel;
30 mA). After transfer to a PVDF membrane blots were analyzed with NA-HRP
conjugate (from Pierce).

Cross-Linking of α-factor analogs to Ste2p:
Membranes (220 µg/ml of total protein) from BJS21, BJS21 pNED strains [31],
and LM102 pGA314.Cys-less.STE2.FT.HT strains carrying various Ala mutants were
incubated with 975 µL of PPBi buffer (with 0.1%BSA) in siliconized microfuge tubes for
10 min at ambient temperature. Bpa scanned biotinylated α-factor analogs (10 to 20 nM)
were added, and the reaction was incubated for 30 min at room temperature with gentle
mixing. The reaction mixture was aliquoted into 3 wells of a chilled 24 well plastic
culture plate preblocked with PPBi (0.1% BSA). Division of the reaction mixtures into
separate wells kept the depth of the samples minimal for efficient UV penetration of the
sample. The samples were held at 4 °C and irradiated without the culture plate lid at 365
nm for 1 h at a distance of 12 cm in a Stratlinker (Stratagene, La Jolla, CA). Membrane
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samples were recombined in siliconized microfuge tubes and washed twice by
centrifugation (14000g) with PPBi (0.1% BSA). Membrane pellets were dissolved in 5µl
sample buffer (0.25 M Tris-HCl, pH 8.8, 0.005% bromphenol blue, 5% glycerol, 1.25%‚
β-mercaptoethanol, 2% SDS). Samples were heated to 37 °C for 10 min and separated by
SDS-PAGE (10% gel; 30 mA). In competition cross-linking experiments, 100x cold αfactor was added together with biotinylated peptide. For subsequent receptor digestion
analysis, the band between 45 and 60 kDa covering cross-linked Ste2p mass was excised
and placed into dialysis tubing (30000 molecular weight cutoff) with buffer (0.2 M Trisacetate, pH 7.4, 1.0% SDS, 100 mM dithiothreitol). Electro-elution was performed by
placing dialysis tubing that contains the gel in a horizontal electrophoresis chamber with
running buffer (50 mM Tris-acetate, pH 7.4, 0.1% SDS, 0.5 mM sodium thiogylcolate).
Elution was carried out at 100 V for 3 h. The buffer in the dialysis tubing was transferred
to a Millipore Ultrafree-15 centrifuge filter device (30 000 molecular weight cutoff) and
concentrated by centrifugation. Concentrated sample was washed 3 times with 50 mM
Tris-HCl, pH 7.5. The cross-linked samples were resolved with SDS-PAGE, transferred
to a PVDF membrane and assayed for the detection of proteins that are covalently linked
with biotinylated analogs with NeutrAvidin-HRP conjugate (NA-HRP) (Pierce). All the
gels used in these blots were analyzed by staining with coomassie blue to ensure efficient
transfer of the protein to the membrane.

Digestion of Cross-Linked Ste2p:
Cross-linked samples were digested with CNBr, trypsin, or BNPS-skatole. For
CNBr digestion, samples were dissolved in 70% formic acid, and 200 mg/ml of CNBr
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were added. For trypsin digestion, samples were dissolved in trypsin digestion buffer
(100 mM Tris-HCl, pH 8.5), and 6.25 µg of trypsin (Sequencing Grade modified trypsin,
Roche) was added to 250µg of total proteins. After 6 hr of incubation a second batch of
trypsin (6.25 µg) is added to achieve complete digestion. Ste2p contains a lysine residue
(K269) followed by a proline residue (P270) in the extracellular loop 3, which makes it
less likely to be digested by trypsin. Nevertheless, we found that this region is
reproducibly susceptible to trypsin digestion under the conditions described above. For
BNPS-skatole digestion, samples were dissolved in 50% acetic acid with addition of
10mg/ml BNPS-skatole. To prevent anomalous cleavage of Ste2p at histidine and
tyrosine residues, tyrosine at 100-fold molar excess was added to the reaction mixture
during BNPS-skatole digestion [42]. Deglycosylated samples for BNPS-skatole digestion
were prepared by treatment with PNGaseF (500 units/µl, BioLabs). Briefly, ~ 10 µl of
partially purified Ste2p-containing membrane proteins (1µg/µl) was incubated with 5 µl
of 10x glycoprotein denaturing buffer (5% SDS, 10% β-mercaptoethanol) at 100 ˚C for
10 min. After 10 min, 5 µl of 10x G7 buffer (0.5M sodium phosphate, pH=7.5) and 5 µl
of 10% NP-40 were added. Finally, 5µl PNGase F and 20µl of water was added (total
volume, 50µl) and incubated at room temperature overnight. All digestion reactions took
place under nitrogen and complete darkness at 37°C. After digestion, samples were dried
by vacuum centrifugation, resuspended in 50 µL of 0.5 M Tris, pH 8.25, and re-dried.
The digested samples were dissolved in loading buffer (Bio-Rad) and resolved on 12%
NuPAGE Bis-tris gels with MES running buffer (Invitrogen).
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CHAPTER 3
Results

Synthesis of α-factor analogs:
N-α-Fmoc protected α-factor analogs containing Bpa1, Bpa3, Bpa5, Bpa8, or Bpa13
were prepared by automated solid phase synthesis using standard coupling and
deprotection protocols. During several of the syntheses we noted partial Fmoc removal
occurred using the “complete wash protocol” of the Applied Biosystems 433A
synthesizer. This problem was eliminated by washing only with DCM. N-α-Fmocprotected Bpa-containing α-factor analogs were purified by semi-preparative HPLC
(Waters µ-Bondopack C18, 125Å, 19x300mm, gradient 20-60% acetonitrile in 150 min).
After lyophilization they were used in the synthesis of the corresponding biotinylamidocaproate (BioACA) derivatives. Thus all biotinylated analogs used in this part of
the dissertation were biotinylated at the epsilon amine of Lys7 and a spacer was used to
ensure that the biotin group was available to the avidin detection protein. The final
products containing both Bpa and biotin were more than 99% pure as determined by
analytical reversed-phase HPLC and had the expected molecular weight (Table 1).

Receptor Affinities of Bpa-Scanned Biotinylated α-factor analogs:
α-factor analogs that bind tightly to the pheromone receptor (Ste2p) were
essential to achieve an efficient cross-linking. Studies detailed in part II showed that Bpa
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Table 1: Βiotinylation yield for α-factor analogs. Table represents yields of biotinylation and results of mass spectral
analysis

a

The extinction coefficients were calculated by the DNASTAR™ program (Lasergene, Madison, WI) on the basis of the

peptide sequence.
b

Mass-spectral analysis of biotinylated analogs were performed by Dr.Cliff Soll, Hunter College,CUNY

c

This synthesis was not optimized.
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replacements were well tolerated at positions 1(Trp), 3(Trp), 5(Gln), 7(Lys), 8(Pro),
12(Met), and 13(Tyr) of α-factor pheromone with Ki values indicating poorer binding
from 4-fold to 45-fold in comparison to α-factor [30]. Based on these data and our
current working model for pheromone binding to receptor [43], we chose photo-crosslinkable analogs with Bpa at positions 1, 3, 5, 8, and 13 to determine contact points
between the peptide and its receptor. This placed potential crosslink sites in side chains
throughout the pheromone. The position seven side-chain was used for the biotin tag for
detection purposes [44].
Binding affinities of the Bpa-scanned biotinylated α-factor analogs were
determined by measuring their ability to compete with [3H]α-factor as described under
Experimental Details. Analogs containing Bpa1 and Bpa5 exhibited only a 3- to 4-fold
reduction in binding affinity compared to native α-factor (Figure 1). The binding affinity
for Bpa13 was relatively poor (~12 fold lower than wild type). [Bpa8]α-factor showed
very poor competition and did not compete fully at the highest concentration tested
making the binding affinity for this analog only an estimate. [Bpa3]α-factor exhibited a
comparatively intermediate binding of ~40 nM, although this is also only an estimate as
full competition did not occur at the highest concentration tested.

Bioactivities of Bpa-Scanned Biotinylated α-factor analogs:
For the cross-linking studies to relate to a biologically relevant receptor-ligand
interaction it is important to determine whether the ligand has biological activity.
Therefore, the ability of the Bpa-scanned biotinylated α-factor analogs, used in this part
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Figure 1: Competition binding assay of various α-factor analogs vs. tritiated αfactor. Competitors were cold α-factor (■), Bpa1 (▲), Bpa3 (▼), Bpa5 (♦), Bpa8 (●),
and Bpa13 (□).
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of the dissertation, to cause growth arrest in MATa as tested by growth arrest assay
(Figure 2, Table 2). Semi-logarithmic plots of halo diameter versus amount of peptide
applied to the disk were all linear and exhibited similar slopes (data not shown). All
analogs used in this assay were stable to enzymatic cleavage under the conditions tested
as strains used in this analysis lacked the Bar1p protease that cleaves α-factor. Therefore,
the growth arrest data are indicative of the relative agonist activity of each peptide. The
data show that the biotinylated peptides, where Bpa is at position 1, 3, 5, and 13 retained
detectable agonistic activity, although the Bpa3, Bpa5, and Bpa13 pheromones had
relatively low ability to trigger signal transduction (Table 2). On the other hand
biotinylated [Bpa8]α-factor did result in a small halo (~2 mm around the filter disk) at the
highest concentration (20 µg/disk) used in this assay. None of the α-factor analogs
induced growth arrest in a mutant lacking Ste2p (BJS21), confirming that the α-factor
receptor was required for the biological activity of these peptides.

Optimization of Cross-linking of Bpa-Scanned Biotinylated α-factor analogs:
The cross-linking reaction between the photoactivatable Bpa group and the
receptor is affected by the concentration of the reactants, temperature, and time.
Throughout this study, temperature and the concentration of the receptor were kept
constant, while the concentrations of Bpa-containing α-factor analogs and the time of UV
irradiation varied. Following cross-linking under these various conditions, the yield was
determined by the comparison of the signal intensities detected by NA-HRP blots.
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Figure 2: Halo assay with Bpa-scanned biotinylated α-factor analogs. Various
amounts (labeled on the disks [µg]) of α-factor analog were spotted on sterile filter disks
placed on solid agar media and the growth arrest was quantified by measuring the
diameter of the halo formed after 48 hr incubation at 30 ˚C.
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Table 2: Summary of receptor affinities and biological activities for Bpa-scanned
biotinylated α-factor analogs.
Position of
Bpa

WT

Bpa1

Bpa3

Bpa5

Bpa8

Bpa13

Ki [nM]

6

20

~40

25

~160

75

Biological
Activitya

0.4

1.5

3.5

9.4

~50b

9

% affinity

100

30

15

24

~4

8

% activity

100

23

10

4

<1

5

a

Amount of analog (µg) needed to form 15 mm halo of growth arrest.

b

Out of linear range the highest amount (20µg) tested in this assay gave only 13mm halo.
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Figure 3a and 3b showe representations of these studies carried out with the [Bpa1]αfactor analog. Results for all the Bpa-containing analogs are summarized in table 3.

Cross-linking of Bpa-Scanned Biotinylated α-factor analogs to Ste2p:
The membranes derived from cells with a deletion in the α-factor receptor
encoding gene STE2 (BJS21) and membranes from these same cells transformed with a
plasmid (pNED) encoding Ste2p (BJS21 pNED) were incubated with Bpa-scanned
biotinylated α-factor analogs, and cross-linking was carried out using UV light (365 nm).
BJS21 membranes were used as control in this experiment to check the possible
interference from endogenous biotin signal and/or non-specific cross-linking products.
Aliquots from each reaction mixture were removed following cross-linking and tested for
incorporation of the biotinylated ligand to Ste2p by western blot analysis probed with
NA-HRP (Figure 4). The cross-linked product (54 kDa), which migrated to the expected
size of Ste2p (52 kDa) + α-factor analog (2 kDa) was detected in all lanes that contain
cross-linked BJS21 pNED membranes, although the [Bpa8]α-factor analog exhibited a
low degree of cross-linking consistent with its low biological activity and poor binding
data. During the scanning of the film for preparation of the figure, a doublet seen for
Ste2p on the original gels faded into the broader single band seen at ~54 kDa. No
detectable signal was present on lanes loaded with BJS21 membranes (that lack Ste2p).
In addition no cross-linked products were visible with samples that were not UVirradiated (data not shown).
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Figure 3: Optimization of the [Bpa1]α-factor analog concentration and time for
cross-linking. A) Different concentrations of [Bpa1]α-factor analog were incubated with
the membranes from BJS21 pNED strain (45 min. UV irradiation). B) Duration of UV
irradiation was varied at constant concentration (10µg/ml) of [Bpa1]α-factor analog.
After cross-linking the samples were solubilized in sample buffer and resolved by 10%
SDS-PAGE. Following the transfer of proteins to PVDF membranes cross-linking was
identified by NA-HRP conjugate, which detected the biotin tag on the ligands.
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[Bpa1]µg/ml

0

20

10

5

0.3

A
208
105
78
XL Ste2p
~54 kDa 53
34
23
17
16
17
16

Time (min)

90

60

45

B
208
105
78
XL Ste2p
~54 kDa
53
34
23

17
16
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25

20

15

5

Table 3: Summary of the cross-linking optimization with Bpa scanned α-factor
analogs.
Position of Bpa

Bpa1 Bpa3 Bpa5 Bpa8 Bpa13

Time for XL (min)

45

45

60

ND

30

Amount of Bpa Analog
(µg/ml)

5

5

10

ND

3

ND: Due to the low binding affinity and poor biological activity this analog was not used
in the optimization studies.
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Figure 4: Western blot analysis of BJS21 pNED (expresses Ste2p), and BJS21 (∆
Ste2p) photo-cross-linked membranes. Membranes photo-cross-linked with various
Bpa containing α-factor analogs were dissolved in Tricine sample buffer and resolved by
Nu-PAGE 12% Bis-Tris gel. Proteins were transferred to a PVDF membrane and probed
with NA-HRP to detect the biotin signal on the analog.

127

128

In a follow up experiment, the BJS21 pNED membranes were co-incubated with Bpascanned biotinylated α-factor analogs and 100-fold molar excess of wild type α-factor
pheromone (Figure 5). Results indicated that in the presence of excess α-factor
pheromone the cross-linking of the biotinylated analogs was greatly diminished
indicating that the cross-linking to Ste2p with the Bpa-scanned biotinylated α-factor
analogs occurs at the α-factor binding site. Cross-linking of [Bpa8]α-factor was not
blocked by addition of 100-fold molar excess of α-factor (data not shown). We
concluded that the low amount of cross-linking observed with the Bpa8 analog (Figure 4)
may not reflect interaction with the α-factor binding site. This conclusion is supported by
the relatively poor competition of this analog for α-factor binding (Figure 1) and the poor
biological activity of this analog (Table 2). Therefore, further investigations with this
probe were discontinued. Cross-linking of [Bpa5]α-factor was blocked by excess αfactor, however, the amount of cross-linked product was very low in comparison to the
amount of cross-linked product using Bpa1, Bpa3, and Bpa13 analogs (Figure 5).
Therefore, experiments using this analog were also discontinued. Cross-linking efficiency
for Bpa1, Bpa3, and Bpa13 analogs was estimated to be around 50% by comparison of the
chemiluminescence signals from two different blots, one probed with NA-HRP (to detect
cross-linked Ste2p by the reaction with the biotinylated analog) and the other probed with
a FLAG® antibody detected by anti-mouse IgG HRP (Promega, to detect the total FLAGtagged Ste2p; data not shown).
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Figure 5: Western blot analysis of BJS21 pNED photo-cross-linked membranes in
the presence or absence of excess α-factor. Membranes photo-cross-linked with various
Bpa containing α-factor analogs either in the presence or in the absence of 100x excess
wt. ligand and resolved by Nu-PAGE 12% Bis-Tris gel. Proteins were transferred to a
PVDF membrane and probed with NA-HRP to detect the biotin signal on the analog.
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Fragmentation Analysis of Cross-linked Ste2p:
Membranes containing Ste2p (BJS21 pNED) cross-linked with various Bpascanned analogs described in this part were resolved by preparative SDS-PAGE. Crosslinked Ste2p was electro-eluted from the gel and was treated with various cleavage agents
to identify a fragment that covalently attached to the biotinylated ligand. Fragments of the
cross-linked receptor were analyzed after Trypsin, CNBr and BNPS-skatole digestion to
identify a putative Bpa1, Bpa3, and Bpa13 cross-linked fragment(s). Trypsin digestion of
the cross-linked receptor was carried out with sequencing grade trypsin at 37 ˚C for 16 hr.
To monitor trypsin digestion, we used a T7 epitope-tagged Ste2p [45] and detected a ~4
kDa band (residues 270-303 +T7 tag) by T7 antibody instead of a ~8kDa band (residues
240-303 + T7-tag), indicating that the Lys-Pro site in the 3rd extracellular loop was
susceptible to complete trypsin digestion under current digestion conditions (data not
shown). A similar unexpected trypsin digestion at a Lys-Pro bond was observed by others
[46]. Chemical cleavage was performed by CNBr or BNPS-skatole under strongly acidic
conditions. BNPS-skatole digestion was carried out on native and deglycosylated Ste2p
prepared by treatment of Ste2p with PNGase-F. These methods were previously used in
our laboratory and applied by other groups in studies on Ste2p [30, 47, 48].
Trypsin digestion resulted in fragments around 5 kDa for both Bpa1 and Bpa3 αfactor analogs whereas ~10 and ~8 kDa bands for Bpa13 α-factor were detected on the
same blot (Figure 6). The theoretical digestion of Ste2p by trypsin shows multiple
possible fragments that might correspond to 5 kDa after cross-linking with Bpa1 or Bpa3
(Figure 7A). CNBr digestion of the cross-linked receptor was carried out to narrow down
the putative cross-linked regions. Following CNBr digestion a band approximately 6 kDa
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Figure 6: Western blot analysis of Trypsin digested BJS21 pNED photo-cross-linked
membranes. Membranes photo-cross-linked with various Bpa containing α-factor
analogs were digested with Trypsin and resolved by Nu-PAGE 12% Bis-Tris gel.
Proteins were transferred to a PVDF membrane and probed with NA-HRP to detect the
biotin signal on the analogs. Membranes, cross-linked with α-factor, were used as
negative control, and ligand alone was used for positive control.
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Figure 7: Schematic representation of receptor fragments after chemical or
enzymatic cleavage of Ste2p. These figures represent the theoretical BNPS-skatole,
Trypsin, and CNBr cleavage sites for the Ste2p receptor. For simplicity purposes the
cytoplasmic tail is not represented in these cartoons. (Panel A) Represents the peptides
resulting from a complete Trypsin digestion of Ste2p. (Panel B) Represents the receptor
fragments generated after a complete CNBr cleavage of the receptor. (Panel C) Cleavage
of the receptor by BNPS-skatole results in four fragments three of which represented IC
(residues 1-70 of Ste2p), IIC (71-295), and IIIC (296-424). Molecular weights are
represented on the figure in kDa. N-terminus fragments IA, IB, and IC contains two
known N-linked glycosylation sites which adds ~2 kDa to these fragments thus the
molecular weights for these fragments indicated as approximations.

133

134

was detected for both Bpa1 and Bpa3 (Figure 8). This result in combination with the
trypsin digestion narrows the possible cross-linking to two regions: VIB (190-218), or
VIIIB (251-294) (Figure 7B), where the latter is in agreement with our previous findings
for Bpa1 [30] . CNBr digestion of Bpa13 cross-linked Ste2p resulted in a ~3 kDa band
(Figure 8). The overlapping region of the two digestions (Trypsin and CNBr)
corresponded to the region of Ste2p between residues F55 to R58 for Bpa13 cross-linking.
Further analysis of Bpa13 cross-linked Ste2p with BNPS-skatole was carried out.
Digestion of the cross-linked native receptor resulted in two detectable bands around 12
and 10 kDa (Figure 9). Similar digestion with the deglycosylated receptor resulted in a
single band around 10 kDa indicating that Bpa13 cross-linked to a glycosylated region of
Ste2p represented by IC (region 1 to 70 of Ste2p) (Figure 9, Figure 7C). As a control to
determine whether anomalous cleavage occurred with the BNPS-skatole reagent, we
subjected the Bpa1-cross-linked receptor to fragmentation under similar conditions. In
this case only one band (~27 kDa) was observed (Figure 9). Although one might predict
that the BNPS-skatole reagent would cleave inside the peptide ligand thus releasing this
ligand, we believe that the proximity of the cross-linked site (position one) to Trp3 in the
analog might significantly slow down this reaction.

Site-directed Ala mutations between residues M54 and R58 of Ste2p:
After assignment of a region of interaction for [Bpa13]α-factor analog by crosslinking studies, site-directed Ala mutations in this region were carried out to identify a
possible contact point. Five individual alanine mutations were introduced in the region of
Ste2p between M54 and R58. Additionally two mutants (R58D and R58E) generated by
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Figure 8: Western blot analysis of CNBr digested BJS21 pNED photo-cross-linked
membranes. Membranes photo-cross-linked with various Bpa containing α-factor
analogs were digested with CNBr and resolved by Nu-PAGE 12% Bis-Tris gel. Proteins
were transferred to a PVDF membrane and probed with NA-HRP to detect the biotin
signal on the analogs. Membranes, cross-linked with α-factor, were used as negative
control, and ligand alone was used for positive control.
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Figure 9: Western blot analysis of BNPS-skatole digested BJS21 pNED photo-crosslinked membranes. Bpa1 and Bpa13 cross-linked BJS21 pNED membranes [native (-)
or deglycosylated (+)]were digested with BNPS-skatole (Pierce) for 16 hr @ 37 °C, then
resolved by 12% Bis-Tris gel (Invitrogen) and transferred to PVDF membrane.
Membranes were probed with NA-HRP conjugate to detect the biotin signal on the Bpa1
and Bpa13 analogs. A) ~27 kDa band corresponding to a region of Ste2p between
residues 71 to 295 (25 kDa) plus the ligand (2 kDa) B) Left lane is the BNPS-skatole
digest of the native (-) membranes and generates two bands (~12 and ~10 kDa), right lane
is the BNPS-skatole digest of the PNGaseF treated [deglycosylated (+)] membranes.
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Ayca Akal-Strader and a double mutant F55A-R58A were used in these experiments.
Halo assays indicated that the biological activity for the mutant receptors, except F55AR58A double mutant and G56A mutant, were similar or slightly reduced as compared to
the wild type receptor (Table 4). The G56A mutant was previously characterized by
Blumer et al. with similar results [49]. This study concluded that G56 residue was
involved in receptor dimerization forming a GXXXG motif like that found in glycophorin
A; mutation at this residue resulted a 3-5 fold lower response to α-factor induced growth
arrest as detected by the halo assay.
Binding affinities for the mutant receptors, detected by saturation binding assay,
showed that receptors carrying a mutation at the R58 position had poor binding to the αfactor indicated by a large decrease in the Ki (Figure 10, Table 4). Other mutant receptors
had similar or slightly lower binding affinities to α-factor. The combination of our
previous results for position 13 α-factor analogs [50] (Table 5) and the current findings
by cross-linking and site-directed mutagenesis suggested that position 13 of α-factor
might be interacting with R58 of Ste2p. In order to further validate this hypothesis crosslinking experiments were carried out with the five Ala mutants generated in this study.
Western blot analysis detecting the FLAG tag on Ste2p showed that all of the mutants
were expressed in the membrane (data not shown). Detection of biotin tag on the
[Bpa13]α-factor analog by NA-HRP showed that cross-linking of [Bpa13]α-factor analog
to the R58A mutant was highly diminished. Similarly a lower amount of cross-linking
was observed to the M54A mutant (Figure 11). Unlike R58A and M54A, the remaining
Ala mutants (F55A, G56A, and V57A) showed relatively equal amounts of biotin signal.
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Table 4: Summary of the binding affinities and biological activities of Ala mutants.

a

Receptor

Binding affinity
(Ki, nM)

% Biological activity
(Halo assay)

Wild type

2.7 ±0.5

100

M54A

3.6 ±0.3

~80

F55A

7.6 ±1.4

~70

F55A & R58A

>100a

~50

G56A

3.7 ±1.1

~20

V57A

2.7 ±0.5

~70

R58A

20.4 ±5.5

~80

R58D

>100a

~70

R58E

20.9 ±6.7

~70

Saturation curve was linear under the tested concentrations, thus the Ki is only an

estimation.
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Saturation Binding Assay
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1500
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R58A
R58E
R58D
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0
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Figure 10: Saturation binding assay with R58 mutants. Site-directed mutagenesis of
the R58 residue in Ste2p (to Ala, Glu, and Asp) was carried out and the binding affinities
of the mutants were determined by a saturation binding assay. (■)Wild type receptor,
(▲)R58A mutant, (▼)R58E mutant, and (∆)R58D mutant.
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Table 5: Summary of the binding affinities and biological activities of position 13 αfactor analogs.

Peptide

Binding affinity
(Ki, nM)

% Biological activity
(Halo assay)

α-factor

11 ±3

100

Phe13

22 ±3

120

p-F-Phe13

16 ±3

110

m-F-Phe13

59 ±6

86

p-NO2-Phe13

58 ±7

94

Ala13

>1000

40

Ser13

>1000

55

Table adapted from S. Liu et al. [50]
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R58A

V57A

G56A

F55A

M54A

250
150
100
75
XL
Ste2p 50
37
25
20
10

Figure 11: Western blot analysis of photo-cross-linked Ala mutant BJS21
pGA314.Cys-less.STE2.FT.HT membranes. Membranes carrying five individual Ala
mutants of Ste2p (M54A, F55A, G56A, V57A and R58A) were photo-cross-linked with
biotinylated [Bpa13]α-factor analog and resolved by 10% SDS-PAGE. Proteins were
transferred to a PVDF membrane and probed with NA-HRP to detect the biotin signal on
the analog.
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CHAPTER 4
Discussion

This part of the dissertation details the synthesis and characterization of a new set
of α-factor analogs containing Bpa as a photoactivatable cross-linker and biotin as a tag
for detection. Photoaffinity labeling of receptor residues with Bpa has been used as a
powerful tool to obtain constraints to better understand the molecular basis of ligand
binding and activation of receptors [11-13, 15-17, 25, 26, 29, 51]. Most of these studies
used 125I as a tag to track the cross-linking efficiency and detect the resulting cross-linked
fragment after various chemical and enzymatic digestions for mapping the contact region.
Previous studies described in part II showed that iodination of Bpa-scanned α-factor
analogs except Bpa at position 1, resulted in either loss of function due to multiple
iodination or drastic decrease in binding affinity, which made it impractical for crosslinking studies [30]. Although biotin detection uses an indirect method that includes
transfer to membrane, probing with NA-HRP and detection by a colorimetric enzymatic
reaction compared to direct detection of radioiodine, the relatively unstable nature and
high hydrophobicity of the 125I tagged ligand raised additional problems during
comparison of consecutive experiments. Furthermore, in future investigations
biotinylated peptide fragments generated by chemical or enzymatic degradation can be
isolated by affinity purification procedures and subjected to mass spectrometry.
Therefore, in this part (part III) of the dissertation the use of biotin instead of 125I as a
reporting tag with a series of Bpa scanned α-factor analogs was summarized.
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Early studies on angiotensin II receptor [52] and recent work on chemotactic
peptide analogs [53] and the integrin receptor [54] showed that biotin can be used as a
reporting tag instead of radioactive isotopes. However, most of these studies were
hampered by the low affinity of the ligand analogs due to incorporation of biotin as a
reporter tag. Results presented in this part (part III) indicated that all of the
Bpa/biotinylated analogs tested except Bpa8 retained binding affinities within
approximately one order of magnitude of that of α-factor and were agonists (Table 2).
Detection of the biotin tag was achieved by NeutrAvidin-horse radish peroxidase
conjugate, which takes advantage of the strong interaction between the biotin and
NeutrAvidin and a powerful reporting signal from the product of the peroxidase reaction
thus avoiding the use of iodine at any point in the detection protocol.
Cross-linking experiments done with the membranes from a Ste2p knock-out
strain (BJS21) showed that under the conditions tested no nonspecific cross-linking or
endogenous biotin signal in the region of Ste2p was detected (Figure 4), although some
higher molecular weight bands were detected (Figure 5). In addition cross-linking of the
biotinylated Bpa analogs to Ste2p was prevented by mixing 100-fold molar excess of
wild type pheromone into the reaction mixture prior to UV irradiation (Figure 5). Thus, in
principle these α-factor analogs can be used to determine contacts between ligand side
chains and receptor residues involved in binding interactions between α-factor and its
GPCR Ste2p.
The [Bpa5]α-factor had good binding affinity but was a weak agonist (Table 2).
Using an excess of ligand we obtained reasonable cross-linking of this analog (Figure 4).
However, only limited amounts of cross-linked product were recovered from preparative
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gels and digestion with both chemical and enzymatic reagents resulted in loss of signal
(data not shown). Considering our current working model for ligand-receptor
interactions, residue 5 of α-factor might be exposed to solvent or involved in interactions
with the extracellular loops. Relative to the trans-membrane (TM) domains, the loops are
more mobile which might cause the environment around Bpa5 to be more dynamic. Such
mobility around Bpa5 might influence cross-linking efficiency and thus hinder Bpa5-αfactor incorporation compared to the other analogs that seem to be interacting with the
TMs. Supporting the lack of importance of the position 5 side chain in tight interactions
with the binding site was our observation that the [L-Ala5]α-factor had the highest
receptor affinity of any of the alanine scanned α-factors [55]. Thus, further analysis was
not carried out with [Bpa5]α-factor although we plan to revisit this issue if we can
optimize cross-linking efficiencies in future studies. Due to lack of detectable biological
activity and poor competition between the [Bpa8]α-factor analog and α-factor for
receptor binding (Figure 1, Table 2), fragmentation analysis for the receptor cross-linked
with this analog was not carried out.
Trypsin digestion of the cross-linked receptor resulted in a band ~5 kDa for both
[Bpa1]α-factor and [Bpa3]α-factor analogs (Figure 6). The presence of multiple possible
trypsin digestion fragments that could gave a band around 5 kDa (IIIA, IVA, VA, VIA,
VIIIA, IXA, and XA, Figure 5A, when cross-linked to the 2 kDa Bpa1 or Bpa3 analogs
would give a ~5 kDa fragment) made it very difficult to assign a cross-link region for
Bpa1 and Bpa3 with only these results. On the other hand, when these results were
combined with the CNBr digestion data, the region of the Ste2p interacting with [Bpa1]α146

factor and [Bpa3]α-factor analogs was narrowed down to two possibilities: a region
covering part of EL2 and an extracellular portion of TM5 (Figure 7B, VIB) or part of
TM6, EL3 and part of TM7 (Figure 7B, VIIIB). In part II, it has been determined that
[Bpa1]α-factor cross-linked to a portion of Ste2p comprising TM6-EL3-TM7 [30] in
agreement with the second possibility mentioned above. If both N-terminal tryptophan
residues of α-factor interact with the same portion of Ste2p, then [Bpa3]α-factor might
interact as well with the TM6-EL3-TM7 region. However, based on the present
experimental results, we can not rule out the interaction of [Bpa3]α-factor with EL2TM5.
Trypsin digestion of the Bpa13-cross-linked receptor resulted in bands of ~8 and
~10 kDa (Figure 6). After complete trypsin digestion of cross-linked Ste2p there is only
one theoretical Ste2p region that could give these bands with the cross-linked ligand: the
glycosylated and unglycosylated N-terminus of the receptor (residues 1-58; Figure 7A,
fragment IA) [56]. Additional digestions with CNBr and BNPS-skatole were carried out
to further probe the cross-linking. Detection of a ~3 kDa band after CNBr digestion
(Figure 8) in combination with two bands, ~12 kDa (presumably the glycosylated Nterminal ~10 kDa fragment plus ligand) and ~10 kDa (the unglycosylated N-terminal plus
ligand) after BNPS-skatole digestion (Figure 9), strongly indicated that the N-terminus
of the receptor was the region cross-linked with [Bpa13]α-analog. The higher intensity of
the lower molecular weight band observed in figure 9 (middle lane) suggests one of two
explanations: glycosylation may interfere with either cross-linking efficiency or detection
by NA-HRP. To further test whether the ~12 kDa, BNPS-skatole fragment, was
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glycosylated, deglycosylation of the cross-linked receptor followed by BNPS-skatole
digestion was carried out. Results showed that upon deglycosylation only a single band
~10 kDa was detected (Figure 9). Thus, we conclude that the [Bpa13]α-analog interacts
with the junction between the N-terminus of Ste2p and the start of TM1. The smallest
overlapping region between the three different digestions (trypsin, CNBr, and BNPSskatole) carried with Ste2p cross-linked with [Bpa13]α-analog indicated that cross-linking
occurs at a region between residues F55 to R58. Although the [Bpa13]-analog had a
relatively higher loss in affinity and efficacy, almost complete competition with the wild
type ligand in a receptor binding assay, detection of biological activity by the halo assay,
and prevention of cross-linking by an excess of α-factor indicated that this analog
interacted with the receptor in a similar manner as the wild type ligand. Thus information
gathered from this ligand will be helpful to interpret the possible contact(s) of position 13
of α-factor with its receptor Ste2p. Nevertheless, it is conceivable that the presence of the
large diphenylketone group in the position 13 side-chain does result in a reorientation of
the peptide in the binding site. The identification of contacts between the position 1, 3
and 13 side chains of α-factor and specific regions of Ste2p leads refinement of the
current working model [30] for the placement of the pheromone into its binding pocket
on the receptor. Results presented herein indicate that the [Bpa1]α-factor analog and the
[Bpa3]α-factor analog interact with a region of Ste2p covering EL2-TM5 or TM6-EL3TM7. Results reported in part II using an iodinated [Bpa1]α-analog showed a contact
between position one of the ligand and TM6-EL3-TM7 [30]. Taken together, the present
and previous results suggested that the N-terminus of the pheromone interacts with a
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binding domain consisting of residues from the extracellular ends of TM5, TM6, and
TM7 and portions of EL2 and EL3 close to these TMs. These conclusions are consistent
with a previously proposed model [57] for α-factor bound to Ste2p. Nevertheless, it is
important to emphasize that the cross-linking results do not preclude other portions of
Ste2p participating in the binding domain for the N-terminus of α-factor.
This part also presented a direct interaction between the [Bpa13]α-analog and a
region of Ste2p at the extracellular end of TM1. Supporting this interaction are studies
from our laboratory demonstrating that changes at both residue 58 in TM1 and position
13 of the ligand exhibit a similar phenotype (Tables 3 and 4). Site-directed mutagenesis
studies in TM1 showed that mutation of the R58 residue (R58A, R58D, or R58E) results
in a 25-100 fold decrease in binding affinity of the wild type pheromone (Figure 10) and
only 20-30% decrease in the biological activity determined by halo assay (Table 4).
Similarly, previous work reported by Liu et al. [50] showed that position 13 analogs of αfactor, where Tyr was replaced by Ala or Ser had very poor binding affinities, but
showed relatively good biological activity (Table 5). Thus, data from pheromone-receptor
cross-linking studies, receptor mutagenesis analysis, and the structure-activity
relationships of α-factor analogs would be consistent with an interaction between
position 13 of the pheromone and TM1. However, this conclusion conflicts with a
previously reported hypothesis on a possible interaction between position 13 of α-factor
and F204 (located at the extracellular end of TM5) of Ste2p [57]. This hypothesis was
mainly based on site-directed mutagenesis (F204C) resulting in a receptor defective in αfactor binding, and previous studies from our laboratory [55] showing defective binding
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of position 13 α-factor analogs. Considering the current working model and results
presented in this part (part III) of the dissertation, an interaction between position 13 of
α-factor and TM5 of Ste2p is unlikely.
Cross-linking analyses, presented in this part of the dissertation, suggested that
Trp1, Trp3 and Tyr13 of the pheromone interact with TM6-EL3-TM7, EL2-TM5 or TM6EL3-TM7, and TM1 regions of Ste2p, respectively. These findings have led the
refinement of the working model for fitting the tridecapeptide into the pheromone
binding site (Figure 12). This model has a contact of Tyr13 of the pheromone with Ste2p
residues between F55 to R58, an interaction between pheromone residue Gln10 with
receptor residues S47 and/or T48, contacts of residues Trp1 and Trp3 of α-factor with
Y266 and F204 of Ste2p, and a β-turn around the Pro-Gly sequence in the center of αfactor allowing the middle of the pheromone to interact with extracellular loops.
Additional constraints of the bound structure should be forthcoming as further
refinements achieved by cross-linking studies with Bpa3 and Bpa5 analogs and
sequencing analysis of the cross-linked fragments by mass spectrometry currently in
progress in our laboratory.
Understanding how G protein-coupled receptors are activated by ligand binding is
an important goal of workers in the GPCR field. A de novo computer model of Ste2p in
the resting state (G. Nikiforovich, unpublished data) suggests that R58 and Y98 are in
close enough proximity to be involved in a cation-pi interaction. An interaction between
the Tyr13 of the pheromone and R58 of Ste2p, as described in the binding model
presented herein, would disturb this cation-pi interaction leading to a conformational
change that might facilitate a receptor shift to a more active state. Mutational studies on
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Figure 12: Working model for the fitting of α-factor pheromone into the ligand
binding site on its GPCR, Ste2p. α-factor and the loops are represented by the grey
curve and dotted lines respectively. Contact residues determined in this study and
previous studies indicated by a star symbol with the residue number of the pheromone.
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Y98 showed that replacing this residue with a histidine resulted in a receptor that was
weakly constitutive and supersensitive to pheromone [59], which supports the idea that
Y98 is important for stabilizing the inactive state of Ste2p, perhaps by interacting with
R58. Additional studies on this GPCR system should lead to valuable insights into the
mechanism of GPCR activation by a peptide ligand.
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PART IV
Purification of Cross-linked Receptor Fragments
and Mass Spectrometry Analysis
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CHAPTER 1
Introduction

Photoaffinity labeling is one of the few direct experimental strategies used to
identify ligand-binding sites in biomolecules like GPCRs (see reviews [1-5]). Since the
introduction of this technique, researchers have used tagged photoaffinity reagents
(mostly radioactively labeled) and purified photolabelled fragments by conventional
purification techniques. These fragments are usually further analyzed either by amino
acid sequence analysis or fragmentation studies with chemical or enzymatic reagents.
Although valuable information may be gained, many of these studies had limited
resolution due to the size of the digested photolabelled fragments (in the order of several
kDa in most cases) [6-9] or resistance to classical sequencing techniques [2]. Sitedirected or random mutagenesis experiments have contributed to the identification of
receptor regions that are important in agonist selectivity or affinity, however these studies
lack direct structure information about the agonist-receptor complexes.
Mass spectrometry (MS) is becoming the method of choice to overcome problems
caused by limited sample yields for labeled peptide fragments produced in small
quantities and to obtain better resolution in sequencing. In addition to the development of
methods for the identification of post-translational modifications (for example,
glycosylation and phosphorylation), electrospray (ES) [10-15] and matrix-assisted laserdesorption ionization (MALDI) MS [16-18] have been used for studies on ligand-
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receptor interactions, suicide inhibitors and affinity labels. Recent progress in MS enables
detection and sequencing of peptides in sub-picomolar quantities (see reviews [19-22]).
Identification of a cross-linking site generated by photoaffinity labeling often
requires the sequencing of the cross-linked fragment. Sequencing could be performed in
the conventional fashion by Edman degradation or with exoproteases, however the
amount of sample requirement is much greater than that needed for MS (>100 pmol) [23]
and neither method is useful for membrane proteins due to low yields in purification and
inadequate digestion by proteases [2]. Recently, several MS methods, including postsource-decay MALDI-time of flight (MALDI-TOF) MS [24-26] and tandem MS
(MS/MS) [27-30], have been used to analyze the sequence of a peptide fragment.
A few groups have reported successful identification of the specific amino acids
labeled in a protein using photoaffinity labeling combined with MALDI-TOF MS, such
as the study on NK-1 receptor by Sachon et al. [31]. Leite et al. [32]used benzophenone
based photo-probes and employed on-line liquid chromatography/tandem mass
spectrometry (LC-MS/MS) with an ion trap to identify the photolabeled peptides and
amino acid residues in the nicotinic acetylcholine receptor. Although the sample amount
and handling is minimal with these methods, determination of the primary sequence from
the fragmentation pattern of a branched peptide can be quite difficult due to the
complexity of the fragmentation process [33, 34]. Frequently, a proteolytic digest of a
cross-linked protein includes multiple species: cross-linked peptides, linear peptides, and
modified peptides thus making it difficult to identify and analyze the desired labeled
fragments at normal instrument resolution. Furthermore presence of complete and
incomplete digest fragments increases the number of possible cross-linked peptides in the
163

complex mixture. While all these cross-linked peptides will not be observed due to
chemical preference and proper geometric orientation of the cross-linker and the target
residue(s), all possibilities must be considered in interpreting experimentally observed
mass/charge (m/z) values. Despite the fact that there are a few computer programs used
for the analysis of mass spectra obtained from digested cross-linked proteins[35-38],
careful examination of the data manually is often required.
Several methods have been described for distinguishing cross-linked peptides in
mass spectra of cross-linked and digested proteins. Some of these methods use
isotopically labeled cross-linkers [39, 40] or proteins [41] that yield a distinctive
signature in the mass spectrum. These techniques rely on the observation of a
characteristic pattern in the mass spectrum or tandem mass spectrum of the analyte
mixture. However, if the signal-to-noise ratio of the cross-linked species yielding this
pattern is insufficient, the pattern cannot be reliably distinguished.
The few successful examples mentioned above, where mass spectrometry was
used to identify photoaffinity labeled residues, revealed that an efficient purification of
the cross-linked peptide from a complex mixture is essential prior to MS analyses.
Inadequate purification further complicates the collision induced dissociation (CID)-MS,
thus making it almost impossible to identify the modified residue. Therefore, a separation
method for enriching the cross-linked species from the analyte mixture would be useful
for reducing levels of complexity caused by the non-cross-linked peptides. An affinity
separation provides such an advantage, as described by Trester-Zedlitz et al. [42]. This
part of the dissertation mainly describes the use of avidin-biotin interaction to purify the
biotinylated α-factor analogs and the cross-linked receptor fragments from a yeast
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membrane digest. It has been previously shown that a similar approach aided analysis of
biotinylated fragments of avian skeletal muscle troponin C (TnC) from various mixtures
of biotinylated TnC, BSA and equine cytochrome c following different enzymatic
digestions [43].
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CHAPTER 2
Materials and Methods

Chemical Reagents:
Immunopure immobilized monomeric avidin and streptavidin beads were
purchased from Pierce (Rockford, IL). The acetone, water, and acetonitrile used in all
HPLC applications and sample purifications were HPLC grade and obtained from
Burdick & Jackson (Muskegon, MI). The 98% formic acid used in these applications was
purchased from EM Science (an affiliate of MERCK KgaA, Darmstadt, Germany).
Buffer components and salts were from Sigma (St. Louis, MO). Alpha-Cyano-4hydroxycinnamic acid (CHCA) and Sinapinic acid were purchased from Aldrich
(Milwaukee, WI). CHCA was re-crystallized from ethanol before use. Immobilon NC
Pure nitrocellulose was obtained from Millipore. Sequencing grade modified trypsin was
used as supplied by Roche Diagnostics (Indianapolis, IN). Bovine serum albumin (BSA)
and CNBr were from ICN Biomedicals (Aurora, OH). Dialysis tubing was from
Spectrapor (Annex, LA). Immobilized-metal affinity chromatography (IMAC) was
carried out either with Nitrilotriacetic acid pre-charged with Ni2+ (Ni-NTA) from Qiagen
(Valencia, CA), or with HiTrap chelating column charged with Cu2+ from Amersham
Biosciences (Piscataway, NJ).
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Photoaffinity cross-linking:
Photoaffinity cross-linking was carried out with various 4-benzoyl-Lphenylalanine (Bpa)-containing α-factor analogs as described in Part II and III. Briefly
BJS21 pNED membranes (220 µg/ml of total protein) were incubated with PPBi buffer
(total volume 1ml, with 0.1%BSA) in siliconized microfuge tubes for 10 min at ambient
temperature. Bpa-scanned biotinylated α-factor analogs (10 to 20 nM) were added, and
the reaction was incubated for 30 min at room temperature with gentle mixing. The
reaction mixture was aliquoted into 3 wells of a chilled 24 well plastic culture plate preblocked with PPBi (0.1% BSA). The samples were held at 4 °C and irradiated without the
culture plate lid at 365 nm for 1 hour at a distance of 12 cm in a Stratlinker (Stratagene,
La Jolla, CA). Membrane samples were recombined in siliconized microfuge tubes and
washed twice by centrifugation (14000g) with PPBi (0.1% BSA). Then membrane pellets
were stored at -80 ˚C for further experiments.

Purification of intact cross-linked Ste2p:
Immobilized-metal affinity chromatography (IMAC), and size exclusion
(preparative gel extraction) were used to partially purify the cross-linked Ste2p prior to
further analysis. Partial purification before fragmentation and affinity purification helped
to increase the yield and decreased the complexity in mass spectrometry analysis. The
purification efficiency was tested by western blot analysis of the fractions collected from
the columns and total protein in each elution was checked with Silver or Coomassie
staining of the protein bands after SDS-PAGE.
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a. Hi-Trap column:
HiTrap chelating HP from Amersham Biosciences was used for IMAC. This
column is composed of highly-cross-linked agarose beads to which iminodiacetic acid
(IDA) has been coupled by stable ether groups via a spacer arm. The column is charged
with 0.1 M CuSO4 and used by following the supplier’s protocol with the following
modifications: The membranes containing Ste2p from BJS21 pNED (cross-linked or not,
~ 1.5 mg/ml total protein) were solubilized in 6M urea (pH = 8.0) for at least 5hr (final
volume 1 ml) followed by direct injection to a HiTrap column. The column was then
connected to a high performance liquid chromatography (HPLC) instrument (Hewlett
Packard, 1100 series). A wash step was then carried out with 50 mM ammonium
bicarbonate buffer (pH=8.0), containing 50 mM imidazole and 6M urea. Elution of the
bound proteins was achieved by the same buffer with 200 mM imidazole.
b. Ni-NTA column:
Ni-NTA agarose from Qiagen was used as an alternative metal-chelating matrix.
This column is composed of Ni-NTA coupled to Sepharose® CL-6B and offers high
binding capacity and minimal nonspecific binding. The protocol was adapted from a
previous Ste2p purification study by David et al. [44]. Briefly, the membranes (510mg/ml total protein) were solubilized in solubilization buffer (1% Dodecyl β
Maltoside, 10% glycerol, 150 nM NaCl in 50 mM HEPES, pH=7.5, plus protease
inhibitors;final volume 2 ml) and were incubated with 1ml Ni-NTA (pre-equilibrated
with equilibration buffer: 10% glycerol, 500 nM NaCl in 50 mM HEPES, pH=7.5, plus
protease inhibitors) overnight (o/n) by end-to-end mixing. The flowthrough was collected
from the column as the resin packed. The column was washed with 5 column volumes of
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equilibration buffer, followed by 10 column volumes of wash buffer (10% glycerol, 150
nM NaCl, 50 mM imidazole in 50 mM HEPES, pH=7.5, plus protease inhibitors).
Column-bound material was then eluted with 5 column volumes of elution buffer (10%
glycerol, 150 nM NaCl, 300 mM imidazole in 50 mM HEPES, pH=7.5, plus protease
inhibitors). Fractions were concentrated with Microcon® YM-30 (Millipore, MW cutoff =
30,000 Da.) before further analysis.
c. Preparative Gel extraction:
BJS21 pNED membranes and cross-linked membranes (~1.5 mg total protein)
were dissolved in 400 µl 1x loading buffer (BIO-RAD tricine sample buffer) for at least
an hour. The dissolved membranes were then loaded on a preparative 10% SDS gel and
resolved for 80 min at 25 mAmp. After the proteins resolved according to size, a 10 mm
wide strip around the 50 kDa marker was cut out of the gel. The strip was then placed in
dialysis tubing (MW cutoff = 25,000 Da.) with transfer buffer (25 mM Tris, 0.2 M
Glycine and 20% methanol) and electro-eluted for 3 hr at 400 mAmp in a vertical transfer
apparatus (Hoefer Scientific Inst.). Following electro-elution the dialysis tubing (20 ml)
was placed in a 4 liters beaker filled with 25 mM ammonium bicarbonate. The buffer was
changed every hour for three hours and then kept o/n at 4 °C.

Digestion of cross-linked Ste2p:
Chemical and enzymatic digestions were carried out after the partial purification
of the cross-linked samples. The fragmentation was achieved as described in parts II and
III. In brief, the concentrated samples (~0.1-0.2 mg/ml) were either re-suspended in 70%
formic acid for CNBr digestion or in buffer (100 mM Tris-HCl, pH 8.5) for trypsin
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digestion. All digestions were carried out in complete darkness, under nitrogen gas, and
at 37 °C for at least 24 hr. All digests were concentrated by vacuum centrifugation
(SpeedVac) and analyzed by SDS-PAGE or mass spectrometry.

Test of avidin purification:
Immunopure immobilized monomeric avidin and streptavidin beads were tested
for the efficiency of capturing biotinylated peptides from simple and complex mixtures.
The compatibility of these beads with MALDI-TOF was analyzed and compared. Ten µl
of the biotinylated α-factor analog (Bpa8, 0.1µg/µl) was mixed with an equal volume of
beads. The mixture was incubated at room temperature with continuous agitation for an
hour. After the incubation the beads were washed with 50 µl PBS (0.1 M sodium
phosphate, 0.15 M NaCl, pH = 7.2) 4 times, followed by washing with 50 µl water (5
times). The beads were then left to settle and the supernatant was withdrawn after
approximately 15 min.. The pellet was re-suspended in a minimal amount of water (10
µl) and used in a MALDI-TOF experiment.
Capture of biotinylated α-factor analog from a simple and a complex mixture was
carried out by applying a similar protocol. Preparation of a simple and a complex mixture
of [Bpa8]α-factor analog was achieved by mixing with an equal amount of α-factor (0.1
µg/µl, 10 µl final volume) or CNBr digested BJS21 pNED membranes (~300µg total
protein), respectively. Ten µl of these mixtures were incubated with the beads as
described above. After the wash steps the beads were directly analyzed by MALDI-TOF.
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CNBr digested BJS21 pNED membranes cross-linked with various Bpa-scanned
biotinylated α-factor analogs were examined under similar conditions.

Purification of cross-linked Ste2p fragments with Monomeric avidin column:
After the fragmentation of the cross-linked membranes (~0.1-0.2 mg/ml) with
CNBr or Trypsin, the digests were loaded onto a 1 ml packed monomeric avidin column.
The column was washed with at least 5 column volumes of PBS followed by a second
wash with 10 column volumes of 10% methanol, 50 mM ammonium bicarbonate. The
bound biotinylated fragments were eluted with 5 column volumes of 50% acetonitrile,
0.4% TFA [45]. The elutions were then pooled and concentrated by vacuum
centrifugation to a final volume of 100 µl and analyzed by mass spectrometry.

Mass spectrometry:
All of the mass spectrometry experiments were carried out in collaboration with
the Biological Mass Spectrometry group in Oak Ridge National Laboratory (ORNL).
Sample preparation and cleanup was done at the University of Tennessee and analysis
was accomplished at ORNL. Two main mass spectrometry techniques were applied as
described below:
a. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry
(MALDI-TOF-MS):
MALDI-TOF experiments were performed on a PerSeptive Biosystems Voyager
Elite MALDI-TOF, equipped with a 337 nm nitrogen laser, operating in the positive ion
mode (delayed extraction/linear mode). Spectra were obtained in reflector mode, with
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+20 kV total acceleration voltage, +18 kV applied to the grid, +10 V applied to the guide
wire, and 210 ns acceleration delay. Spectra were averaged from up to 256 individual
laser pulses, obtained from several locations on each sample spot. Sample aliquots were
applied to a pre-spotted thin-layer matrix. CHCA was prepared by dissolving 40 mg of
CHCA in 1 ml of 2-propanol: acetone (50:50, v/v). Nitrocellulose was prepared by
dissolving 10 mg in 1 ml 2-propanol: acetone (50:50, v/v). An equal volume of CHCA
and nitrocellulose were mixed to give 20 mg/ml CHCA and 5 mg/ml nitrocellulose. A 0.5
µl aliquot was dispensed onto the MALDI plate and allowed to dry. One-half µl volume
of samples were applied to the thin layer and allowed to dry. Sinapinic acid (SA) was
prepared by dissolving 10 mg SA in acetonitrile: 0.1% aqueous TFA (50:50, v/v).
Samples were applied as described above. External calibration of the m/z axis was
performed using gramicidin S and bovine insulin β-chain. Expected masses were
calculated using Protein Prospector [46].
Direct application of the avidin beads to MALDI plate was carried out by the
protocol adapted from Li et al. [47]. Briefly, a layer of CHCA or SA (dissolved in
acetone, 25 mg/ml) was applied to the MALDI plate, forming a dense layer of small
crystals to allow adsorption of the beads. One µl of the bead slurry was then added and
allowed to dry partially. An aliquot of a second matrix solution (CHCA or SA dissolved
in aceteone, >50mg/ml) then was applied to allow solubilization of adsorbed peptides
from the beads into the matrix solution. Upon complete drying, the beads were blown off
with a stream of dry nitrogen leaving un-adsorbed peptides within the matrix ready for
MALDI-TOF analysis. A schematic of the sample preparation procedure is shown in
Figure 1.
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Figure 1: Schematic representation of the MALDI procedure with avidin beads.
Avidin beads were used to capture biotinylated peptides from simple or complex
mixtures. Beads were spotted directly on the MALDI matrix for analysis (figure adapted
from [47]).
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b. Nanospray mass spectrometry (NS-MS):
NS-MS was performed on a LCQ-DECA instrument (Thermo Finnigan) operating in
the positive ion mode. Nanospray voltage was set to 2.0kV (Thermo Finnigan nanospray
source) and the heated capillary was set at 200°C. A 20µm id fused silica was directly
connected to a liquid junction (Thermo Finnigan), which was connected to a 10µm id
uncoated fused silica tip (New Objective, Woburn, MA). The MS was operated with 5
microscans averaged for full scans and MS/MS scans, 5 m/z isolation widths for MS/MS
isolations and 35% collision energy for collision-induced dissociation. For all
experiments, the MS was operated in the data dependent MS/MS mode, where the four
most abundant peaks in every full MS scan were subjected to MS/MS analysis. To
prevent repetitive analysis of the same intense peptides, dynamic exclusion was enabled
with a repeat count of 2. The exclusion duration was set to 1 minute. LC-MS/MS
experiments were performed on an integrated Famos/Switchos/Ultimate 1D/2D HPLC
system (LC Packings, a division of Dionex, San Francisco, CA) directly coupled to a
quadrupole ion trap mass spectrometer (LCQ-DECA Thermo Finnigan, San Jose, CA)
outfitted with a Finnigan nanospray (NS) source. The entire system was fully automated
and under direct control of the Xcalibur software system (Thermo Finnigan). For all
reverse phase separations, gradients were run from 100% Solvent A (95% H2O/ 5%
ACN/ 0.1% formic acid) to 100% Solvent B (30% H2O/ 70% ACN/ 0.1% formic acid),
followed by a wash with 100% Solvent B and a 20 minute equilibration back to Solvent
A before the next run (run times dependent upon experiment type). The loading solvent
used in the 1D LC-MS/MS experiments was 100% H2O with 0.1% formic acid. For all
nano mode reverse phase separations the flow rate was set at 200nL/min. The reverse
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phase separations were carried out by a VYDAC C18 column (Part No. 218MS5.07515;
75µm id x 15cm, 300Å with 5µm particles). All injections were made by an autosampler
(Famos) onto a 50µL loop and flushed onto a LC Packings C18 precolumn (300µm id x
5mm, 100Å with PepMap C18 5µm particles), and eluted after desalting onto the VYDAC
C18 column. The outlet from the resolving column was directly connected to the NS
source with a short piece of fused silica (20µm id for NS).
The theoretical masses of the fragment ions were calculated by Prowl web site
“http://prowl.rockefeller.edu/”. This site considers the common modifications to amino
acids during fragmentation such as homoserine lactone formation at methionine residues
after CNBr digestion (-48 Da)
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CHAPTER 3
Results

Purification of intact cross-linked Ste2p:
Membranes obtained from BJS21 strain transformed with pNED (an over
expression vector carrying the STE2 gene) [44] were used in the purification experiments.
The α-factor receptor encoded by this plasmid is tagged at its C-terminus with an epitope
tag (FLAG) and a 6xHis tag. Two of the methods applied in this study took advantage of
the 6xHis affinity tag, which facilitates binding to metal ions. Immobilized-metal affinity
chromatography (IMAC), based on this principle, was first used to purify proteins in
1975 by Porath et al. [48]. The method was further optimized by other groups to purify a
variety of different proteins and peptides [49].
Two different IMAC beads were used to purify the Ste2p (Ste2p.FT.HT) as
detailed in Material and Methods. The HiTrap Chelating column from Amersham
Biosciences was used by connecting it to a HPLC system. Various concentrations of
imidazole (0, 25, 50, and 75 mM) in the wash buffer were tested to optimize the elution
of non-specifically bound proteins. Results indicated that most of the protein was washed
from the column in the flow-through (Figure 2, fractions 1-10; Figure 3, fractions 2, 4,
and 6) and that 50 mM imidazole in the wash buffer effectively removed the proteins that
are non-specifically attached to the resin as indicated by the absorbance of fractions 1730 (Figure 2). Western blot analysis (probed with anti-FLAG antibody) of the fractions
showed that elutions with 200 mM imidazole released the bound 6xHis tagged Ste2p in
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Figure 2: Elution of Ste2p.FT.HT from HiTrap column. HPLC elution profile (Abs. 280nm) of BJS21 pNED membranes from
Cu2+ charged HiTrap column is plotted. The inset shows the western blot of the selected fractions probed with anti-FLAG
antibody. Lanes labeled with the fraction number (indicating the elution time in minutes).
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fractions 42, 43 and 44. The higher molecular weight bands in fractions 42-44 were due
to aggregation of Ste2p in the absence of detergents. The high absorbance observed after
fraction 45 was due to the 200 mM imidazole in these fractions.
Similarly proteins solubilized from BJS21 pNED membranes that had been
subjected to cross-linking with biotinylated [Bpa1]α-factor were also partially purified by
a HiTrap column. Figure 4 illustrates that cross-linked Ste2p could be eluted with 200
mM imidazole and detected on a blot probed with NA-HRP. Most of the proteins eluted
in the flow-through as indicated by the abundance of proteins in the flow-through
fractions indicated by high absorbance (Figure 4) and in a silver-stained gel (data not
shown). In addition, the lack of bands in the NA-HRP probed blots (Figure 4) indicated
that the cross-linked Ste2p was not eluted in these fractions. Washing the column with 50
mM imidazole removed loosely bound proteins leading to a slight increase in absorption.
The cross-linked Ste2p was eluted after increasing the imidazole concentration to 200
mM. Both the increase in the absorption and bands detected by the NA-HRP blot
indicated that fractions 52-54 contained biotinylated protein. Washing the column with
500 mM imidazole after the elution did not lead to further release of tagged proteins. The
overall yield of cross-linked Ste2p (Figure 4) was lower than that obtained from uncrosslinked membranes (Figure 2).
The second matrix used for IMAC was Ni-NTA from Qiagen, which is a Ni2+charged Sepharose resin. Fractionation of proteins solubilized from the cross-linked
membranes was performed by following the supplier’s protocol with the modifications
described in Materials and Methods. Elutions from the Ni-NTA column were analyzed
after concentrating with vacuum centrifugation. Briefly, proteins were resolved by SDS179
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Figure 4: Elution of cross-linked Ste2p.FT.HT from HiTrap column. HPLC elution profile (Abs. 280nm) of cross-linked
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PAGE and transferred to PVDF membrane for western blot analysis. Blots were probed
with either Konopka antibody (this antibody was obtained from Prof. James Konopka,
SUNY Stony Brook; the antibody reacts specifically to the N-terminal 100 amino acids
of Ste2p) or NA-HRP to detect the presence of Ste2p.FT.HT and cross-linked
Ste2p.FT.HT, respectively (Figure 5). Analysis of both blots (Figure 5 A and B) showed
that elution 2 (E2) contained a protein of approximately 54 kDa that was biotinylated
(Figure 5A) and reacted with a specific antibody that recognized Ste2p (Figure 5B).
Retention of this protein through the wash steps indicated that it interacted with the
column tightly (due to the presence of a 6xHis tag). This blot also showed that a small
amount of Ste2p was present in the flow-through and washes 1 (W1) suggesting that
either the column was slightly over loaded or there was a small population of Ste2p
which lost the 6xHis tag during sample preparation. Detection of these bands with NAHRP was not observed, probably due to a lower sensitivity of this detection compared to
the Konopka antibody. Elutions from the Ni-NTA column were analyzed by silver
staining to determine the presence of other proteins that co-eluted with the bound Ste2p
(Figure 6). The presence of multiple bands revealed that several other membrane proteins
retained on the column after the 50 mM imidazole wash. Comparison of the two IMAC
matrices will be detailed in the Discussion part (Chapter 4).
An alternative approach for purification of intact Ste2p was based on size
exclusion. This method involved very little sample handling potentially giving higher
yield. Briefly, proteins solubilized from cross-linked membranes were dissolved in
loading buffer and resolved by 10% SDS-PAGE. After separation of proteins a 10 mm-
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Figure 5: Western blot analysis of the fractions from Ni-NTA column. Fractions collected from a Ni-NTA column loaded
with cross-linked BJS21 pNED membranes were concentrated and resolved by 10% SDS-PAGE. After transferred to PVDF
membranes blot A) probed with NA-HRP to detect biotin signal, and blot B) probed with Konopka antibody to detect Ste2p.
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Figure 6: Silver stained SDS-PAGE gel loaded with Ni-NTA column elutions. Crosslinked BJS21 pNED membranes resolved by 10% SDS-PAGE and protein bands detected
by silver staining.
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wide region of the gel around the 50 kDa band was removed, and proteins were electroeluted. Following dialysis the samples were concentrated by vacuum centrifugation and
assayed with western blot analysis and silver staining (Figure 7). The results showed that
there was no other detectable biotinylated protein in the purified sample. Also no
aggregation or degradation products were observed. Analysis of the silver stained gels
indicated the presence of a few other proteins in the partially purified sample (Figure
7A).

Analysis of partially purified Ste2p with Nanospray-MS (NS-MS):
Following the partial purification of Ste2p the compatibility of the purified
sample with tandem mass spectrometry was analyzed. For this assay FLAG-tagged,
6xHis tagged Ste2p was partially purified by a HiTrap column as described above (Figure
2). Following the purification step the concentrated sample (Fractions 42-44, Figure 2)
was re-suspended in 70% formic acid and digested with CNBr for 18hr at 37 °C. Digests
were then dried by vacuum centrifugation and neutralized with 50 mM ammonium
bicarbonate buffer (final volume ~ 100 µl). Analysis of the neutralized sample was
carried out with LCQ-DECA (Thermo Finnigan) operating in the positive ion mode. The
total ion spectrum obtained from this sample indicated that there were several ion packets
throughout the spectrum, indicating the presence of many peptides (Figure 8). Manual
analysis of the MS/MS data showed that at least 10% sequence coverage for Ste2p was
obtained. Representative spectra of two such fragments are shown in Figure 9. In one
spectrum (Figure 9A), a sequence of AAALTLIVM was clearly obtained allowing
assignment to the CNBr theoretical peptide FGVRCGAAALTLIVM. However, the
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Figure 7: Partial purification of cross-linked Ste2p by gel extraction. A) Silver
stained gel to show the total proteins present. Lane one is the unpurified cross-linked
BJS21 pNED membranes, lane two is after gel extraction. B) NA-HRP blot of the same
samples to detect the biotin tag (from the analog) on Ste2p. Lane 1 is the total membrane
and lane 2 is the partially purified sample.
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Figure 8: Total ion spectrum of CNBr digested HiTrap elution from LCQ-DECA. Multiple ion packets were observed
through out the chromatogram. Most of the peptides start eluting after 25 min.
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Figure 9: MS/MS spectrums of CNBr digested HiTrap elution from LCQ-DECA.
Two representatives for MS/MS spectrums revealing sequence information of CNBr
digested Ste2p fragments A) covering residues 55-69 and B) covering residues 181-189.
* Cleavage at methionine causes loss of 48 Da (formation of homoserine lactone).
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sequence coverage and the presence of many other peptides in the CNBr-digested HiTrap
elution necessitated the use of an alternative purification method to enrich cross-linked
Ste2p fragment(s).

Optimization of avidin purification and MALDI analysis:
As an alternative purification method, biotinylated samples were enriched by an
affinity capture method modified from Li et al. [47] and analyzed with MALDI-TOF.
This method allowed high sensitivity while minimizing sample handling by taking
advantage of the extremely strong interaction between avidin and biotin (having
dissociation constant on the order of 10-15) and incorporating this property into mass
spectrometry. Two types of immunopure immobilized avidin beads (monomeric avidin
and streptavidin from Pierce) were used and compared in this study. Biotinylated
[Bpa8]α-factor analog was used as the probe throughout the method optimizations,
carried out with uncross-linked samples, for mass spectrometry analysis. Capture and
detection of the biotinylated ligand from a simple (a 1:1 mixture of the probe with αfactor) and a complex (a 1:300, 1:30, and 1:6 mixture of the probe with CNBr digested
BJS21 pNED membranes) mixture was tested.
Analysis of mass spectra from the monomeric avidin beads after incubation with
the biotinylated [Bpa8]α-factor analog alone indicated that this peptide was captured on
the beads, ionized from the matrix during MALDI-TOF analysis, and detected as a
2159.11 m/z ion (theoretical, 2159 Da) (Figure 10). The mixture of α-factor and
biotinylated [Bpa8]α-factor showed that two peptides were detected in washes, designed
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Figure 10: Capture of biotinylated peptides from a simple mixture with monomeric
avidin beads. A) Biotinylated [Bpa8]α-factor mixed with monomeric avidin beads, B)
washes from the monomeric avidin beads after incubation with a mixture of biotinylated
[Bpa8]α-factor and α-factor (1:1), C) analysis of the washed monomeric avidin beads.
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to remove peptides not bound to avidin from the beads (Figure 10B). The detected
masses for these two peptides, 1668.19 and 1503.52 Da, matched the theoretical masses
for α-factor (1668 Da) and an autolysis product that was missing Tyr13 (1504 Da). There
were a few minor peaks around 2158 m/z indicating that a very small quantity of the
biotinylated probe was eluted in the wash. Spectra from material adsorbed on the washed
beads (Figure 10C) had one main peak at 2160 m/z corresponding to biotinylated
[Bpa8]α-factor (theoretical = 2159 Da) and a neighboring peak possibly due to two
sodium (2x22 Da) adduct, observed as 2204.08 Da.
Following the testing of the monomeric avidin beads, streptavidin beads were also
tested for the ability to capture biotinylated peptides. The control experiment to confirm
the binding to the beads was carried out by incubating the beads with biotinylated
[Bpa8]α-factor alone. Similar to monomeric avidin beads, analysis of the streptavidin
beads resulted in detection of a single peak around 2160 m/z (data not shown). However,
analysis of the washes from streptavidin beads showed that these samples contain
relatively more biotinylated [Bpa8]α-factor as revealed by the detection of peaks at
2159.93 and 2219.19 (a sodium + potassium adduct = +60 Da) m/z (Figure 11A). This
result indicated that the streptavidin beads did not bind this ligand as tightly as the
monomeric avidin beads. Spectra from washed streptavidin beads (Figure 11B) showed a
lower signal at 2161m/z as compared to the signal at this mass obtained from monomeric
avidin beads (Figure 10C). In addition, there were other peaks at lower m/z, perhaps due
to the presence of residual α-factor. Due to relatively lower binding of the biotinylated
peptide to streptavidin beads as compared to monomeric avidin bead, further experiments

191

Figure 11: Capture of biotinylated peptides from a simple mixture with streptavidin
beads. A) Washes from the streptavidin beads incubated with mixture of biotinylated
[Bpa8]α-factor and α-factor (1:1), B) analysis of the washed streptavidin beads.
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involving purification of biotinylated [Bpa8]α-factor from complex mixture was only
carried out with monomeric avidin beads.
Analysis of monomeric avidin beads, mixed with CNBr-digested membranes,
showed that a major peak at 4418.53 m/z was detected (Figure 12). This peak was likely
due to an endogenously biotinylated protein in yeast membranes. Such biotinylated
proteins are detected in blots of yeast membranes probed with NA-HRP (See part III of
this dissertation). The 4418 m/z peak was detected in all samples (Figure 12 A, B, and
C). This mass was excluded from subsequent spectral analyses in this dissertation.
Examination of various complex mixtures containing different ratios of biotinylated
peptide and membranes digested with CNBr suggested that even at a 1:300 mixture (by
weight) the biotinylated [Bpa8]α-factor analog (2166 m/z) was captured and identified by
MALDI-TOF analysis of monomeric avidin beads (Figure 12B). The 2166 m/z ion
detected in this experiment did not coincide exactly with the theoretical 2159 Da peptide.
This was attributed to an inaccurate assignment of the m/z ion in a dilute sample with a
low signal to noise ratio. A more accurate mass detection was obtained when the mixture
had a relatively higher amount of biotinylated probe in the mixture (ratio of biotinylated
[Bpa8]α-factor to membrane digest approximately 1:30, w/w) (Figure 12C). The
discrepancy between the theoretical mass of 2159 Da and the obtained 2161 m/z ion
might be due to an inexact calibration of the mass spectrometer.
Following these analyses, CNBr-digested cross-linked membranes were examined
under the same conditions. Cross-linking experiments were carried out, as detailed in
materials and methods chapter of Part III of this dissertation, with biotinylated [Bpa1]α-
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Figure 12: Capture of biotinylated peptides from a complex mixture with
monomeric avidin beads. CNBr-digested membranes were mixed with various amounts
of biotinylated [Bpa8]α-factor and the beads were analyzed with MALDI-TOF after
several washes. A) Beads incubated with CNBr-digested membranes alone, B) beads
incubated with[Bpa8]α-factor mixed with membrane digest (ratio,1:300 by weight), C)
beads incubated with [Bpa8]α-factor with membrane digest (ratio,1:30 by weight).
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factor analog. Analysis of the CNBr-digested membranes prior to cross-linking resulted
in detection of a peak at 4417.95 m/z (Figure 13A), the endogenous, biotinylated CNBr
fragment in yeast membranes, similar to the fragment found in previous experiments
(Figure 12A). The spectrum from the beads that were incubated with CNBr-digested
cross-linked membranes had three main peaks, 2071.98, 4413.49, and 6863.9 m/z (Figure
13B). As biotinylated [Bpa1]α-factor (theoretical mass = 2070 Da) was used in the crosslinking reaction, the 2071.98 ion corresponded to uncross-linked ligand. The peak at
4413.49 was assigned to the endogenously biotinylated peptide and did not match the
mass of any cross-linked Ste2p fragments. In addition a peak at 6863.9 m/z was
observed. In order to identify a possible cross-linked fragment that could give a signal in
this range the theoretical CNBr digestion map of Ste2p was examined. The closest
fragment that could generate a signal at this m/z is the region of Ste2p between residues
251 and 294 that gave a mass of 6639 upon cross-linking with biotinylated [Bpa1]αfactor .The region of Ste2p between residues 251 to 294 was previously identified as the
cross-linking region for [Bpa1]α-factor analogs as described in part II and III of this
dissertation. The 6639 theoretical mass was about 224 Da lower than the observed m/z.
A literature search on MALDI adducts showed that an adduct of 224 Da from the matrix
(SA) used in the MALDI-TOF experiment was observed [50]. If this adduct was indeed
associated with the ion found in the experiment (Figure 13), then the experimental mass
minus the adduct would match the theoretical mass for biotinylated analog cross-lined to
the region of Ste2p covering residues 251 to 294.
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Figure 13: Capture of cross-linked fragments with monomeric avidin beads. A)
CNBr digested yeast membranes were incubated with monomeric avidin beads and
analyzed with MALDI-TOF. B) Membranes cross-linked with biotinylated [Bpa1]αfactor analog were digested with CNBr, biotinylated fragments captured by monomeric
avidin beads and analyzed with MALDI-TOF.
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Purification and cleanup of biotinylated samples for Nanospray-MS (NS-MS):
Although the information obtained from MALDI-TOF was much more accurate
then calculating peptide masses from SDS-PAGE, sequencing was not possible with this
method. In order to identify the Ste2p residue(s) where the cross-linking takes place,
sequencing the cross-linked fragments is necessary. Tandem mass spectrometry analyses
were carried out, with a LCQ DECA instrument, to obtain sequence information from
biotinylated [Bpa8]α-factor and cross-linked Ste2p fragments. A column containing
monomeric avidin beads was used to purify biotinylated fragments prior to tandem NSMS analysis. The protocol was first tested with a complex mixture of CNBr-digested
yeast membranes and biotinylated [Bpa8]α-factor (300:1 mixture, w/w). Elutions from
the column were analyzed with the LCQ-DECA instrument. The results (Figure 14)
showed that there were relatively few peaks in the total ion spectra in comparison to the
HiTrap elutions previously analyzed with the same method (Figure 8).
MS/MS analysis of the main ions at 53 minutes covered almost the complete
sequence of biotinylated [Bpa8]α-factor (Figure 15). This spectrum also showed that the
biotin tag attached to Lys7 of the analog can be cleaved during fragmentation inside the
ion trap. This experiment showed that a monomeric avidin column could be used to
capture biotinylated peptides of sufficient purity for sequence analysis by tandem MS.
Following these results a similar purification protocol was applied to membranes
cross-linked with various biotinylated Bpa-scanned α-factor analogs (Bpa1, Bpa3, Bpa5
and Bpa13). Cross-linked Ste2p was first partially purified with gel extraction from the
solubilized membranes. This initial purification was required to get rid of the uncross-
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Figure 14: Analysis of elutions from monomeric avidin column with LCQ-DECA.
A) The total ion spectrum of the elutions from monomeric avidin column which was
incubated with a complex mixture (CNBr digested yeast membranes + biotinylated
[Bpa8]α-factor), B) the full MS spectra at 53rd minute indicating detection of a peptide
with a mass of ~2160 Da.
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Figure 15: MS/MS analysis of the 1080.79 m/z ion at 53rd minute. The main ion at 53rd min was selected and analyzed after
fragmentation by CID.
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linked ligand that would decrease the purification yield from avidin column. The
concentrated electro-elution samples were then re-suspended in 70% formic acid and
digested with CNBr. Concentrated digests were neutralized and loaded on a monomeric
avidin column to enrich the biotinylated fragments. Analysis of the elutions with LCQDECA showed that the total ion spectra contained a few main ion packets as shown in a
representative spectrum obtained from biotinylated [Bpa5]α-factor cross-linked
membrane digests (Figure 16A). Unfortunately, the fragmentation spectra for these ions
were too complex to analyze by hand and a proper software was not available to analyze
the data automatically. Manual analysis of the total ion spectra obtained from these
experiments revealed identification of a few peptide masses. For example the full MS
spectrum for biotinylated [Bpa5]α-factor cross-linked sample suggested that a 4678 Da
peptide was eluted at 37th minute of the MS analysis. The ion packet observed in figure
16B showed that this peptide is highly charged, thus the fragmentation spectrum could
contain multiply charged ions. Examination of the theoretical fragments from crosslinked Ste2p illustrated that the CNBr fragment covering residues 166-189 had the
closest mass (fragment mass 2488.23 + ligand mass 2128 = 4616.23 Da) to the mass
observed. The difference between the theoretical and observed masses was 61 Da, which
could be due to a sodium + potassium adduct (60 Da) during the sample preparation. A
similar adduct of 60 Da was observed when the biotinylated Bpa8 scanned ligand was
analyzed by MALDI-TOF (Figure 11A). Although an MS/MS sequence was obtained for
the major ions at this time point (data not shown), the sensitivity of the instrument was
not great enough to deconvolute the charge states of the fragment ions to identify the
sequence. However, the observed mass implied cross-linking of biotinylated [Bpa5]α202

Figure 16: Analysis of monomeric avidin column purified CNBr digested crosslinked membranes with LCQ-DECA. A) The total ion spectrum of the elutions from
monomeric avidin column loaded with CNBr digested membranes, cross-linked with
biotinylated [Bpa5]α-factor analog B) the full MS spectra at 37th minute showing the
multiple charge states of 4678 Da peptide.
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factor analog to a region of Ste2p covering residues 166-189 (TM4) with the assumption
of a 60 Da adduct as discussed above.
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CHAPTER 4
Discussion

In order to determine the Ste2p residue where the cross-linking of biotinylated
Bpa scanned α-factor analogs takes place, accurate mass detection is crucial. Recent
developments in mass spectrometry combined with a proper affinity purification make
this technique an invaluable method for detection of peptide masses with very high
accuracy and sensitivity [63-65].
Although purification techniques have been previously optimized to purify αfactor pheromone receptor (Ste2p) [44], application of these methods to cross-linked
membranes and compatibility of the elutions with mass spectrometry have not been
tested. This part of the dissertation outlined the use of different affinity chromatography
methods to purify intact Ste2p or biotinylated cross-linked fragments from a complex
membrane mixture, and a size exclusion protocol applied to partially purify Ste2p. Also
two mass spectrometry techniques were used to identify cross-linked regions on the αfactor pheromone receptor.
Currently, many affinity purification techniques are commonly used to purify
various proteins. In this study a 6xHis tagged Ste2p construct was used to take advantage
of the immobilized-metal affinity chromatography (IMAC). The FLAG tag present in the
same construct was used for detection purposes. After comparing two different metal
chelating resins as described in the results, the HiTrap column from Amersham
Biosciences was shown to be preferable to the Ni-NTA resin from Qiagen under the
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conditions tested. The main difference between the two resins is their interaction with the
metal ions. While the HiTrap column uses iminodiacetic acid (IDA) to interact with the
metal ions, Ni-NTA resin carries nitrilotriacetic acid (NTA), which provides an
additional interaction site for the metal ion (Figure 17A). The supplier of this resin claims
that this extra interaction with the metal ion increases the stability of the charged column
thus binding to 6xHis tagged proteins would be tighter than IDA matrices. However,
occupation of four out of six binding sites of (+2) charged metal ion leaves only two
possible sites for the interaction with His from 6xHis tag (Figure 17B). On the other hand
IDA matrices could interact with the 6xHis tag at the remaining 3 contact sites potentially
yielding higher specificity.
Results from purification with both resins showed that Ste2p.FT.HT could be
captured and partially purified from yeast membrane preparations. Elutions from both
resins carried a few non-specifically bound proteins detected by silver stain (Figure 3&6).
When the specifications of these two resins were compared, the main differences were
the ability of the HiTrap column to withstand higher flow-rates and back pressure, thus
allowing coupling to a HPLC instrument. Due to this reason and the flexibility in the
choice of metal ions that could be used to charge the resin, HiTrap columns were
preferred throughout this study for partial purification of Ste2p.FT.HT.
Besides the IMAC, electro-elution from preparative SDS gels was also applied for
partial purification of cross-linked Ste2p. Following cross-linking (UV exposure), many
proteins in membrane preparations aggregate, causing a decrease in their solubility.
Unless treated with denaturants like urea or guanidine-HCl, use of these samples with an
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Figure 17: Comparison of the interaction of different metal chelating matrices with
nickel ion. A) Shows how the two metal chelating matrices, NTA and IDA, interact with
metal ions, B) an illustration of how two His could interact with the NTA bound Ni2+
(Figures adapted from “A handbook for high-level expression and purification of 6xHistagged proteins” available online at
“http://www1.qiagen.com/literature/handbooks/PDF/Protein/Expression/QXP_QIAexpre
ssionist/1024473_QXPHB_0603.pdf”)
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affinity chromatography (like IMAC) is not feasible. Although most of the affinity
columns are compatible with many of the denaturants, additional sample cleanup is often
necessary, which in most cases could cause low yield. In order to decrease sample
handling, a simple and efficient gel extraction method was applied to partially purify
cross-linked Ste2p. As detailed in results, this technique was particularly good at
removing the aggregates or degradation products that usually co-purified by affinity
chromatography (Figure 4 inset). The presence of multiple forms of the cross-linked
Ste2p in the purified sample would complicate the fragmentation and the analysis of the
fragments afterwards. One disadvantage of gel extraction is the requirement of a dialysis
step after the electro-elution to remove the excess detergent and buffer components from
the SDS-PAGE. The purity (Figure 7A, lane 2) and the ease of sample handling by gel
extraction were comparable to the IMAC method.
The IMAC and gel extraction methods were satisfactory for analysis of crosslinked Ste2p fragments, following chemical or enzymatic digestion, with western blot
analysis. On the other hand use of highly sensitive mass spectrometric techniques like
MALDI-TOF, or NS-MS requires much purer and enriched samples. For this purpose,
during the synthesis of the Bpa-scanned α-factor analogs incorporation of a biotin tag
was included to take advantage of the well-studied avidin-biotin chemistry [51, 52]. The
extremely strong interaction between the avidin and biotin was useful for both detection
and affinity purification [53, 54]. Two different immunopure immobilized avidin beads
(monomeric avidin and streptavidin from Pierce) were used and compared in this study.
Streptavidin, immobilized on beaded agarose, is an avidin-like protein that carries
four binding sites for biotin, each with a similar binding affinity (dissociation constant ~
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10-15). Unlike avidin this protein has a lower pI (5-6) and is not a glycoprotein, therefore
it is postulated to be less prone to nonspecific binding [51]. Monomeric avidin,
immobilized on beaded agarose, has only one binding site for biotin (dissociation
constant ~ 10-8). Both beads were incubated with a simple mixture containing a
biotinylated α-factor analog and the wild type α-factor pheromone in a 1:1 mixture.
Analysis with MALDI-TOF showed that capture of the biotinylated analog from this
simple mixture with monomeric avidin beads was more efficient compared to the
streptavidin beads. A similar study by Gitlin et al. [70] suggested that the biotin binding
site of streptavidin could be buried more deeply compared to monomeric avidin [55]
requiring a long-chain spacer arm between the analyte and biotin tag for efficient binding.
Thus depending on these analyses, monomeric avidin beads were preferred for further
experiments.
Following the success in capturing a biotinylated analog from a simple mixture,
monomeric avidin beads were tested with a complex mixture that mimics the actual
digests containing cross-linked Ste2p fragment(s). Briefly, yeast membranes carrying
Ste2p (~300µg total protein) were digested with CNBr and mixed with a biotinylated αfactor analog. Mixtures containing various ratios of ligand to membrane digest were then
incubated with monomeric avidin beads and subjected to several washes as described in
Materials and Methods. Results showed that biotinylated analog can be captured even
from a mixture where the ligand to total membrane digest ratio is 1:300 by weight. There
was only one main contamination peak probably originating from an endogenously
biotinylated protein. At the lowest ratio tested, peak broadening and adducts were
observed. However analysis of higher intensity signals (from 1:30 mixture) revealed an
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experimental mass for the biotinylated analog, which was only 2 Da higher than the
theoretical weight (Figure 12C).
Although these results suggested that for lower concentration samples, like crosslinked fragments, there could be deviations from mass accuracy, the method was much
more sensitive than calculating masses from relative mobility on SDS-PAGE. Therefore
the method was applied to a sample where a CNBr digested cross-linked membrane was
used (membranes were cross-linked with biotinylated [Bpa1]α-factor). Detection of three
main peaks, including a peak at 4417 Da, previously observed in membrane only assay
(Figure 12A), was quite promising. Analysis of the masses obtained from these peaks
suggested the presence of uncross-linked free ligand (theoretical mass = 2070) and
another peptide with observed weight of 6863.9 Da. This observed mass was 224.51 Da
higher then the theoretical weight of a possible cross-linked fragment resulting from
linking of the biotinylated [Bpa1]α-factor analog (2070 Da) to a region of Ste2p covering
residues 251-294 (4569.39 Da) generated by CNBr digestion. Even though this difference
is very big considering the mass accuracy of MALDI-TOF, it has been reported that a
matrix adduct from sinapinic acid (SA = 224 Da) could be observed in such analyses [47,
50], which will result in such a mass deviation. Testing of a different matrix, α-Cyano-4hydroxycinnamic acid (CHCA), to solve this problem caused the disappearance of signal
at high m/z region from the sample. CHCA matrix is commonly used for small size (2 to
3 kDa) peptides and thus might not be effective in the ionization of bigger fragments
observed with SA matrix. These results showed that although the MALDI-TOF-MS is a
very sensitive and accurate method to determine masses of peptides, without sequence
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information, assignment of these masses to possible cross-linked fragments could not be
done unambiguously.
Thus partially purified Ste2p, digested with CNBr, was analyzed with NS-MS to
obtain sequence information from receptor fragments. Results indicated that IMAC or gel
extraction alone was not enough to obtain sufficient purity for NS-MS. Although a few
peptides were detected and sequenced from Ste2p (Figure 9 A and B), the sequence
coverage was very low (~10% of the receptor sequence). The presence of several
additional peptides from various other proteins complicated the full MS and MS/MS
sequences, making it very hard to analyze. Therefore alternative affinity purification
methods were tested to obtain purer samples before NS-MS analysis.
A monomeric avidin column was quite successful when tested for purification of
biotinylated ligands from CNBr digested yeast membranes. Figure 14 shows that the
main ion in the chromatogram belongs to the biotinylated analog, which was mixed with
the complex membrane digest. There were only a few other peptides from this mixture
observed in the total ion spectrum indicating the sample was relatively pure. In addition,
the MS/MS spectrum from this high intensity ion revealed almost the complete sequence
for the biotinylated analog (Figure 15). Unfortunately application of this method without
any modification to the cross-linked membranes was not as successful. The presence of
uncross-linked ligand in these samples competed against the cross-linked fragments from
Ste2p during purification with monomeric avidin column. Additionally, the uncrosslinked peptides were smaller in size, thus their ionization in the NS-MS experiments was
more efficient. The signal from these small peptides masked signal from less abundant
peptides like the bulky cross-linked fragments. To overcome these problems, application
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of monomeric avidin column following gel extraction and CNBr digestion of cross-linked
Ste2p was applied prior to NS-MS analysis. This two-step purification was designed to
eliminate the uncross-linked ligand prior to monomeric avidin column resulting in better
enrichment of the biotinylated cross-linked fragments.
Preliminary results from these experiments suggested that a few peptides could be
enriched and detected by NS-MS. However the MS/MS spectra of these peptides were
complicated. Presence of multiple charge states of the fragment ions made it very hard to
obtain a series of related ions to determine a sequence tag. Due to the resolution limit of
the mass spectrometer used in this study the identification of the charge states of these
ions was not possible, thus deconvolution of the sequence information from these
MS/MS spectra could not be accomplished. In the absence of sequence information, data
obtained from NS-MS studies was only supportive instead of being informative. These
problems could be solved with a more sensitive instrument like a Fourier Transform Ion
Cyclotron Resonance (FT-ICR) that could do MS/MS analysis, or by the use of
isotopically labeled cross-linkers resulting in doublet ions that would aid identification of
cross-linked fragments in total ion spectra. The details of these methods are further
discussed in Part V, Chapter 2 of this dissertation.
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CHAPTER 1
General Conclusions and Discussion

This dissertation details how Bpa-scanned α-factor analogs have been used to
gain insights into structure-function relationships between α-factor, the Saccharomyces
cerevisiae peptide pheromone, and Ste2p, its G protein-coupled receptor. New detection
and purification methods were introduced by the use of biotin as an affinity tag attached
to cross-linkable α-factor analogs. The major findings of the studies, contributions to
current knowledge of how peptide ligands interact with their GPCRs, and possible future
experiments that would provide further details on the mechanism(s) of signal
transduction through GPCRs upon ligand binding are summarized in this final part of the
dissertation.

Use of Bpa-scanned α-factor Analogs:
It has been shown previously that benzoyl-L-phenylalanine (Bpa) can be
introduced at positions 1, 3, 5, 7, 8, 12 and 13 replacing the native α-factor residues (Trp,
Trp, Gln, Lys, Pro, Met, and Tyr, respectively) to give potential photo-affinity labels with
slight decreases in Ki from 4-fold to 45-fold in comparison to α-factor [1]. Based on these
observations and our working model for pheromone binding to Ste2p [1, 2], iodinatable
α-factor analogs carrying Bpa at position 1, 3, 5, or 13 were synthesized. Studies with
these analogs, as detailed in Part II, showed that except for [Bpa1(I2)Y3R7F13]α-factor,
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iodinated [Bpa3], [Bpa5] and [Bpa13]α-factor analogs had poor biological activity and
decreased Kis. In addition, chemical iodination of these analogs resulted in multiple
iodination at Tyr residue and caused further loss of function. Based on these studies, it
was decided to pursue a different mode of tagging the α-factor analog in order to obtain
modified analogs with sufficient biological activity and receptor binding to ensure their
usage for photo-affinity studies.
Design and syntheses of biotinylated, Bpa-scanned α-factor analogs were
achieved (covered in Part III). Analysis of these analogs illustrated that, except for the
[Bpa8]α-factor analog, the presence of a biotin tag on Lys7 had minor effects on
biological activity and binding affinity. Photo-activated cross-linking of these analogs to
yeast membranes expressing Ste2p resulted in one major band around 54 kDa detected by
western blot analysis probed with NA-HRP (NeutraAvidin-Horse Radish Peroxidase
conjugate). The NA-HRP detected the biotinyl group which was the tag on α-factor that
was cross-linked into Ste2p. The intensity of the bands was reduced by addition of excess
α-factor pheromone during the cross-linking reaction. These results indicated that
biotinylated [Bpa1], [Bpa3], [Bpa5], and [Bpa13]α-factor analogs specifically cross-linked
to the Ste2p and could be used in identification of contact sites between α-factor and its
GPCR.

Purification of intact Ste2p and enrichment of biotinylated cross-linked fragments:
In order to identify the interaction site(s) between a peptide ligand and its GPCR,
fragmentation of the cross-linked receptor followed by analysis of the resulting fragments
223

is often applied [3, 4](see review [5]). The use of a reporter tag on the peptide ligand, like
125

I as mentioned in Part II or biotin as discussed in Part III of this dissertation, aids the

identification and analysis of the cross-linked fragments. In the case of the biotin tag, due
to the presence of possible endogenously biotinylated proteins in the sample mixture, a
partial purification of the cross-linked receptor prior to fragmentation is essential. Two
main approaches (IMAC and size exclusion) for partial purification of the intact crosslinked Ste2p were detailed in Part IV. Although a single-step purification was sufficient
for western blot analyses, further enrichment of the cross-linked fragments was necessary
for the highly sensitive mass spectrometry studies. In order to achieve this goal,
following partial purification and fragmentation, the cross-linked fragments were
enriched by using monomeric avidin beads, which takes advantage of the strong
interaction between biotin and avidin [6, 7]. Results presented in parts III and IV of this
dissertation showed that purification methods applied were adequate to obtain samples
pure enough to analyze with either western blots or mass spectrometry analyses.

Identification of Ste2p regions cross-linked with Bpa-scanned α-factor analogs:
Following partial purification of the cross-linked Ste2p, chemical and enzymatic
fragmentation was carried out to identify the cross-linked region(s). Detection of the
cross-linked fragments was achieved by autoradiography or analysis of protein blots by
probing with NA-HRP according to the tag attached to the ligand used. Fragmentation of
the [Bpa1, Tyr3(125I), Arg7, Phe13]α-factor cross-linked Ste2p using CNBr, trypsin, and
BNPS-skatole reagent resulted in distinct fragmentation patterns as explained in Part II.
Using these analyses and an epitope tagged Ste2p (Ste2p-T7; [8]) the region of cross224

linking was localized to residues 251 to 294 of the receptor. This region corresponds to a
portion of Ste2p comprising the sixth and seventh transmembrane domains and the
connecting the third extracellular loop.
Similarly, Part III of this dissertation details the use of biotinylated Bpa-scanned
α-factor analogs to identify the contact regions between the peptide ligand and Ste2p.
Findings from biotinylated [Bpa1]α-factor were in agreement with the results obtained
from studies using [Bpa1, Tyr3(125I), Arg7, Phe13]α-factor, suggesting an interaction
between position one of the α-factor side chain and a region of Ste2p covering residues
251 to 294. In addition, studies with biotinylated [Bpa3]α-factor showed similar
fragmentation patterns observed from biotinylated [Bpa1]α-factor, revealing that position
three of α-factor might be interacting with a region of Ste2p covering part of EL2 and an
extracellular portion of TM5 or the extracellular portions of TM6 and TM7 including the
EL3. Furthermore, results obtained from biotinylated [Bpa13]α-factor indicated that the
C-terminus of α-factor is in close proximity to the extracellular portion of TM1, covering
a region of Ste2p between residues F55 and R58.

Further analysis of the [Bpa13] cross-linked Ste2p region covering residues F55-R58:
After identification of cross-linking regions on Ste2p with various Bpa-scanned
α-factor analogs, the next step was to identify contact residues, which will provide a
better understanding of agonist-mediated receptor activation. The F55 to R58 residues of
Ste2p, identified by cross-linking studies using biotinylated [Bpa13]α-factor, were further
analyzed by site-directed Ala mutagenesis. Binding analyses carried out with the mutants
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generated in these residues indicated that mutations at residue R58 caused a 10- to 50fold poorer binding of α-factor to the mutant receptor compared to the wild type receptor.
Western blot analyses and biological activity assays with these mutants showed that the
receptors were expressed on the yeast membranes. Additionally, cross-linking studies
done with the mutants using biotinylated [Bpa13]α-factor showed that similar biotin
signal was detected around 54 kDa from all of the Ala mutants (in the region of Ste2p
between residues M54 to R58), except for the R58A mutant. These results suggested that
the R58 residue of Ste2p has an important role in ligand binding and that this residue is in
close proximity to position 13 of α-factor.

Mass spectrometry analysis and preliminary results:
An alternative approach to site-directed mutagenesis for identification of contact
residues between α-factor analogs and Ste2p is the sequencing of the cross-linked
fragments. Part IV of this dissertation summarized the use of two mass spectrometry
approaches using MALDI-TOF and LCQ DECA instruments to analyze the cross-linked
receptor fragments. Although the MALDI-TOF instrument was not used for the
sequencing of the cross-linked fragments, valuable information was gained during the
optimization of biotinylated peptide enrichment. Results from this instrument showed
that a biotinylated peptide ([Bpa8]α-factor analog) could be captured and enriched from a
complex peptide mixture (CNBr-digested yeast membrane prep.). A protocol adapted
from Li et al. [9] was used to illustrate the power of an affinity purification combined
with MALDI-TOF. Analysis of biotinylated [Bpa1]α-factor cross-linked membranes after
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CNBr digestion with this method revealed the identification of a 6863.9 Da biotinylated
peptide. With the assumption of a weight shift due to a matrix adduct from sinapinic acid,
this result was in agreement with previous findings suggesting the interaction of position
1 of α-factor with a Ste2p region covering residues 251 to 294 as reported in parts II and
III.
Following the optimization of an affinity purification technique to enrich the
biotinylated cross-linked fragments, nanospray mass spectrometry (NS-MS) analysis was
carried out by a LCQ DECA instrument. This instrument was preferred due to its
capabilities of doing tandem mass spectrometry (MS/MS) analysis. The basic principle
behind these experiments was to obtain pure and enriched cross-linked fragments that
could be analyzed by NS-MS. Preliminary experiments carried out with biotinylated
[Bpa8]α-factor in a complex peptide mixture showed that monomeric avidin purification
was sufficient to capture and enrich enough peptides for sequencing. Similar analyses,
after a two-step purification of CNBr-digested cross-linked membranes, resulted in
detection of several clean ion packets representing biotinylated peptide masses. These
results showed that the optimized purification methods were compatible with the mass
spectrometric analyses. Previous tries of NS-MS analyses with samples prepared by
single-step purifications led to a very low signal-to-noise ratio due to the presence of
many other peptides, buffer components and detergents. Examination of the MS/MS
spectra from the peptides identified were hampered by the insufficient resolution of the
instrument used to resolve the charge states of the fragment ions and lack of suitable
software to aid the analysis. Manual analysis of these spectra did not reveal more than
two consecutive residues during sequencing, which was not enough to identify a contact
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residue. Further analysis of the data with specific software would be required to assign
cross-linking regions or contact residues.

Working model for pheromone binding to Ste2p and receptor activation:
Although identification of contact residues between the α-factor and its GPCR
Ste2p was not accomplished by mass spectrometry, invaluable information was gained
from the photoaffinity cross-linking studies. Data obtained from these studies and others
including receptor mutagenesis analyses and structure-activity relationships of α-factor
analogs allowed the proposal of a binding model for the peptide ligand. The model
(Figure 1) suggests a bend in the α-factor around the Pro8-Gly9 bound [10], with the Lys7
side chain facing away from the transmembrane domains and interacting with a binding
pocket formed by the extracellular loops [11]. Studies with position one α-factor analogs
[12] indicated a strong preference for a large hydrophobic residue at the amino-terminal
position of the pheromone. In addition fluorescence analyses with Trp3 indicated that the
side chain of this residue is in a hydrophobic cavity (Ding, Becker, and Naider,
unpublished results). Based on these studies and cross-linking data presented in this
dissertation (parts II and III) it is likely that N-terminus of the pheromone interacts with a
pocket consisting of aromatic residues from the extracellular ends of TM5, TM6, and
TM7 and the loops EL2 and EL3 attached to these TMs. Depending on the analyses of
these regions by site-directed mutagenesis studies [2, 13] our binding model suggests that
Trp1 and Trp3 residues of α-factor could interact with Tyr266 (TM6) and Phe204 (TM5),
respectively. Furthermore, the C-terminus of the pheromone interacts with the
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Figure 1: Working model for the fitting of α-factor pheromone into the ligand
binding site on its GPCR, Ste2p. A) Possible contact residues and their interactions in
resting state, B) possible interactions between the α-factor (green) and Ste2p (red)

229

A
Tyr 98
TM 4
4.5

TM 6
Tyr 266

Arg 58

Phe 262
TM 2
TM 5

TM 3

TM 7

TM 1

B
Tyr 98

TM 4
TM 6

Tyr 13
Arg 58

Trp 1

Tyr 266
Phe 262
TM 2
TM 5

TM 3

230

TM 7

TM 1

extracellular tip of TM1, where Gln10 of α-factor is in close proximity to residues 47 and
48 of Ste2p [2] and position 13 localized between receptor residues Arg58 and Tyr98.
Given the interactions described above, the activity and receptor affinity of
truncated pheromones [14], and recent studies with fluorescent α-factor analogs [15] a
multi-step binding and activation of Ste2p upon agonist binding is envisaged. According
to this hypothesis, first the C-terminus of the pheromone binds to the receptor. Tyr13
interacts with Arg58 (TM1) disturbing an interaction between this residue and Tyr98
(TM2), which could destabilize the inactive state of Ste2p. Following this interaction the
receptor undergoes a conformational change; the active conformation is stabilized by
interactions between the N-terminus of the pheromone and the hydrophobic pocket
formed by aromatic residues at the extracellular regions of TM5, TM6 and TM7. Similar
stepwise mechanisms have been proposed for other GPCRs, where agonists bind and
initiate movements of transmembrane domains of receptor, thus these movements
increase the interactions with the various functional groups on the ligand [16-20].
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CHAPTER 2
Future Studies

Despite the tremendous progress in understanding the structure of GPCRs over
the last few years including the solving of the crystal structure of rhodopsin [21] only
partial information is known concerning GPCR binding sites for most molecules
including peptides. This dissertation summarizes the first steps accomplished in mapping
the α-factor binding site(s) within Ste2p using benzoyl-L-phenylalanine (Bpa)-containing
analogs of the pheromone. Work to date has determined several interactions between the
side chains of α-factor residues and receptor regions as detailed above. However, in order
to understand the activation mechanism of GPCRs upon agonist binding, further studies
are necessary to reveal additional details of the ligand-bound structure. This final part of
the dissertation outlines a few of the methods that could be applied, in our current model
system, to elucidate the interactions between the α-factor and its GPCR Ste2p.

Cross-linking studies:
Photoaffinity cross-linking studies using a benzophenone chromophore (Bpa)
have been applied successfully throughout this study. Unfortunately, incorporation of the
Bpa replacing every single residue of α-factor was not possible, due to loss of biological
activity and poor binding. In order to overcome these problems relatively smaller
photoactivatable cross-linkers like p-azido-phenylanaline or p-nitro-L-phenylalanine
could be used to complete the scan through the whole pheromone. These new cross232

linkers could also be used to confirm the results obtained by Bpa. In cases, when the
biological activity and binding of a photoaffinity cross-linker was not optimum, as
discussed in Part III of this dissertation, one always can argue the validity of the results.
Obtaining similar cross-linking results by using different cross-linkers at the same
position and comparing the results could resolve these issues.
Beside new cross-linkers, α-factor analogs that carry two cross-linkers can be
designed and synthesized. Such an analog carrying Bpa residues at the first and thirteenth
positions could be used to lock the receptor in a certain conformation. After crosslinking, the receptor can be purified and further analyzed to identify the stabilizing
interactions. A receptor that is locked in the active conformation would be also very
useful for crystallization studies. As there would be relatively less mobility, such a
receptor could yield better diffracting crystals.
Alternatively, cross-linking studies could be used to analyze the interactions
between TM domains under certain conditions such as agonist or antagonist bound states.
Recent studies carried out by Chin et al. [22, 23] described the in vivo incorporation of
photoaffinity cross-linker (Bpa) into any protein sequence (in response to amber codon
TAG) by site-directed mutagenesis. These studies made it possible to analyze proteinprotein interactions or intra molecular interactions by using photoaffinity cross-linking.
Incorporation of Bpa into Ste2p sequence would be very useful to study the proximity of
TMs. Following cross-linking the receptor could be digested chemically or enzymatically
to further analyze which TM is interacting with the residue modified by the cross-linker.
Also this approach can be used to cross-link the receptor back to the ligand to identify the
important residues on the receptor that are likely to interact with the α-factor.
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Combination of results from such cross-linking studies with the results discussed in this
dissertation could reveal contact residues between the pheromone and Ste2p.

Site-directed mutagenesis:
Another way to identify the contact residues between the α-factor and its receptor
is to carry out site-directed mutagenesis. The regions of Ste2p identified by cross-linking
studies could be analyzed by site-directed mutagenesis as described in Part III of this
dissertation. Binding and biological activity assays with these mutants could aid the
identification of the ligand interacting site(s). However, mutagenesis studies carried out
by methionine instead of classical alanine mutagenesis would be useful. Insertion of a
methionine in these regions could be used in combination with further CNBr digestion to
decrease the size of the region identified by cross-linking. In addition a recent approach
reported by Rihakova et al. [24] could be used, which takes advantage of a modified Bpa
analog (NO2Bpa), to determine contact residues. This modified Bpa analog has an
increased selectivity for methionine and does not cross-link unless a methionine residue
is in proper distance and orientation. Use of such a cross-linker and a methionine scanned
receptor will help the identification of contact residues.

Mass Spectrometry:
Part IV of this dissertation details the use of mass spectrometry in the analysis of
cross-linked receptor fragments. However, the data analyses from these studies were
limited due to relatively low sensitivity of the instruments used, lack of proper algorithms
to analyze complex fragmentation patterns, natural loses common in peptide ion
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fragmentation, and unusual and difficult-to-interpret fragmentation of branched peptides.
In addition, the low signal-to-noise ratio observed in the MS/MS spectra further
complicated the analysis and determination of sequence information from cross-linked
peptides.
Recent developments in instrument design and computational analyses could help
to overcome most of these problems. Studies with new instruments, using a combination
of quadrupolar ion trap and a fourier transform ion cyclotron resonance cell, showed that
it is possible to obtain very high mass accuracy (below 2 ppm) and do MS/MS analysis at
the same time [25, 26]. This new strategy suggested that determination of the amino acid
composition of the peptide prior to sequencing would aid the subsequent peptide
sequencing which could be performed by a permutation-based scoring algorithm.
Analysis of the cross-linked fragments by such a powerful instrument and proper
algorithms could help identification of the contact residues between the α-factor and
Ste2p.
Besides the complexity of the fragmentation spectra and the sensitivity of the
mass spectrometer used, identification of the cross-linked fragment ions in a total ion
spectrum was challenging. Specific labeling of the cross-linked fragments by the use of
α-factor analogs that are identical except from the overall mass would result in twin
peaks in relative abundance vs. time spectrum (Figure 2). This property could be used to
identify parent ions from cross-linked fragments in complex mixtures. The idea is based
on the principle of identifying target peptides by the use of stable-isotope labeling named
as the isotope coded affinity tag (ICAT)-based protein profiling [27, 28]. Such α-factor
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Figure 2: Total ion spectrum of two [Bpa1]α-factor analogs, obtained by LCQ DECA. Two analogs containing Bpa at
position one and had a mass difference of 42 Da were mixed and analyzed by NS-MS. Twin peaks were observed at about 30 min
of the elution from a C18 column.
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analogs that carry the cross-linker at the same position and differ by only several Da in
mass could be designed and used for identification of cross-linked fragments in mass
spectrometry analysis. Currently in our lab, studies with such peptides that have Bpa at
position 1 and carry a mass difference of 42 Da (due to different length linkers between
the biotinyl group and the epsilon amine of lysine at position seven in α-factor) are being
used to optimize conditions to identify cross-linked fragments (Figure 2). After
fragmentation, Ste2p cross-linked with analogs that only differ by mass will generate
cross-linked fragments that are 42 Da apart with the assumption that they cross-link to the
same fragment. Detection and analysis of twin peaks generated by this method will
simplify the data analysis, thus increase accuracy.
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